<div id="page0" style="width:595.3pt;height:793.7pt">
<p style="top:148.8pt;left:42.5pt;line-height:9.6pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:9.6pt">Review</span></p>
<img style="position:absolute;transform:matrix(1.3333334,0,0,1.3333334,678.6667,222.66667)" src="data:image/png;base64,
iVBORw0KGgoAAAANSUhEUgAAAB0AAAAdCAYAAABWk2cPAAAACXBIWXMAAA7EAAAO
xAGVKw4bAAAAn0lEQVR4nMXDCQqCAAAEwP3/j6LMMjNEzA47zMQMkSRJBEmSZPvF
NjDAP3yHger49D3V8e46qqNtW6qjaRqq41XXVMezqqiOR1lSHUVRUB15nlMd2T2j
OtJbSnVck4TquMQx1XGOIqrjcDpSHfswpDo2uy3VsQ4CqsPzfarD9Tyqw3FdqsN2
VlSHZS+pDtNaUB3GbE51jKcm1TGaGFT/AbvwRK1ZPv2zAAAAAElFTkSuQmCC">
<p style="top:167.5pt;left:42.5pt;line-height:13.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:13.4pt">11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:13.4pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:13.4pt">-hydroxysteroid dehydrogenase type 1 inhibitor use in human</span></p>
<p style="top:184.7pt;left:42.5pt;line-height:13.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:13.4pt">disease-a systematic review and narrative synthesis</span></p>
<p style="top:209.4pt;left:42.5pt;line-height:10.6pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:10.6pt">Sarah Gregory</span><span style="font-family:AdvTT5235d5a9,serif;font-size:7.5pt;color:#2e3092"> </span><sup><span style="font-family:AdvTT5235d5a9,serif;font-size:7.5pt;color:#2e3092">a</span></sup><sup><span style="font-family:AdvTT5235d5a9,serif;font-size:7.5pt">,</span></sup><span style="font-family:AdvTT5235d5a9+20,serif;font-size:12.0pt;color:#2e3092">&#x204e;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:10.6pt">, David Hill</span><span style="font-family:AdvTT5235d5a9,serif;font-size:7.5pt;color:#2e3092"> </span><sup><span style="font-family:AdvTT5235d5a9,serif;font-size:7.5pt;color:#2e3092">a</span></sup><span style="font-family:AdvTT5235d5a9,serif;font-size:10.6pt">, Ben Grey</span><span style="font-family:AdvTT5235d5a9,serif;font-size:7.5pt;color:#2e3092"> </span><sup><span style="font-family:AdvTT5235d5a9,serif;font-size:7.5pt;color:#2e3092">a</span></sup><span style="font-family:AdvTT5235d5a9,serif;font-size:10.6pt">, William Ketelbey</span><span style="font-family:AdvTT5235d5a9,serif;font-size:7.5pt;color:#2e3092"> </span><sup><span style="font-family:AdvTT5235d5a9,serif;font-size:7.5pt;color:#2e3092">b</span></sup><span style="font-family:AdvTT5235d5a9,serif;font-size:10.6pt">, Tamara Miller</span><span style="font-family:AdvTT5235d5a9,serif;font-size:7.5pt;color:#2e3092"> </span><sup><span style="font-family:AdvTT5235d5a9,serif;font-size:7.5pt;color:#2e3092">b</span></sup><span style="font-family:AdvTT5235d5a9,serif;font-size:10.6pt">,</span></p>
<p style="top:222.4pt;left:42.5pt;line-height:10.6pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:10.6pt">Graciela Muniz-Terrera</span><span style="font-family:AdvTT5235d5a9,serif;font-size:7.5pt;color:#2e3092"> </span><sup><span style="font-family:AdvTT5235d5a9,serif;font-size:7.5pt;color:#2e3092">a</span></sup><span style="font-family:AdvTT5235d5a9,serif;font-size:10.6pt">, Craig W. Ritchie</span><span style="font-family:AdvTT5235d5a9,serif;font-size:7.5pt;color:#2e3092"> </span><sup><span style="font-family:AdvTT5235d5a9,serif;font-size:7.5pt;color:#2e3092">a</span></sup></p>
<p style="top:239.3pt;left:42.5pt;line-height:4.5pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:4.5pt">a</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt"> Centre for Dementia Prevention, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK</span></p>
<p style="top:247.8pt;left:42.5pt;line-height:4.5pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:4.5pt">b</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt"> Actinogen Medical Ltd, Sydney, Australia</span></p>
<p style="top:278.7pt;left:206.9pt;line-height:9.0pt"><span style="font-family:AdvTT0f485e03,serif;font-size:9.0pt">a b s t r a c t</span></p>
<p style="top:278.7pt;left:42.5pt;line-height:9.0pt"><span style="font-family:AdvTT0f485e03,serif;font-size:9.0pt">a r t i c l e</span></p>
<p style="top:278.7pt;left:107.3pt;line-height:9.0pt"><span style="font-family:AdvTT0f485e03,serif;font-size:9.0pt">i n f o</span></p>
<p style="top:299.1pt;left:42.5pt;line-height:6.4pt"><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">Article history:</span></p>
<p style="top:307.6pt;left:42.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Received 3 January 2020</span></p>
<p style="top:316.2pt;left:42.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Accepted 20 April 2020</span></p>
<p style="top:334.1pt;left:42.5pt;line-height:6.4pt"><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">Keywords:</span></p>
<p style="top:342.7pt;left:42.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">HPA axis</span></p>
<p style="top:351.3pt;left:42.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Cortisol</span></p>
<p style="top:359.8pt;left:42.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">-HSD1</span></p>
<p style="top:368.4pt;left:42.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Systematic review</span></p>
<p style="top:298.4pt;left:206.9pt;line-height:7.2pt"><span style="font-family:AdvTT94c8263f.I,serif;font-size:7.2pt">Introduction:</span><span style="font-family:AdvTT5235d5a9,serif;font-size:7.2pt"> 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:7.2pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:7.2pt">-hydroxysteroid dehydrogenase type 1 (11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:7.2pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:7.2pt">-HSD1) is an intracellular enzyme that catalyses</span></p>
<p style="top:308.0pt;left:206.9pt;line-height:7.2pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:7.2pt">conversion of cortisone into cortisol; correspondingly, 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:7.2pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:7.2pt">-HSD1 inhibitors inhibit this conversion. This system-</span></p>
<p style="top:317.5pt;left:206.9pt;line-height:7.2pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:7.2pt">atic review focuses on the use of 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:7.2pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:7.2pt">-HSD1 inhibitors in diseases known to be associated with abnormalities in</span></p>
<p style="top:327.1pt;left:206.9pt;line-height:7.2pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:7.2pt">hypothalamic pituitary adrenal (HPA) axis function.</span></p>
<p style="top:336.7pt;left:206.9pt;line-height:7.2pt"><span style="font-family:AdvTT94c8263f.I,serif;font-size:7.2pt">Methods:</span><span style="font-family:AdvTT5235d5a9,serif;font-size:7.2pt"> The databases screened for suitable papers were: MedLine, EMBASE, Web of Science,</span><span style="font-family:AdvTT5235d5a9,serif;font-size:7.2pt;color:#2e3092"> ClinicalTrials.gov</span><span style="font-family:AdvTT5235d5a9,serif;font-size:7.2pt">,</span></p>
<p style="top:346.3pt;left:206.9pt;line-height:7.2pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:7.2pt">and Cochrane Central.</span></p>
<p style="top:355.8pt;left:206.9pt;line-height:7.2pt"><span style="font-family:AdvTT94c8263f.I,serif;font-size:7.2pt">Results:</span><span style="font-family:AdvTT5235d5a9,serif;font-size:7.2pt"> 1925 papers were identi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:7.2pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:7.2pt">ed, of which 29 were included in the</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:7.2pt"> &#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:7.2pt">nal narrative synthesis. 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:7.2pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:7.2pt">-HSD1 and its</span></p>
<p style="top:365.4pt;left:206.9pt;line-height:7.2pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:7.2pt">inhibitors have been studied in diabetes, obesity, metabolic syndrome (MetS), and Alzheimer&apos;s disease (AD). Higher</span></p>
<p style="top:375.0pt;left:206.9pt;line-height:7.2pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:7.2pt">expression of 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:7.2pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:7.2pt">-HSD1 is seen in obesity and MetS, but has not yet been described in obesity or AD. Genetic studies</span></p>
<p style="top:384.5pt;left:206.9pt;line-height:7.2pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:7.2pt">identify 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:7.2pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:7.2pt">-HSD1 SNPs of interest in populations with diabetes, MetS, and AD. One phase II trial successfully re-</span></p>
<p style="top:394.1pt;left:206.9pt;line-height:7.2pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:7.2pt">duced HbA1c in a diabetic population, however trials in MetS, obesity, and AD have not met primary endpoints.</span></p>
<p style="top:403.6pt;left:206.9pt;line-height:7.2pt"><span style="font-family:AdvTT94c8263f.I,serif;font-size:7.2pt">Conclusions:</span><span style="font-family:AdvTT5235d5a9,serif;font-size:7.2pt"> Translation of this research from preclinical studies has proved challenging so far, however this is a</span></p>
<p style="top:413.2pt;left:206.9pt;line-height:7.2pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:7.2pt">growing area of research and more studies should focus on understanding the complex relationships between</span></p>
<p style="top:422.7pt;left:206.9pt;line-height:7.2pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:7.2pt">11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:7.2pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:7.2pt">-HSD1 and disease pathology, especially given the therapeutic potential of 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:7.2pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:7.2pt">-HSD1 inhibitors in development.</span></p>
<p style="top:432.3pt;left:439.3pt;line-height:7.2pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:7.2pt">&#xa9; 2020 Elsevier Inc. All rights reserved.</span></p>
<p style="top:481.5pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT28000ce1.B,serif;font-size:8.0pt">1. Introduction</span></p>
<p style="top:502.4pt;left:54.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">The hypothalamic-pituitary-adrenal (HPA) axis is the body&apos;s major</span></p>
<p style="top:512.8pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">neuroendocrine system secreting cortisol, a glucocorticoid. When func-</span></p>
<p style="top:523.3pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">tioning normally cortisol follows a diurnal rhythm with exposure to</span></p>
<p style="top:533.7pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">stress activating the HPA axis to temporarily increase cortisol and then</span></p>
<p style="top:544.2pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">return to baseline via a negative feedback system [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">1</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">]. Abnormal func-</span></p>
<p style="top:554.7pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">tion, or dysregulation, of the HPA axis is associated with a large number</span></p>
<p style="top:565.1pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">of diseases.</span></p>
<p style="top:590.3pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT94c8263f.I,serif;font-size:8.0pt">1.1. Cortisol abnormalities in psychiatric and neurological illnesses</span></p>
<p style="top:611.2pt;left:54.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">In melancholic depression the dexamethasone challenge (whereby</span></p>
<p style="top:621.6pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">exposure to dexamethasone should result in decreased cortisol) results</span></p>
<p style="top:632.1pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">in increased cortisol levels demonstrating an abnormality in HPA axis</span></p>
<p style="top:642.5pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">function [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">2</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">]. A recent systematic review found that basal cortisol levels</span></p>
<p style="top:653.0pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">vary across studies of depression, with both normal and abnormal levels</span></p>
<p style="top:663.4pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">seen in patients with this condition [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">2</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">]. This disparity may be due to the</span></p>
<p style="top:481.5pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">heterogeneity of sampling often seen in studies of depression. When</span></p>
<p style="top:491.9pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">looking at an older adult population there is more clarity, with multiple</span></p>
<p style="top:502.4pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">studies reporting signi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">cantly increased levels of morning cortisol for</span></p>
<p style="top:512.8pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">older adults with depression compared to older healthy controls [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">3</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">].</span></p>
<p style="top:523.3pt;left:322.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">Increased cortisol levels are seen in the manic phase of bipolar disor-</span></p>
<p style="top:533.7pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">der, suggesting HPA hyperactivity [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">4</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">]. Abnormal HPA function has been</span></p>
<p style="top:544.2pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">targeted in treatment trials in mood disorders with mifepristone, a glu-</span></p>
<p style="top:554.7pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">cocorticoid receptor (GR) antagonist. Mifepristone works to displace</span></p>
<p style="top:565.1pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">cortisol from glucocorticoid receptors thereby moderating the activity</span></p>
<p style="top:575.6pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">of the HPA axis [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">5</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">]. Trials have focussed on cognitive enhancement in bi-</span></p>
<p style="top:586.1pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">polar disorder and schizophrenia, and symptom management of psy-</span></p>
<p style="top:596.5pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">chotic depression [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">6</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">]. Mifepristone was associated with improvements</span></p>
<p style="top:607.0pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">in cognition in people with bipolar disorder [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">7</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">,</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">8</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">] but no change in peo-</span></p>
<p style="top:617.4pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">ple with schizophrenia [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">9</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">]. There have been mixed results when trialled</span></p>
<p style="top:627.9pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">as a treatment for psychotic depression, with results suggesting there</span></p>
<p style="top:638.4pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">may be a strata of patients who will respond best to this treatment</span></p>
<p style="top:648.8pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">[</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">10</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:8.0pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">13</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">]. There are currently no ongoing trials of GR antagonists for</span></p>
<p style="top:659.3pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">these indications.</span></p>
<p style="top:669.7pt;left:322.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">Elevated cortisol has been associated with Alzheimer&apos;s disease (AD)</span></p>
<p style="top:680.2pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">in many cross-sectional and cohort studies [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">14</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">] as well as with cognitive</span></p>
<p style="top:690.7pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">decline in preclinical AD [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">15</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">] and in cognitively healthy older subjects</span></p>
<p style="top:701.1pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">[</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">16</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:8.0pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">18</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">]. Elevated 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">-HSD1 is seen in the hippocampal and neocortical</span></p>
<p style="top:37.7pt;left:219.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">Metabolism Clinical and Experimental 108 (2020) 154246</span></p>
<p style="top:685.2pt;left:48.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt">&#x204e;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> Corresponding author at: Edinburgh Dementia Prevention, Biocube 1, 9 Little France</span></p>
<p style="top:693.8pt;left:42.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Road, Edinburgh EH16 4UX, UK.</span></p>
<p style="top:702.4pt;left:54.7pt;line-height:6.4pt"><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">E-mail address:</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Sarah.Gregory@ed.ac.uk</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> (S. Gregory).</span></p>
<img style="position:absolute;transform:matrix(.32034908,0,-0,.31927235,594.98336,-24.315323)" src="data:image/jpeg;base64,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">
<p style="top:730.3pt;left:42.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">https://doi.org/10.1016/j.metabol.2020.154246</span></p>
<p style="top:738.8pt;left:42.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">0026-0495/&#xa9; 2020 Elsevier Inc. All rights reserved.</span></p>
<img style="position:absolute;transform:matrix(.31971506,0,-0,.31903435,-27.51133,-8.628662)" src="data:image/png;base64,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">
<p style="top:63.6pt;left:232.6pt;line-height:8.0pt"><span style="font-family:AdvTTc8c83e50,serif;font-size:8.0pt">Contents lists available at</span><span style="font-family:AdvTTc8c83e50,serif;font-size:8.0pt;color:#2e3092"> ScienceDirect</span></p>
<p style="top:85.5pt;left:183.8pt;line-height:13.9pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:13.9pt">Metabolism Clinical and Experimental</span></p>
<p style="top:119.3pt;left:195.0pt;line-height:8.0pt"><span style="font-family:AdvTTc8c83e50,serif;font-size:8.0pt">journal homepage:</span><span style="font-family:AdvTTc8c83e50,serif;font-size:8.0pt;color:#2e3092"> www.metabolismjournal.com</span></p>


<p style="top:57.3pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">regions associated with ageing and cognitive decline. Studying the HPA</span></p>
<p style="top:67.7pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">axis as a possible treatment target for AD has been gathering traction in</span></p>
<p style="top:78.2pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">recent years, with interventions such as GR antagonists in development</span></p>
<p style="top:88.6pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">alongside work on 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">-HSD1 inhibitors [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">19</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">].</span></p>
<p style="top:99.1pt;left:45.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">Research into HPA axis function and Parkinson&apos;s disease (PD) is still</span></p>
<p style="top:109.6pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">in its infancy, however early studies suggest this may be an area of inter-</span></p>
<p style="top:120.0pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">est for future research. Compared to control participants, people with</span></p>
<p style="top:130.5pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">mild to moderate PD had signi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">cantly higher levels of morning salivary</span></p>
<p style="top:141.0pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">cortisol [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">20</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">]. A recent systematic review found signi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">cant cortisol eleva-</span></p>
<p style="top:151.5pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">tion in people with PD in half of the studies included, with higher corti-</span></p>
<p style="top:161.9pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">sol levels related to worse functional scores, depression, and risk</span></p>
<p style="top:172.4pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">behaviours [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">21</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">].</span></p>
<p style="top:182.8pt;left:45.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">HPA axis function in post-traumatic stress disorder (PTSD) has been</span></p>
<p style="top:193.3pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">widely studied with inconsistent study results. People with PTSD ap-</span></p>
<p style="top:203.7pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">pear to have an elevated cortisol response when the HPA axis is acti-</span></p>
<p style="top:214.2pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">vated using psychological stressors [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">22</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">]. However basal cortisol levels</span></p>
<p style="top:224.6pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">in those with an established PTSD diagnosis demonstrate huge</span></p>
<p style="top:235.1pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">heterogeneity [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">23</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">]. To understand HPA axis dysfunction in PTSD it is</span></p>
<p style="top:245.6pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">likely necessary to identify subgroups of the population. For example,</span></p>
<p style="top:256.1pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">female participants with PTSD or those who experienced trauma from</span></p>
<p style="top:266.5pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">sexual or physical abuse had signi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">cantly lower basal cortisol than in</span></p>
<p style="top:277.0pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">controls [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">23</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">].Sri Lankan girls who experienced the 2004 tsunami were</span></p>
<p style="top:287.4pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">more likely than boys to have elevated cortisol levels when re-</span></p>
<p style="top:297.9pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">experiencing symptoms [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">24</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">]. In contrast to this male 9/11 survivors</span></p>
<p style="top:308.3pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">were more likely to have increased cortisol levels when re-</span></p>
<p style="top:318.8pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">experiencing symptoms compared to women with the same experi-</span></p>
<p style="top:329.2pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">ences [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">25</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">].</span></p>
<p style="top:339.7pt;left:45.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">Psychosis is another diagnostic area where research to date has pro-</span></p>
<p style="top:350.2pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">duced con</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb02;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">icting results, with hyperactivity of the HPA axis associated</span></p>
<p style="top:360.6pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">with higher risk states for development of psychosis, but a blunting of</span></p>
<p style="top:371.1pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">cortisol activity demonstrated during psychological stressor tests</span></p>
<p style="top:381.6pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">[</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">26</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">,</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">27</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">]. Similarly generalised anxiety disorders present with a mixed</span></p>
<p style="top:392.0pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">picture in studies completed to date with both hyperactive and</span></p>
<p style="top:402.5pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">hypoactive cortisol reactivity found [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">28</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">].</span></p>
<p style="top:423.4pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT94c8263f.I,serif;font-size:8.0pt">1.2. The HPA axis in metabolic syndrome, obesity, diabetes, and</span></p>
<p style="top:433.9pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT94c8263f.I,serif;font-size:8.0pt">hypertension</span></p>
<p style="top:454.8pt;left:45.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">A recent systematic review and meta-analysis of 27 studies found no</span></p>
<p style="top:465.2pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">overall evidence of an association between basal cortisol levels and met-</span></p>
<p style="top:475.7pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">abolic syndrome (MetS) [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">29</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">]. Despite this many of the component diag-</span></p>
<p style="top:486.2pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">noses of MetS have been associated with dysregulations in cortisol and</span></p>
<p style="top:496.7pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">the HPA axis. Hypercortisolism appears to correlate with abdominal ad-</span></p>
<p style="top:507.1pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">iposity [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">30</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">].The relationship is more complex when considering general</span></p>
<p style="top:517.6pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">obesity or body mass index (BMI) with divergent results reported [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">30</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">].</span></p>
<p style="top:528.0pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">Abnormal cortisol has been associated both with type 2 diabetes and</span></p>
<p style="top:538.5pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">with the risk of developing type 2 diabetes up to 9 years after the base-</span></p>
<p style="top:548.9pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">line cortisol measurement [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">31</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:8.0pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">34</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">]. Hypertension has also been associ-</span></p>
<p style="top:559.4pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">ated with raised evening cortisol levels in men [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">33</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">].</span></p>
<p style="top:580.3pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT94c8263f.I,serif;font-size:8.0pt">1.3. 11</span><span style="font-family:AdvTT94c8263f.I+03,serif;font-size:8.0pt">&#x3b2;</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:8.0pt">-HSD1 inhibitors</span></p>
<p style="top:601.3pt;left:45.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">Tissue glucocorticoid levels are regulated not only by central HPA axis</span></p>
<p style="top:611.7pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">activity, but also by 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">-hydroxysteroid dehydrogenase enzymes. The</span></p>
<p style="top:622.2pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">type 1 isozyme (11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">-HSD1) is abundant in the liver and adipose tissue,</span></p>
<p style="top:632.7pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">as well as the hippocampus and central nervous system [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">35</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">,</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">36</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">]. 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">-</span></p>
<p style="top:643.1pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">HSD1 ampli</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">es the active glucocorticoid hormone cortisol by catalysing</span></p>
<p style="top:653.6pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">the conversion of inactive cortisone into the active cortisol [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">35</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">]. A novel</span></p>
<p style="top:664.0pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">class of drugs, the 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">-HSD1 inhibitors, is currently in development for</span></p>
<p style="top:674.5pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">multiple diseases. 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">-HSD1 inhibitors partially inhibit the enzymatic</span></p>
<p style="top:684.9pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">conversion of cortisone to cortisol, thereby adjusting cortisol levels [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">37</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">].</span></p>
<p style="top:695.4pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">Inhibitors of 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">-HSD1 are believed to lower cortisol selectively within</span></p>
<p style="top:705.9pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">the tissues without impacting the normal variations of plasma cortisol</span></p>
<p style="top:716.3pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">during stress response.</span></p>
<p style="top:726.8pt;left:45.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">This review is aimed at understanding 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">-HSD1 inhibitors as one of</span></p>
<p style="top:737.3pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">the potential treatment avenues for HPA axis abnormalities. To the</span></p>
<p style="top:57.3pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">authors&apos; knowledge there are no known systematic reviews of the evi-</span></p>
<p style="top:67.7pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">dence base for the therapeutic uses of 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt"> -HSD1 inhibitors; there is a</span></p>
<p style="top:78.2pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">useful summary review highlighting the main areas, which has been</span></p>
<p style="top:88.6pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">utilised as a basis for the search strategies, however whilst it is compre-</span></p>
<p style="top:99.1pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">hensive, it is non-systematic in nature and has thus led to this review</span></p>
<p style="top:109.6pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">[</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">38</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">].</span></p>
<p style="top:130.5pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT28000ce1.B,serif;font-size:8.0pt">2. Methods</span></p>
<p style="top:151.5pt;left:313.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">The Preferred Reporting for Systematic Reviews and Meta-Analysis</span></p>
<p style="top:161.9pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">(PRISMA) statement was used in the development of this systematic re-</span></p>
<p style="top:172.4pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">view. It is registered in PROSPERO with number CRD42018100458 (ac-</span></p>
<p style="top:182.8pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">cessible here). A complementary review of animal models took place at</span></p>
<p style="top:193.3pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">the same time, registered on PROSPERO with number CRD42018098953.</span></p>
<p style="top:214.2pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT94c8263f.I,serif;font-size:8.0pt">2.1. Search strategy, study selection and data extraction</span></p>
<p style="top:235.1pt;left:313.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">Included in the search were studies that evaluated an 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">-HSD1 en-</span></p>
<p style="top:245.6pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">zyme expression, activity, or trial of an 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">-HSD1 inhibitor in any of the</span></p>
<p style="top:256.0pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">following indications: AD, mild cognitive impairment (MCI), PD, diabe-</span></p>
<p style="top:266.5pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">tes, MetS, hypertension, obesity, hyperlipidemia, anxiety, depression,</span></p>
<p style="top:277.0pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">PTSD, schizophrenia, and cancer in human adults. Disease areas previ-</span></p>
<p style="top:287.5pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">ously associated with abnormal cortisol levels on clinical presentation,</span></p>
<p style="top:297.9pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">were included, with the one exception being cancer. As cortisol is ubiq-</span></p>
<p style="top:308.4pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">uitous in the human body cancer was included as a disease that may af-</span></p>
<p style="top:318.8pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">fect any organ or system, to ensure treatment trials in areas outside of</span></p>
<p style="top:329.3pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">the targeted search were not missed. Exclusion criteria were: exclu-</span></p>
<p style="top:339.7pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">sively subjects under 18 years, toxicology only studies, studies pub-</span></p>
<p style="top:350.2pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">lished before 1993 and those not published or accessible in English (as</span></p>
<p style="top:360.6pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">the review team could not read papers in languages other than English).</span></p>
<p style="top:371.1pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">Excluding non-English studies led to 107 references (2.5%) being ex-</span></p>
<p style="top:381.6pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">cluded from the search prior to de-duplication. The search was per-</span></p>
<p style="top:392.1pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">formed in MedLine, EMBASE, Web of Science,</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092"> ClinicalTrials.gov</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt"> and</span></p>
<p style="top:402.5pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">Cochrane Central, with reference lists manually searched. The search</span></p>
<p style="top:413.0pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">strategy used from EMBASE is included in Appendix 1.</span></p>
<p style="top:423.4pt;left:313.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">Study selection was performed by two independent investigators</span></p>
<p style="top:433.9pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">(SG and DH) in two stages. Initially titles and abstracts were reviewed</span></p>
<p style="top:444.3pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">for suitability, followed by fully text review against the inclusion and ex-</span></p>
<p style="top:454.8pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">clusion criteria. Con</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb02;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">icts were resolved by discussion and a third re-</span></p>
<p style="top:465.2pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">viewer (CWR) was available if needed. Data was extracted by three</span></p>
<p style="top:475.7pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">reviewers (SG, DH and BG) using a standardised form to gather: design,</span></p>
<p style="top:486.2pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">diagnosis, gender, age, intervention name, placebo type, method of</span></p>
<p style="top:496.7pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">randomisation, primary outcome measure, and secondary outcome</span></p>
<p style="top:507.1pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">measures. The Cochrane Risk of Bias Tool for Randomised Controlled</span></p>
<p style="top:517.6pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">Trials [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">39</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">] and the NIH Quality Assessment Tool for Observational</span></p>
<p style="top:528.0pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">Cohort and Cross-Sectional Studies were used to assess risk of bias [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">40</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">].</span></p>
<p style="top:549.0pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT28000ce1.B,serif;font-size:8.0pt">3. Results</span></p>
<p style="top:569.9pt;left:313.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">In total 1925 studies were identi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">ed for review, 49 full texts were</span></p>
<p style="top:580.3pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">considered, and 29 articles included in the narrative synthesis.</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092"> Fig. 1</span></p>
<p style="top:590.8pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">presents reasons for article exclusion. Included papers reported studies</span></p>
<p style="top:601.2pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">in diabetes, MetS, obesity, and AD. Six of the papers were randomised</span></p>
<p style="top:611.7pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">controlled trials of investigational medicinal products and the remain-</span></p>
<p style="top:622.2pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">ing 24 reported on gene expression, metabolism or genome wide asso-</span></p>
<p style="top:632.7pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">ciation studies. Full details of the studies and data extracted are</span></p>
<p style="top:643.1pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">provided in</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092"> Table 1</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">.</span></p>
<p style="top:664.0pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT94c8263f.I,serif;font-size:8.0pt">3.1. Tissue and gene expression studies</span></p>
<p style="top:684.9pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT94c8263f.I,serif;font-size:8.0pt">3.1.1. Obesity</span></p>
<p style="top:695.4pt;left:313.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">Ten studies looked at 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">-HSD1 expression in participants with obe-</span></p>
<p style="top:705.9pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">sity. Nine studies used abdominal tissues and one study utilised blood</span></p>
<p style="top:716.3pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">samples [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">41</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">]. In all but one study [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">41</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">], 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">-HSD1 expression was higher</span></p>
<p style="top:726.8pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">in participants who were obese compared to lean controls, with higher</span></p>
<p style="top:737.3pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">mRNA levels also seen in multiple studies [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">42</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:8.0pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">50</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">]. Four studies identi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">ed</span></p>
<p style="top:37.7pt;left:33.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">2</span></p>
<p style="top:37.7pt;left:190.4pt;line-height:6.4pt"><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">S. Gregory et al. / Metabolism Clinical and Experimental 108 (2020) 154246</span></p>


<p style="top:548.9pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">higher 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">-HSD1 mRNA levels in subcutaneous adipose tissue (SAT)</span></p>
<p style="top:559.4pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">[</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">45</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">,</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">46</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">,</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">49</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">,</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">50</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">], three studies identi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">ed higher levels of 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">-HSD1 mRNA</span></p>
<p style="top:569.9pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">in visceral adipose tissue (VAT) [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">44</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">,</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">47</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">,</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">48</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">] and one study identi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">ed higher</span></p>
<p style="top:580.3pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">levels of 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">-HSD1 mRNA in both SAT and VAT [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">43</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">]. No study reported</span></p>
<p style="top:590.8pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">lower 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">-HSD1 mRNA levels in SAT or VAT in obese populations.</span></p>
<p style="top:601.3pt;left:54.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">Valsamakis and colleagues found no signi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">cant differences in serum</span></p>
<p style="top:611.7pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">-HSD1 expression between lean and obese diabetic men [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">41</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">]. Shao</span></p>
<p style="top:622.2pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">and colleagues found higher levels of 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">-HSD1 VAT mRNA in obesity</span></p>
<p style="top:632.6pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">compared to controls, with signi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">cant associations found between</span></p>
<p style="top:643.1pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">-HSD1 mRNA expression and waist to hip ratio, BMI, homeostasis</span></p>
<p style="top:653.5pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">model assessment-insulin resistance (HOMA-IR), fasting insulin, total</span></p>
<p style="top:664.0pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">cholesterol and triglycerides [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">42</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">]. Obese women showed a signi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">cant</span></p>
<p style="top:674.4pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">increase in 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">-HSD1 mRNA concentrations in both VAT and SAT com-</span></p>
<p style="top:684.9pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">pared to lean women, with VAT mRNA correlating with BMI, waist cir-</span></p>
<p style="top:695.4pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">cumference, abdominal diameter and percentage fat [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">43</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">]. In a Chinese</span></p>
<p style="top:705.9pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">population 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">-HSD1 mRNA levels in VAT and SAT correlated with</span></p>
<p style="top:716.3pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">BMI and were both increased in obesity compared to controls [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">47</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">].</span></p>
<p style="top:726.8pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">-HSD1 mRNA levels were higher in SAT than VAT in a Chilean pop-</span></p>
<p style="top:737.2pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">ulation of morbidly obese participants [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">45</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">]. 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">-HSD1 mRNA levels, and</span></p>
<p style="top:548.9pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">activity [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">49</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">,</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">50</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">], increased with obesity and correlated with hip, but not</span></p>
<p style="top:559.4pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">waist, circumference [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">45</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">]. This increase in activity was seen both in Cau-</span></p>
<p style="top:569.8pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">casian and Pima Indian populations [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">50</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">].</span></p>
<p style="top:580.3pt;left:322.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">Omental tissues from obese participants showed higher 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">-HSD1</span></p>
<p style="top:590.8pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">mRNA compared to both normal weight controls and participants with</span></p>
<p style="top:601.3pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">Cushing&apos;s disease [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">44</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">]. 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">-HSD1 mRNA correlated with BMI in all subject</span></p>
<p style="top:611.7pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">groups in this study [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">44</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">]. Data from a subset of participants enrolled in the</span></p>
<p style="top:622.2pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">MONICA project found both higher overall 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">-HSD1 levels and higher</span></p>
<p style="top:632.6pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">-HSD1 mRNA levels were associated with obesity [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">46</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">]. Overall 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">-</span></p>
<p style="top:643.1pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">HSD1 levels were also associated with hyperinsulinemia in a study of</span></p>
<p style="top:653.5pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">high and low insulin fasting concentrations [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">46</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">]. A longitudinal study</span></p>
<p style="top:664.0pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">found 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">-HSD1 SAT expression in overweight and obese participants</span></p>
<p style="top:674.4pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">was decreased in with worsening glucose area under curve pro</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">les and</span></p>
<p style="top:684.9pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">increased in those with improving glucose pro</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">les [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">48</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">], suggested a pos-</span></p>
<p style="top:695.4pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">sible bene</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">cial aspect of higher SAT 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">-HSD1 expression.</span></p>
<p style="top:716.3pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT94c8263f.I,serif;font-size:8.0pt">3.1.2. Metabolic syndrome and obesity</span></p>
<p style="top:726.8pt;left:322.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">Two studies reported on 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">-HSD1 expression in participants with</span></p>
<p style="top:737.3pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">co-morbid MetS and obesity. Co-morbid obese and MetS participants</span></p>
<p style="top:121.5pt;left:135.2pt;line-height:8.3pt"><span style="font-family:Calibri,serif;font-size:8.3pt;color:#ffffff">Iden&#xfffd;&#xfb01;ca&#xfffd;on</span></p>
<p style="top:229.8pt;left:135.0pt;line-height:8.3pt"><span style="font-family:Calibri,serif;font-size:8.3pt;color:#ffffff">Screening</span></p>
<p style="top:346.6pt;left:135.0pt;line-height:8.3pt"><span style="font-family:Calibri,serif;font-size:8.3pt;color:#ffffff">Eligibility</span></p>
<p style="top:468.0pt;left:135.2pt;line-height:8.3pt"><span style="font-family:Calibri,serif;font-size:8.3pt;color:#ffffff">Included</span></p>
<p style="top:97.8pt;left:174.3pt;line-height:8.3pt"><span style="font-family:Calibri,serif;font-size:8.3pt">Records iden&#xfffd;&#xfb01;ed through </span></p>
<p style="top:107.8pt;left:170.8pt;line-height:8.3pt"><span style="font-family:Calibri,serif;font-size:8.3pt">database screening (n=4174)</span></p>
<p style="top:97.6pt;left:305.3pt;line-height:8.3pt"><span style="font-family:Calibri,serif;font-size:8.3pt">Records identi&#xfb01;ed through </span></p>
<p style="top:107.6pt;left:315.4pt;line-height:8.3pt"><span style="font-family:Calibri,serif;font-size:8.3pt">other sources (n=12)</span></p>
<p style="top:198.5pt;left:235.0pt;line-height:8.3pt"><span style="font-family:Calibri,serif;font-size:8.3pt">Records a&#xfffd;er duplicates </span></p>
<p style="top:208.6pt;left:244.6pt;line-height:8.3pt"><span style="font-family:Calibri,serif;font-size:8.3pt">removed (n=1920)</span></p>
<p style="top:203.3pt;left:366.9pt;line-height:8.3pt"><span style="font-family:Calibri,serif;font-size:8.3pt">Records excluded (n=1881)</span></p>
<p style="top:322.9pt;left:227.4pt;line-height:8.3pt"><span style="font-family:Calibri,serif;font-size:8.3pt">Full text ar&#xfffd;cles assessed for </span></p>
<p style="top:333.0pt;left:248.5pt;line-height:8.3pt"><span style="font-family:Calibri,serif;font-size:8.3pt">eligibility (n=39)</span></p>
<p style="top:329.5pt;left:360.2pt;line-height:8.3pt"><span style="font-family:Calibri,serif;font-size:8.3pt">Full text ar&#xfffd;cles excluded (n=9)</span></p>
<p style="top:339.6pt;left:373.2pt;line-height:8.3pt"><span style="font-family:Calibri,serif;font-size:8.3pt">Outcome of interest (5) </span></p>
<p style="top:349.7pt;left:390.4pt;line-height:8.3pt"><span style="font-family:Calibri,serif;font-size:8.3pt">Indica&#xfffd;on (2) </span></p>
<p style="top:359.8pt;left:376.7pt;line-height:8.3pt"><span style="font-family:Calibri,serif;font-size:8.3pt">Systema&#xfffd;c review (1) </span></p>
<p style="top:370.0pt;left:375.8pt;line-height:8.3pt"><span style="font-family:Calibri,serif;font-size:8.3pt">Pa&#xfffd;ent popula&#xfffd;on (3) </span></p>
<p style="top:440.8pt;left:225.0pt;line-height:8.3pt"><span style="font-family:Calibri,serif;font-size:8.3pt">Studies included in qualita&#xfffd;ve </span></p>
<p style="top:450.8pt;left:248.2pt;line-height:8.3pt"><span style="font-family:Calibri,serif;font-size:8.3pt">synthesis (n=28)</span></p>
<p style="top:524.9pt;left:261.0pt;line-height:6.4pt"><span style="font-family:AdvTT28000ce1.B,serif;font-size:6.4pt">Fig. 1.</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> PRISMA</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt"> &#xfb02;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">ow diagram.</span></p>
<p style="top:37.7pt;left:557.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">3</span></p>
<p style="top:37.7pt;left:199.2pt;line-height:6.4pt"><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">S. Gregory et al. / Metabolism Clinical and Experimental 108 (2020) 154246</span></p>


<p style="top:57.7pt;left:33.7pt;line-height:6.4pt"><span style="font-family:AdvTT28000ce1.B,serif;font-size:6.4pt">Table 1</span></p>
<p style="top:66.2pt;left:33.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Extracted data from studies included in narrative synthesis including description of study design, participants, statistical analysis, outcome measures and results. *ADCS-ADL =</span></p>
<p style="top:74.8pt;left:33.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Alzheimer&apos;s Disease Cooperative Study Activities of Daily Living Scale; ADAS-Cog = Alzheimer&apos;s Disease Assessment Scale-cognitive subscale; ALT = alanine transaminase; ANHLBI</span></p>
<p style="top:83.3pt;left:33.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">= American Heart Association and National Heart, Lung, and Blood Institute; AU = arbitrary units; AUC = area under curve; BMI = body mass index; CIBIS = Clinician Interview</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Based</span></p>
<p style="top:92.0pt;left:33.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Impression of Severity; DXA = Dual-energy X-ray absorptiometry; FBS = fasting blood sugar; HDL = high-density lipoprotein; HOMA-IR = homeostasis model assessment-insulin re-</span></p>
<p style="top:100.5pt;left:33.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">sistance; LDL = low-density lipoprotein; MetS = metabolic syndrome; MMSE = mini mental state examination; MRI = magnetic resonance imaging; mRNA = messenger ribonucleic</span></p>
<p style="top:109.1pt;left:33.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">acid; NPI: neuropsychiatric inventory; OGTT = oral glucose tolerance test; SAT = subcutaneous adipose tissue; SNP: single nucleotide polymorphism; VAT = visceral adipose tissue.</span></p>
<p style="top:123.6pt;left:39.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Study</span></p>
<p style="top:132.2pt;left:39.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">(Author,</span></p>
<p style="top:140.8pt;left:39.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">date)</span></p>
<p style="top:123.6pt;left:80.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Disease</span></p>
<p style="top:123.6pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Study design</span></p>
<p style="top:123.6pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Participants</span></p>
<p style="top:123.6pt;left:302.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Statistical analysis</span></p>
<p style="top:123.6pt;left:374.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Outcome measures</span></p>
<p style="top:123.6pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Description of</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt"> &#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">ndings</span></p>
<p style="top:153.8pt;left:39.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Crowley</span></p>
<p style="top:162.4pt;left:45.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">et al.,</span></p>
<p style="top:170.9pt;left:45.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">2019</span></p>
<p style="top:153.8pt;left:80.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Obesity</span></p>
<p style="top:153.8pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Analysis of longitudinal</span></p>
<p style="top:162.4pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">-HSD1 activity and</span></p>
<p style="top:170.9pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">expression in overweight</span></p>
<p style="top:179.5pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">and obese participants.</span></p>
<p style="top:188.0pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Following an overnight fast</span></p>
<p style="top:196.7pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">blood samples were taken,</span></p>
<p style="top:205.2pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">participants underwent a</span></p>
<p style="top:213.8pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">DXA total body scan for</span></p>
<p style="top:222.3pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">body composition analysis,</span></p>
<p style="top:230.9pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">provided a 24 h urine</span></p>
<p style="top:239.5pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">sample and underwent SAT</span></p>
<p style="top:248.0pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">biopsies under local</span></p>
<p style="top:256.6pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">anaesthetic. This was</span></p>
<p style="top:265.2pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">repeated at follow up (3.9 &#xb1;</span></p>
<p style="top:273.8pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">1.5 years)</span></p>
<p style="top:153.8pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">65 overweight or obese</span></p>
<p style="top:162.4pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">participants, 50.3 &#xb1; 7.3</span></p>
<p style="top:170.9pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">years, 62% male, BMI 33.7 &#xb1;</span></p>
<p style="top:179.5pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">4.3.</span></p>
<p style="top:153.8pt;left:302.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Paired</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt"> t-</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">tests,</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt"> t-</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">tests</span></p>
<p style="top:153.8pt;left:374.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">-HSD1 activity and</span></p>
<p style="top:162.4pt;left:374.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">-HSD1 mRNA expression</span></p>
<p style="top:170.9pt;left:374.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">from SAT.</span></p>
<p style="top:153.8pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">The cohort was divided into</span></p>
<p style="top:162.4pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">decliners and improvers</span></p>
<p style="top:170.9pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">based on change in glucose</span></p>
<p style="top:179.5pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">AUC. There was no</span></p>
<p style="top:188.0pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">relationship seen between</span></p>
<p style="top:196.7pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">urinary 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">-HSD1 activity</span></p>
<p style="top:205.2pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">and longitudinal change in</span></p>
<p style="top:213.8pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">glucose AUC. In contrast</span></p>
<p style="top:222.3pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">-HSD1 mRNA expression</span></p>
<p style="top:230.9pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">in SAT changed over time,</span></p>
<p style="top:239.5pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">with decreased expression</span></p>
<p style="top:248.0pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">in decliners and increased</span></p>
<p style="top:256.6pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">expression in improvers</span></p>
<p style="top:265.2pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">compared to baseline.</span></p>
<p style="top:273.8pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">-HSD1 was the only one</span></p>
<p style="top:282.3pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">of 52 genes studies that was</span></p>
<p style="top:290.9pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">differentially expression in</span></p>
<p style="top:299.4pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">the two groups at follow up</span></p>
<p style="top:308.0pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">(16.8 &#xb1; 2.1 vs. 14.4 &#xb1; 2.7,</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt"> p</span></p>
<p style="top:316.6pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT454a7a89,serif;font-size:6.4pt">b</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> 0.05). Decreasing</span></p>
<p style="top:325.2pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">-HSD1 expression over</span></p>
<p style="top:333.7pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">time was also associated</span></p>
<p style="top:342.3pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">with increasing glucose AUC</span></p>
<p style="top:350.9pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">(</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">r</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> =</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:6.4pt"> &#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">0.4,</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt"> P</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> = 0.04).</span></p>
<p style="top:359.4pt;left:39.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Desbriere</span></p>
<p style="top:368.0pt;left:45.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">et al.,</span></p>
<p style="top:376.5pt;left:45.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">2006</span></p>
<p style="top:359.4pt;left:80.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Obesity</span></p>
<p style="top:359.4pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Analysis of 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">-HSD1 mRNA</span></p>
<p style="top:368.0pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">levels in lean and obese</span></p>
<p style="top:376.5pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">women. Percentage body fat</span></p>
<p style="top:385.1pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">was assessed by</span></p>
<p style="top:393.7pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">impedancemetry.</span></p>
<p style="top:402.3pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Abdominal SAT and VAT</span></p>
<p style="top:410.8pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">biopsies were collected via</span></p>
<p style="top:419.4pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">laparotomy or laparoscopy.</span></p>
<p style="top:359.4pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">22 participants either lean</span></p>
<p style="top:368.0pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">(</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">n</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> = 10) or obese (</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">n</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> = 12),</span></p>
<p style="top:376.5pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">aged 23</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">50 years, 100%</span></p>
<p style="top:385.1pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">female. Mean BMI for lean</span></p>
<p style="top:393.7pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">group 21.1 +</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:6.4pt"> &#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">0.7 kg/m</span><sup><span style="font-family:AdvTT5235d5a9,serif;font-size:4.5pt">2</span></sup><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">,</span></p>
<p style="top:402.3pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">mean BMI for obese group</span></p>
<p style="top:410.9pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">37.9 &#xb1; 1.5 kg/m</span><sup><span style="font-family:AdvTT5235d5a9,serif;font-size:4.5pt">2</span></sup><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">.</span></p>
<p style="top:359.4pt;left:302.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Unpaired student</span></p>
<p style="top:368.0pt;left:302.9pt;line-height:6.4pt"><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">t</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">-test, Mann-Whitney</span></p>
<p style="top:376.6pt;left:302.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">U, Wilcoxon, Spear-</span></p>
<p style="top:385.1pt;left:302.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">man correlation</span></p>
<p style="top:359.4pt;left:374.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Expression of 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">-HSD1</span></p>
<p style="top:368.0pt;left:374.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">mRNA, biochemical and</span></p>
<p style="top:376.6pt;left:374.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">anthropometric parameters.</span></p>
<p style="top:359.4pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">In obese patients, 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">-HSD1</span></p>
<p style="top:368.0pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">mRNA concentrations were</span></p>
<p style="top:376.6pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">increased in both SAT and</span></p>
<p style="top:385.1pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">VAT as compared with lean</span></p>
<p style="top:393.7pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">women (data extracted</span></p>
<p style="top:402.3pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">from graph: subcutaneous:</span></p>
<p style="top:410.9pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">3.63 AU vs 0.47 AU,</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt"> p</span><span style="font-family:AdvTT454a7a89,serif;font-size:6.4pt"> b</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> 0.05;</span></p>
<p style="top:419.4pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">visceral: 2.17 AU vs 0.45 AU,</span></p>
<p style="top:428.0pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">p</span><span style="font-family:AdvTT454a7a89,serif;font-size:6.4pt"> b</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> 0.05). The levels of VAT</span></p>
<p style="top:436.5pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">11-HSD-1 correlating with</span></p>
<p style="top:445.1pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">anthropometric parameters</span></p>
<p style="top:453.7pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">were: BMI (</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">r</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> = 0.41,</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt"> p</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> =</span></p>
<p style="top:462.3pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">0.05), waist circumference</span></p>
<p style="top:470.8pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">(</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">r</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> = 0.44, p 0.04),</span></p>
<p style="top:479.4pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">abdominal sagittal diameter</span></p>
<p style="top:488.0pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">(r 0.51,</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt"> p</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> = 0.02), and</span></p>
<p style="top:496.5pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">percentage fat (</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">r</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> = 0.51, p</span></p>
<p style="top:505.1pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">0.02). Although there was a</span></p>
<p style="top:513.6pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">signi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">cant difference in age</span></p>
<p style="top:522.3pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">between the groups, there</span></p>
<p style="top:530.8pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">was no effect of age per se</span></p>
<p style="top:539.4pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">on 11-HSD-1 expression (</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">r</span></p>
<p style="top:547.9pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">= 0.29,</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt"> p</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> = 0.19 and</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt"> r</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> =</span></p>
<p style="top:556.5pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">0.21,</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt"> p</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> = 0.36 in SAT and</span></p>
<p style="top:565.1pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">VAT, respectively). There</span></p>
<p style="top:573.6pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">was a signi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">cant correlation</span></p>
<p style="top:582.2pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">between 11-HSD-1 and</span></p>
<p style="top:590.8pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">H6PDH mRNA levels in both</span></p>
<p style="top:599.4pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">SAT and VAT (</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">r</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> = 0.43,</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt"> p</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> =</span></p>
<p style="top:607.9pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">0.049, and r = 0.44,</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt"> p</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> =</span></p>
<p style="top:616.5pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">0.042, respectively)</span></p>
<p style="top:625.0pt;left:39.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Lindsay</span></p>
<p style="top:633.6pt;left:45.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">et al.,</span></p>
<p style="top:642.2pt;left:45.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">2003</span></p>
<p style="top:625.0pt;left:80.0pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Obesity</span></p>
<p style="top:625.0pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Analysis of 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">-HSD1 mRNA</span></p>
<p style="top:633.6pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">levels in obese Caucasian</span></p>
<p style="top:642.2pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">and Pima Indian partici-</span></p>
<p style="top:650.7pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">pants. Subcutaneous adi-</span></p>
<p style="top:659.3pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">pose fat biopsies were</span></p>
<p style="top:667.9pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">collected from participants</span></p>
<p style="top:676.5pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">as well as plasma glucose</span></p>
<p style="top:685.0pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">samples and body composi-</span></p>
<p style="top:693.6pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">tion measurements.</span></p>
<p style="top:625.0pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">19 Pima Indian (10 male, 9</span></p>
<p style="top:633.6pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">female, age 29.5 &#xb1; 7.4 years,</span></p>
<p style="top:642.2pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">BMI 34.6 &#xb1; 6.7 kg/m</span><sup><span style="font-family:AdvTT5235d5a9,serif;font-size:4.5pt">2</span></sup><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">), 12</span></p>
<p style="top:650.7pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Caucasian (7 male, 5 female,</span></p>
<p style="top:659.3pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">age 27.6 &#xb1; 8.1 years, BMI</span></p>
<p style="top:667.9pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">36.6 &#xb1; 8.6 kg/m</span><sup><span style="font-family:AdvTT5235d5a9,serif;font-size:4.5pt">2</span></sup><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">).</span></p>
<p style="top:625.0pt;left:302.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Pearson correlation,</span></p>
<p style="top:633.6pt;left:302.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">general linear</span></p>
<p style="top:642.2pt;left:302.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">modelling</span></p>
<p style="top:625.0pt;left:374.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">-HSD1 activity levels,</span></p>
<p style="top:633.6pt;left:374.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">-HSD1 mRNA</span></p>
<p style="top:642.2pt;left:374.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">expression, association with</span></p>
<p style="top:650.7pt;left:374.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">obesity variables</span></p>
<p style="top:625.0pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">-HSD1 activity was</span></p>
<p style="top:633.6pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">signi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">cantly associated with</span></p>
<p style="top:642.2pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">BMI (0.68,</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt"> p</span><span style="font-family:AdvTT454a7a89,serif;font-size:6.4pt"> b</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> 0.05),</span></p>
<p style="top:650.7pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">percentage body fat (0.48, p</span></p>
<p style="top:659.3pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT454a7a89,serif;font-size:6.4pt">b</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> 0.05), waist circumference</span></p>
<p style="top:667.9pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">(0.52, p</span><span style="font-family:AdvTT454a7a89,serif;font-size:6.4pt"> b</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> 0.05), fasting</span></p>
<p style="top:676.5pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">glucose (0.43, p</span><span style="font-family:AdvTT454a7a89,serif;font-size:6.4pt"> b</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> 0.05),</span></p>
<p style="top:685.0pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">fasting insulin (0.60, p</span><span style="font-family:AdvTT454a7a89,serif;font-size:6.4pt"> b</span></p>
<p style="top:693.6pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">0.05) and HOMA-IR (0.70, p</span></p>
<p style="top:702.1pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT454a7a89,serif;font-size:6.4pt">b</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> .05). It was not associated</span></p>
<p style="top:710.7pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">with 2-h glucose (0.08,</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt"> p</span><span style="font-family:AdvTT454a7a89,serif;font-size:6.4pt"> N</span></p>
<p style="top:719.3pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">0.05). 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">-HSD1 mRNA</span></p>
<p style="top:727.9pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">expression was signi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">cantly</span></p>
<p style="top:37.7pt;left:33.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">4</span></p>
<p style="top:37.7pt;left:190.4pt;line-height:6.4pt"><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">S. Gregory et al. / Metabolism Clinical and Experimental 108 (2020) 154246</span></p>


<p style="top:57.7pt;left:42.5pt;line-height:6.4pt"><span style="font-family:AdvTT28000ce1.B,serif;font-size:6.4pt">Table 1</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> (</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">continued</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">)</span></p>
<p style="top:72.2pt;left:48.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Study</span></p>
<p style="top:80.8pt;left:48.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">(Author,</span></p>
<p style="top:89.3pt;left:48.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">date)</span></p>
<p style="top:72.2pt;left:88.8pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Disease</span></p>
<p style="top:72.2pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Study design</span></p>
<p style="top:72.2pt;left:222.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Participants</span></p>
<p style="top:72.2pt;left:311.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Statistical analysis</span></p>
<p style="top:72.2pt;left:383.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Outcome measures</span></p>
<p style="top:72.2pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Description of</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt"> &#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">ndings</span></p>
<p style="top:102.4pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">associated with BMI (0.34, p</span></p>
<p style="top:110.9pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT454a7a89,serif;font-size:6.4pt">b</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> 0.05), fasting insulin (0.42,</span></p>
<p style="top:119.5pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">p</span><span style="font-family:AdvTT454a7a89,serif;font-size:6.4pt"> b</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> 0.05) and HOMA-IR</span></p>
<p style="top:128.1pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">(0.46, p</span><span style="font-family:AdvTT454a7a89,serif;font-size:6.4pt"> b</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> 0.05). It was not</span></p>
<p style="top:136.7pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">associated with percentage</span></p>
<p style="top:145.2pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">body fat (0.15), waist</span></p>
<p style="top:153.8pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">circumference (0.26),</span></p>
<p style="top:162.4pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">fasting glucose (0.19) or 2-h</span></p>
<p style="top:170.9pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">glucose (0.09), with all</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt"> p</span></p>
<p style="top:179.5pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">values</span><span style="font-family:AdvTT454a7a89,serif;font-size:6.4pt"> N</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">0.05.</span></p>
<p style="top:188.1pt;left:48.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Mariniello</span></p>
<p style="top:196.7pt;left:54.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">et al.,</span></p>
<p style="top:205.2pt;left:54.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">2006</span></p>
<p style="top:188.0pt;left:88.8pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Obesity</span></p>
<p style="top:188.0pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Analysis of 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">-HSD1</span></p>
<p style="top:196.7pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">expression in simple obesity</span></p>
<p style="top:205.2pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">and Cushing&apos;s syndrome.</span></p>
<p style="top:213.8pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Participants provided</span></p>
<p style="top:222.3pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">omental tissue, body</span></p>
<p style="top:230.9pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">composition data (weight,</span></p>
<p style="top:239.5pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">height, BMI), blood pressure</span></p>
<p style="top:248.0pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">recorded and blood sample</span></p>
<p style="top:256.6pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">for biochemical analysis.</span></p>
<p style="top:188.0pt;left:222.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">24 participants, BMI of</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:6.4pt"> &#x2264;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">25</span></p>
<p style="top:196.7pt;left:222.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">kg/m</span><sup><span style="font-family:AdvTT5235d5a9,serif;font-size:4.5pt">2</span></sup><sup><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> </span></sup><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">was classi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">ed as</span></p>
<p style="top:205.2pt;left:222.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">normal, 25</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">30 kg/m</span><sup><span style="font-family:AdvTT5235d5a9,serif;font-size:4.5pt">2</span></sup></p>
<p style="top:213.8pt;left:222.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">overweight and</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:6.4pt"> &#x2265;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">30 kg/m</span><sup><span style="font-family:AdvTT5235d5a9,serif;font-size:4.5pt">2</span></sup></p>
<p style="top:222.4pt;left:222.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">obese.</span></p>
<p style="top:188.1pt;left:311.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">ANOVA</span></p>
<p style="top:188.1pt;left:383.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Expression of 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">-HSD1</span></p>
<p style="top:196.7pt;left:383.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">mRNA</span></p>
<p style="top:188.1pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Obese participants had</span></p>
<p style="top:196.7pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">signi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">cantly higher</span></p>
<p style="top:205.2pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">-HSD1 mRNA levels</span></p>
<p style="top:213.8pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">compared to controls and</span></p>
<p style="top:222.4pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Cushing&apos;s participants</span></p>
<p style="top:230.9pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">(13.62 &#xb1; 0.15 vs 17.31 &#xb1;</span></p>
<p style="top:239.5pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">0.58 vs 17.37 &#xb1; 0.68,</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt"> p</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> =</span></p>
<p style="top:248.0pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">0.001). There was a</span></p>
<p style="top:256.6pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">signi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">cant positive</span></p>
<p style="top:265.2pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">correlation between</span></p>
<p style="top:273.8pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">-HSD1 mRNA expression</span></p>
<p style="top:282.3pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">and BMI in all subject groups</span></p>
<p style="top:290.9pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">(</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">r</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> = 0.734,</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt"> p</span><span style="font-family:AdvTT454a7a89,serif;font-size:6.4pt"> b</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> 0.001).</span></p>
<p style="top:299.5pt;left:48.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Munoz</span></p>
<p style="top:308.0pt;left:54.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">et al.,</span></p>
<p style="top:316.6pt;left:54.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">2009</span></p>
<p style="top:299.5pt;left:88.8pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Obesity</span></p>
<p style="top:299.5pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Analysis of 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">-HSD1</span></p>
<p style="top:308.0pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">expression in SAT and VAT</span></p>
<p style="top:316.6pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">in a Chilean population and</span></p>
<p style="top:325.2pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">evaluate associations with</span></p>
<p style="top:333.7pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">features of metabolic syn-</span></p>
<p style="top:342.3pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">drome. SAT and VAT biop-</span></p>
<p style="top:350.9pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">sies were collected during</span></p>
<p style="top:359.4pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">routine surgery. Participants</span></p>
<p style="top:368.0pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">also provided blood samples</span></p>
<p style="top:376.6pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">for biochemical analysis and</span></p>
<p style="top:385.1pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">records were used for</span></p>
<p style="top:393.7pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">demographic and body</span></p>
<p style="top:402.3pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">composition data.</span></p>
<p style="top:299.4pt;left:222.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">32 morbidly obese</span></p>
<p style="top:308.0pt;left:222.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">participants meeting criteria</span></p>
<p style="top:316.6pt;left:222.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">for surgical treatment for</span></p>
<p style="top:325.2pt;left:222.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">obesity, mean age 44.5 &#xb1; 12</span></p>
<p style="top:333.7pt;left:222.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">years (female), 46.4 &#xb1; 16</span></p>
<p style="top:342.3pt;left:222.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">years (male), 34.4% male.</span></p>
<p style="top:299.4pt;left:311.6pt;line-height:6.4pt"><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">t</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">-test, Man-Whitney,</span></p>
<p style="top:308.0pt;left:311.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Kruskal-Wallis, Chi</span></p>
<p style="top:316.6pt;left:311.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">square, Fisher exact</span></p>
<p style="top:325.2pt;left:311.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">test, Spearman</span></p>
<p style="top:333.7pt;left:311.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">correlation</span></p>
<p style="top:299.4pt;left:383.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Expression of 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">-HSD1</span></p>
<p style="top:308.0pt;left:383.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">mRNA in adipose tissue,</span></p>
<p style="top:316.6pt;left:383.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">cholesterol, triglycerides,</span></p>
<p style="top:325.2pt;left:383.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">fasting glucose, fasting</span></p>
<p style="top:333.7pt;left:383.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">insulin.</span></p>
<p style="top:299.4pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">There were higher levels of</span></p>
<p style="top:308.0pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">-HSD1 mRNA in SAT</span></p>
<p style="top:316.6pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">compared to VAT samples</span></p>
<p style="top:325.2pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">(data extracted from graph:</span></p>
<p style="top:333.7pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">12.42 AU vs 8.07 AU,</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt"> p</span><span style="font-family:AdvTT454a7a89,serif;font-size:6.4pt"> b</span></p>
<p style="top:342.3pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">0.05). SAT 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">-HSD1 mRNA</span></p>
<p style="top:350.9pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">levels increased consistently</span></p>
<p style="top:359.4pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">with obesity levels (data</span></p>
<p style="top:368.0pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">extracted from graph: BMI</span></p>
<p style="top:376.5pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">30</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">34: 9.43 AU, p</span><span style="font-family:AdvTT454a7a89,serif;font-size:6.4pt"> b</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> 0.05;</span></p>
<p style="top:385.1pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">BMI 35</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">39: 12.02 AU, p</span><span style="font-family:AdvTT454a7a89,serif;font-size:6.4pt"> b</span></p>
<p style="top:393.7pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">0.05; BMI 40</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">49: 19.07 AU,</span></p>
<p style="top:402.3pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">p</span><span style="font-family:AdvTT454a7a89,serif;font-size:6.4pt"> b</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> 0.05) and correlated</span></p>
<p style="top:410.8pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">positively with hip</span></p>
<p style="top:419.4pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">circumference (</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">r</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> = 0.66,</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt"> p</span></p>
<p style="top:428.0pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">= 0.018) but not waist</span></p>
<p style="top:436.5pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">circumference (</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">r</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> = 0.48,</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt"> p</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:6.4pt"> &#x2265;</span></p>
<p style="top:445.1pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">0.05). There were no</span></p>
<p style="top:453.6pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">changes with VAT with</span></p>
<p style="top:462.3pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">levels of obesity or hip or</span></p>
<p style="top:470.8pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">waist circumference. There</span></p>
<p style="top:479.4pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">were no correlations</span></p>
<p style="top:487.9pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">between SAT and VAT with</span></p>
<p style="top:496.5pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">fasting glucose, triglycerides</span></p>
<p style="top:505.1pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">or HDL. There was no</span></p>
<p style="top:513.6pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">signi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">cant difference in SAT</span></p>
<p style="top:522.2pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">and VAT 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">-HSD1</span></p>
<p style="top:530.8pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">expression between</span></p>
<p style="top:539.4pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">participants with and</span></p>
<p style="top:547.9pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">without metabolic</span></p>
<p style="top:556.5pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">syndrome.</span></p>
<p style="top:565.0pt;left:48.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Nixon</span></p>
<p style="top:573.6pt;left:54.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">et al.,</span></p>
<p style="top:582.2pt;left:54.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">2012</span></p>
<p style="top:565.0pt;left:88.8pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Obesity</span></p>
<p style="top:565.0pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Evaluation of salicylate in</span></p>
<p style="top:573.6pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">obesity. Participants were</span></p>
<p style="top:582.2pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">randomised to either</span></p>
<p style="top:590.8pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">placebo or salsalate 1 g</span></p>
<p style="top:599.4pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">every 8 h for 2 weeks orally,</span></p>
<p style="top:607.9pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">followed by a 2-week</span></p>
<p style="top:616.5pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">washout period leading to a</span></p>
<p style="top:625.0pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">crossover of treatment.</span></p>
<p style="top:565.1pt;left:222.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">16 healthy participants with</span></p>
<p style="top:573.6pt;left:222.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">BMI from 20 kg/m</span><sup><span style="font-family:AdvTT5235d5a9,serif;font-size:4.5pt">2</span></sup><sup><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> </span></sup><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">to 50</span></p>
<p style="top:582.2pt;left:222.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">kg/m</span><sup><span style="font-family:AdvTT5235d5a9,serif;font-size:4.5pt">2</span></sup><sup><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> </span></sup><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">(average BMI</span></p>
<p style="top:590.8pt;left:222.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">placebo: 31.9 &#xb1; 8.0 kg/m</span><sup><span style="font-family:AdvTT5235d5a9,serif;font-size:4.5pt">2</span></sup><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">;</span></p>
<p style="top:599.4pt;left:222.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">salicylate: 32.0 &#xb1; 8.0</span></p>
<p style="top:607.9pt;left:222.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">kg/m</span><sup><span style="font-family:AdvTT5235d5a9,serif;font-size:4.5pt">2</span></sup><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">), mean age 40.1</span></p>
<p style="top:616.5pt;left:222.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">(&#xb1;10) years, 100% male</span></p>
<p style="top:565.1pt;left:311.6pt;line-height:6.4pt"><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">t</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">-test, ANOVA</span></p>
<p style="top:565.1pt;left:383.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Waist to hip ratio, percent</span></p>
<p style="top:573.6pt;left:383.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">body fat, systolic and</span></p>
<p style="top:582.2pt;left:383.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">diastolic blood pressure,</span></p>
<p style="top:590.8pt;left:383.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">fasting triglycerides, fasting</span></p>
<p style="top:599.4pt;left:383.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">total cholesterol, fasting LDL,</span></p>
<p style="top:607.9pt;left:383.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">fasting HDL, fasting glucose</span></p>
<p style="top:616.5pt;left:383.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">levels, fasting insulin levels,</span></p>
<p style="top:625.0pt;left:383.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">adipose 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">-HSD1 mRNA</span></p>
<p style="top:565.1pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">There were no signi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">cant</span></p>
<p style="top:573.6pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">differences between</span></p>
<p style="top:582.2pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">treatment groups on any</span></p>
<p style="top:590.8pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">anthropometric or</span></p>
<p style="top:599.4pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">biochemical measures.</span></p>
<p style="top:607.9pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">There were lower levels of</span></p>
<p style="top:616.5pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">-HSD1 mRNA in adipose</span></p>
<p style="top:625.0pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">tissue in participants treated</span></p>
<p style="top:633.6pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">with salicylate compared to</span></p>
<p style="top:642.2pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">placebo (data extracted</span></p>
<p style="top:650.7pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">from graph: 0.65 AU vs 0.99</span></p>
<p style="top:659.3pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">AU, p</span><span style="font-family:AdvTT454a7a89,serif;font-size:6.4pt"> b</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> 0.05).</span></p>
<p style="top:667.9pt;left:48.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Sandeep</span></p>
<p style="top:676.5pt;left:54.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">et al.,</span></p>
<p style="top:685.0pt;left:54.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">2005</span></p>
<p style="top:667.9pt;left:88.8pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Obesity</span></p>
<p style="top:667.9pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Evaluation of carbenoxolone</span></p>
<p style="top:676.5pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">on 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">-HSD1 activity and</span></p>
<p style="top:685.0pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">insulin sensitivity in obese</span></p>
<p style="top:693.6pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">men. Obese men were</span></p>
<p style="top:702.1pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">randomised to placebo or</span></p>
<p style="top:710.7pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">carbenoxolone 100 mg</span></p>
<p style="top:719.3pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">every 8 h orally for 7 days,</span></p>
<p style="top:667.9pt;left:222.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">12 participants, half lean</span></p>
<p style="top:676.5pt;left:222.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">and half obese, age 20</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">50</span></p>
<p style="top:685.0pt;left:222.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">years 100% male.</span></p>
<p style="top:667.9pt;left:311.6pt;line-height:6.4pt"><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">t</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">-test, ANOVA</span></p>
<p style="top:667.9pt;left:383.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Metabolite excretion, D3</span></p>
<p style="top:676.5pt;left:383.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">cortisol presence, glucose</span></p>
<p style="top:685.0pt;left:383.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">kinetics, glucose</span></p>
<p style="top:693.6pt;left:383.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">concentration, insulin</span></p>
<p style="top:702.1pt;left:383.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">concentration</span></p>
<p style="top:667.9pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Obese subjects had</span></p>
<p style="top:676.5pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">signi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">cantly higher total</span></p>
<p style="top:685.0pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">cortisol metabolites and</span></p>
<p style="top:693.6pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">5</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">THE in excretion</span></p>
<p style="top:702.1pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">compared to lean subjects</span></p>
<p style="top:710.7pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">(21.16 &#xb1; 1.90 vs 14.04 &#xb1;</span></p>
<p style="top:719.3pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">1.24,</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt"> p</span><span style="font-family:AdvTT454a7a89,serif;font-size:6.4pt"> b</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> 0.01; 11.89 &#xb1; 1.26</span></p>
<p style="top:732.4pt;left:484.8pt;line-height:6.4pt"><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">(continued on next page)</span></p>
<p style="top:37.7pt;left:557.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">5</span></p>
<p style="top:37.7pt;left:199.2pt;line-height:6.4pt"><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">S. Gregory et al. / Metabolism Clinical and Experimental 108 (2020) 154246</span></p>


<p style="top:57.7pt;left:33.7pt;line-height:6.4pt"><span style="font-family:AdvTT28000ce1.B,serif;font-size:6.4pt">Table 1</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> (</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">continued</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">)</span></p>
<p style="top:72.2pt;left:39.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Study</span></p>
<p style="top:80.8pt;left:39.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">(Author,</span></p>
<p style="top:89.3pt;left:39.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">date)</span></p>
<p style="top:72.2pt;left:80.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Disease</span></p>
<p style="top:72.2pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Study design</span></p>
<p style="top:72.2pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Participants</span></p>
<p style="top:72.2pt;left:302.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Statistical analysis</span></p>
<p style="top:72.2pt;left:374.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Outcome measures</span></p>
<p style="top:72.2pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Description of</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt"> &#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">ndings</span></p>
<p style="top:102.4pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">followed by a 2 week wash</span></p>
<p style="top:110.9pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">out period leading to cross</span></p>
<p style="top:119.5pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">over of treatment.</span></p>
<p style="top:128.1pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Participants provided 24-h</span></p>
<p style="top:136.7pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">urine collections, fasted</span></p>
<p style="top:145.2pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">blood samples, body</span></p>
<p style="top:153.8pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">composition measurements</span></p>
<p style="top:162.4pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">(height, weight, hip and</span></p>
<p style="top:170.9pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">waist circumference, blood</span></p>
<p style="top:179.5pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">pressure) and euglycemic</span></p>
<p style="top:188.1pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">clamp. Lean participants</span></p>
<p style="top:196.7pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">attended only once for</span></p>
<p style="top:205.2pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">measurements without</span></p>
<p style="top:213.8pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">medication.</span></p>
<p style="top:102.4pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">vs 4.50 &#xb1; 0.58,</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt"> p</span><span style="font-family:AdvTT454a7a89,serif;font-size:6.4pt"> b</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> 0.001), as</span></p>
<p style="top:110.9pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">well as lower 5</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt">&#x3b1;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">THF and</span></p>
<p style="top:119.5pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">(5</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt">&#x3b1;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">THF +</span></p>
<p style="top:128.1pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">5</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">THF)-to-5</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">THE (3.62 &#xb1;</span></p>
<p style="top:136.7pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">0.49 vs 5.91 &#xb1; 0.63, p</span><span style="font-family:AdvTT454a7a89,serif;font-size:6.4pt"> b</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> 0.05;</span></p>
<p style="top:145.2pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">0.57 &#xb1; 0.11 vs 1.79 &#xb1; 0.20, p</span></p>
<p style="top:153.8pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT454a7a89,serif;font-size:6.4pt">b</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> 0.001). Carbenoxolone</span></p>
<p style="top:162.4pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">treatment did not affect</span></p>
<p style="top:170.9pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">glucose or insulin</span></p>
<p style="top:179.5pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">concentrations, glucose</span></p>
<p style="top:188.0pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">infusion rate, glucose</span></p>
<p style="top:196.7pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">disposal or glucose</span></p>
<p style="top:205.2pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">production rates compared</span></p>
<p style="top:213.8pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">to placebo.</span></p>
<p style="top:222.3pt;left:39.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Rask et al.,</span></p>
<p style="top:230.9pt;left:45.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">2002</span></p>
<p style="top:222.3pt;left:80.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Obesity</span></p>
<p style="top:222.3pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Analysis of 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">-HSD1</span></p>
<p style="top:230.9pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">expression in adipose tissue</span></p>
<p style="top:239.5pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">in a subgroup of obese</span></p>
<p style="top:248.0pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">participants. Participants</span></p>
<p style="top:256.6pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">provided body composition</span></p>
<p style="top:265.2pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">data, blood tests and</span></p>
<p style="top:273.8pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">subcutaneous fat samples.</span></p>
<p style="top:222.3pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">14 participants participated</span></p>
<p style="top:230.9pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">in the 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">-HSD1 expression</span></p>
<p style="top:239.5pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">sub-study, median BMI 24.8,</span></p>
<p style="top:248.0pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">no other data provided.</span></p>
<p style="top:222.3pt;left:302.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Correlation</span></p>
<p style="top:222.3pt;left:374.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">-HSD1 expression</span></p>
<p style="top:222.3pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">-HSD1 activity increased</span></p>
<p style="top:230.9pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">in subcutaneous fat as</span></p>
<p style="top:239.5pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">obesity increased,</span></p>
<p style="top:248.0pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">correlation between BMI</span></p>
<p style="top:256.6pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">and AUC of enzyme activity</span></p>
<p style="top:265.2pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">(</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">r</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> = 0.55, p</span><span style="font-family:AdvTT454a7a89,serif;font-size:6.4pt"> b</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> 0.05).</span></p>
<p style="top:282.3pt;left:39.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Shao et al.,</span></p>
<p style="top:290.9pt;left:45.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">2016</span></p>
<p style="top:282.3pt;left:80.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Obesity</span></p>
<p style="top:282.3pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Analysis of 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">-HSD1</span></p>
<p style="top:290.9pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">expression in adipose tissue</span></p>
<p style="top:299.5pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">in obese participants.</span></p>
<p style="top:308.0pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Participants provided body</span></p>
<p style="top:316.6pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">composition data (height,</span></p>
<p style="top:325.2pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">weight, waist and hip</span></p>
<p style="top:333.7pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">circumference, BMI,</span></p>
<p style="top:342.3pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">waist-to-hip ration and</span></p>
<p style="top:350.9pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">blood pressure), and blood</span></p>
<p style="top:359.4pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">samples for biochemical</span></p>
<p style="top:368.0pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">analysis. VAT samples were</span></p>
<p style="top:376.6pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">collected during surgical</span></p>
<p style="top:385.1pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">procedures.</span></p>
<p style="top:282.3pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">23 participants undergoing</span></p>
<p style="top:290.9pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">abdominal surgery, split into</span></p>
<p style="top:299.4pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">control (</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">n</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> = 10, BMI</span><span style="font-family:AdvTT454a7a89,serif;font-size:6.4pt"> b</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> 28</span></p>
<p style="top:308.0pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">kg/m2) and obese (</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">n</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> = 13,</span></p>
<p style="top:316.6pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">BMI</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:6.4pt"> &#x2265;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">28 kg/m</span><sup><span style="font-family:AdvTT5235d5a9,serif;font-size:4.5pt">2</span></sup><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">), age 32.5 &#xb1;</span></p>
<p style="top:325.2pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">10.1 years (control), 36.3 &#xb1;</span></p>
<p style="top:333.8pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">17.6 years (obese), 39%</span></p>
<p style="top:342.3pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">male.</span></p>
<p style="top:282.3pt;left:302.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Spearman correlation</span></p>
<p style="top:282.3pt;left:374.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">-HSD1 expression,</span></p>
<p style="top:290.9pt;left:374.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">waist-to-hip ratio, BMI,</span></p>
<p style="top:299.5pt;left:374.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">HOMA-IR, fasting insulin,</span></p>
<p style="top:308.0pt;left:374.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">cholesterol and triglycerides</span></p>
<p style="top:282.3pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">mRNA levels of 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">-HSD1</span></p>
<p style="top:290.9pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">were higher in obese group</span></p>
<p style="top:299.5pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">compared to the control</span></p>
<p style="top:308.0pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">group (data extracted from</span></p>
<p style="top:316.6pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">graph; 145.98% vs 100%, p</span><span style="font-family:AdvTT454a7a89,serif;font-size:6.4pt"> b</span></p>
<p style="top:325.2pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">0.01). 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">-HSD1 expression</span></p>
<p style="top:333.8pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">was associated with</span></p>
<p style="top:342.3pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">waist-to-hip ratio (</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">r</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> =</span></p>
<p style="top:350.9pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">0.5851,</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt"> p</span><span style="font-family:AdvTT454a7a89,serif;font-size:6.4pt"> b</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> 0.0001), BMI (</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">r</span></p>
<p style="top:359.4pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">= 0.4952, p</span><span style="font-family:AdvTT454a7a89,serif;font-size:6.4pt"> b</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> 0.0001),</span></p>
<p style="top:368.0pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">HOMA-IR (</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">r</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> = 0.4637, p</span><span style="font-family:AdvTT454a7a89,serif;font-size:6.4pt"> b</span></p>
<p style="top:376.6pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">0.0001), fasting insulin (</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">r</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> =</span></p>
<p style="top:385.1pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">0.2547, p</span><span style="font-family:AdvTT454a7a89,serif;font-size:6.4pt"> b</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> 0.01), total</span></p>
<p style="top:393.7pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">cholesterol (</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">r</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> = 0.1442, p</span><span style="font-family:AdvTT454a7a89,serif;font-size:6.4pt"> b</span></p>
<p style="top:402.3pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">0.05) and triglycerides (</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">r</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> =</span></p>
<p style="top:410.9pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">0.1974, p</span><span style="font-family:AdvTT454a7a89,serif;font-size:6.4pt"> b</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> 0.01).</span></p>
<p style="top:419.4pt;left:39.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Wake et al.,</span></p>
<p style="top:428.0pt;left:45.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">2003</span></p>
<p style="top:419.4pt;left:80.0pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Obesity</span></p>
<p style="top:419.4pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Analysis of transcriptional</span></p>
<p style="top:428.0pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">upregulation of 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">-HSD1</span></p>
<p style="top:436.5pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">in obesity, associations</span></p>
<p style="top:445.1pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">between 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">-HSD1 and</span></p>
<p style="top:453.7pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">variations in</span></p>
<p style="top:462.3pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">cortisol/cortisone</span></p>
<p style="top:470.8pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">metabolite rate and</span></p>
<p style="top:479.4pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">associations between</span></p>
<p style="top:488.0pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">-HSD1 gene</span></p>
<p style="top:496.5pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">transcription and cortisol</span></p>
<p style="top:505.1pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">intra-adipose levels.</span></p>
<p style="top:513.6pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Participants provided SAT</span></p>
<p style="top:522.2pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">samples via biopsy,</span></p>
<p style="top:530.8pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">alongside anthropometry,</span></p>
<p style="top:539.4pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">blood pressure and body</span></p>
<p style="top:547.9pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">composition measurements.</span></p>
<p style="top:556.5pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Participants also underwent</span></p>
<p style="top:565.1pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">euglycemic hyperinsulemic</span></p>
<p style="top:573.6pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">clamps and provided 24 h</span></p>
<p style="top:582.2pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">urine samples.</span></p>
<p style="top:419.4pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">32 participants representing</span></p>
<p style="top:428.0pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">high and low fasting insulin</span></p>
<p style="top:436.5pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">concentrations and a range</span></p>
<p style="top:445.1pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">of BMIs, recruited as sample</span></p>
<p style="top:453.6pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">from the larger MONICA</span></p>
<p style="top:462.3pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">project, age 53 &#xb1; 3 years</span></p>
<p style="top:470.8pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">(male) and 57 &#xb1; 3 years</span></p>
<p style="top:479.4pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">(female), 50% male.</span></p>
<p style="top:419.4pt;left:302.8pt;line-height:6.4pt"><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">t</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">-tests, multiple</span></p>
<p style="top:428.0pt;left:302.8pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">regression</span></p>
<p style="top:419.4pt;left:374.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">-HSD1 activity,</span></p>
<p style="top:428.0pt;left:374.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">-HSD1 mRNA levels</span></p>
<p style="top:419.4pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Higher 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">-HSD1</span></p>
<p style="top:428.0pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">(expressed as area under the</span></p>
<p style="top:436.5pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">curve) was associated with</span></p>
<p style="top:445.1pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">obesity, log fasting</span></p>
<p style="top:453.6pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">hyperinsulinemia and</span></p>
<p style="top:462.3pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">conversion of oral cortisone</span></p>
<p style="top:470.8pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">to plasma cortisol (log)</span></p>
<p style="top:479.4pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">(0.48, p</span><span style="font-family:AdvTT454a7a89,serif;font-size:6.4pt"> b</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> 0.05; 0.44, p</span><span style="font-family:AdvTT454a7a89,serif;font-size:6.4pt"> b</span></p>
<p style="top:487.9pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">0.05;</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:6.4pt"> &#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">0.40, p</span><span style="font-family:AdvTT454a7a89,serif;font-size:6.4pt"> b</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> 0.05,</span></p>
<p style="top:496.5pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">respectively). Higher</span></p>
<p style="top:505.1pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">-HSD1 mRNA levels</span></p>
<p style="top:513.6pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">were associated with</span></p>
<p style="top:522.2pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">obesity (0.63,</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt"> p</span><span style="font-family:AdvTT454a7a89,serif;font-size:6.4pt"> b</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> 0.01). No</span></p>
<p style="top:530.8pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">other associations of</span></p>
<p style="top:539.4pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">signi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">cance were seen with</span></p>
<p style="top:547.9pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">enzyme activity or mRNA</span></p>
<p style="top:556.5pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">levels. Intra-adipose cortisol</span></p>
<p style="top:565.1pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">and cortisone did not</span></p>
<p style="top:573.6pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">correlate with any markers.</span></p>
<p style="top:590.8pt;left:39.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Zha et al.,</span></p>
<p style="top:599.4pt;left:45.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">2009</span></p>
<p style="top:590.8pt;left:80.0pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Obesity</span></p>
<p style="top:590.8pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Analysis of gene</span></p>
<p style="top:599.4pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">transcription pro</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">les in VAT</span></p>
<p style="top:607.9pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">and SAT for lean and obese</span></p>
<p style="top:616.5pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">participants. VAT and SAT</span></p>
<p style="top:625.0pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">samples were collected</span></p>
<p style="top:633.6pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">during routine surgery.</span></p>
<p style="top:642.2pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Participants provided fasted</span></p>
<p style="top:650.7pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">blood samples and body</span></p>
<p style="top:659.3pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">composition measurements</span></p>
<p style="top:667.9pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">(BMI, waist and hip</span></p>
<p style="top:676.5pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">circumference, waist-to-hip</span></p>
<p style="top:685.0pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">ratio and blood pressure)</span></p>
<p style="top:590.8pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">35 participants split into 20</span></p>
<p style="top:599.4pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">lean (mean BMI 22.7 &#xb1; 1.8</span></p>
<p style="top:607.9pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">kg/m</span><sup><span style="font-family:AdvTT5235d5a9,serif;font-size:4.5pt">2</span></sup><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">, mean age 44.6 &#xb1;</span></p>
<p style="top:616.5pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">14.7 years) and 15 obese</span></p>
<p style="top:625.0pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">(mean BMI 28.2 &#xb1; 1.2</span></p>
<p style="top:633.6pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">kg/m</span><sup><span style="font-family:AdvTT5235d5a9,serif;font-size:4.5pt">2</span></sup><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">, mean age 54.3 &#xb1;</span></p>
<p style="top:642.2pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">10.3), 51% male.</span></p>
<p style="top:590.8pt;left:302.9pt;line-height:6.4pt"><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">t</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">-test, least squares</span></p>
<p style="top:599.4pt;left:302.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">regression</span></p>
<p style="top:590.8pt;left:374.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">-HSD1 mRNA levels</span></p>
<p style="top:590.8pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">-HSD1 mRNA levels</span></p>
<p style="top:599.4pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">were signi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">cantly higher in</span></p>
<p style="top:607.9pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">both SAT and VAT compared</span></p>
<p style="top:616.5pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">to lean participants (</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">p</span><span style="font-family:AdvTT454a7a89,serif;font-size:6.4pt"> b</span></p>
<p style="top:625.0pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">0.01;</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt"> p</span><span style="font-family:AdvTT454a7a89,serif;font-size:6.4pt"> b</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> 0.01). 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">-HSD1</span></p>
<p style="top:633.6pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">mRNA level in both SAT and</span></p>
<p style="top:642.2pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">VAT were signi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">cantly</span></p>
<p style="top:650.7pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">correlated with BMI across</span></p>
<p style="top:659.3pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">both groups (SAT r2 =</span></p>
<p style="top:667.9pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">0.262,</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt"> p</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> = 0.0038; VAT r2 =</span></p>
<p style="top:676.5pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">0.1826,</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt"> p</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> = 0.0185). There</span></p>
<p style="top:685.0pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">were no other correlations</span></p>
<p style="top:693.6pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">with obesity measurements.</span></p>
<p style="top:702.1pt;left:39.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Shah et al.,</span></p>
<p style="top:710.7pt;left:45.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">2011</span></p>
<p style="top:702.1pt;left:80.0pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Obesity and</span></p>
<p style="top:710.7pt;left:80.0pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">hypertension</span></p>
<p style="top:702.1pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Evaluation of MK-0736 and</span></p>
<p style="top:710.7pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">MK-0916 in treatment for</span></p>
<p style="top:719.3pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">overweight and obese</span></p>
<p style="top:727.9pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">participant with</span></p>
<p style="top:702.1pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">734 participants were</span></p>
<p style="top:710.7pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">screened and 249 were</span></p>
<p style="top:719.3pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">randomised. Participants</span></p>
<p style="top:727.9pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">were aged 8</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">75 with a BMI</span></p>
<p style="top:702.1pt;left:302.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">ANCOVA</span></p>
<p style="top:702.1pt;left:374.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Sitting systolic and diastolic</span></p>
<p style="top:710.7pt;left:374.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">blood pressure (SiSBP and</span></p>
<p style="top:719.3pt;left:374.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">SiDBP), body weight, LDL-C,</span></p>
<p style="top:727.9pt;left:374.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">HDL-C, triglycerides and</span></p>
<p style="top:702.1pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Study did not meet primary</span></p>
<p style="top:710.7pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">endpoint and therefore</span></p>
<p style="top:719.3pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">results should be regarded</span></p>
<p style="top:727.9pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">as nominal. Participants</span></p>
<p style="top:37.7pt;left:33.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">6</span></p>
<p style="top:37.7pt;left:190.4pt;line-height:6.4pt"><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">S. Gregory et al. / Metabolism Clinical and Experimental 108 (2020) 154246</span></p>


<p style="top:57.7pt;left:42.5pt;line-height:6.4pt"><span style="font-family:AdvTT28000ce1.B,serif;font-size:6.4pt">Table 1</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> (</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">continued</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">)</span></p>
<p style="top:72.2pt;left:48.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Study</span></p>
<p style="top:80.8pt;left:48.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">(Author,</span></p>
<p style="top:89.3pt;left:48.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">date)</span></p>
<p style="top:72.2pt;left:88.8pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Disease</span></p>
<p style="top:72.2pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Study design</span></p>
<p style="top:72.2pt;left:222.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Participants</span></p>
<p style="top:72.2pt;left:311.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Statistical analysis</span></p>
<p style="top:72.2pt;left:383.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Outcome measures</span></p>
<p style="top:72.2pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Description of</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt"> &#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">ndings</span></p>
<p style="top:102.4pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">hypertension. Participants</span></p>
<p style="top:110.9pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">were randomised to</span></p>
<p style="top:119.5pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">placebo, MK-0736 2 mg,</span></p>
<p style="top:128.1pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">MK-0736 7 mg, MK-0916 6</span></p>
<p style="top:136.7pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">mg once a day for 12 weeks.</span></p>
<p style="top:102.4pt;left:222.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">of below 41 kg/m</span><sup><span style="font-family:AdvTT5235d5a9,serif;font-size:4.5pt">2</span></sup><sup><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> </span></sup><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">with a</span></p>
<p style="top:110.9pt;left:222.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">history of essential</span></p>
<p style="top:119.5pt;left:222.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">hypertension (with a mean</span></p>
<p style="top:128.1pt;left:222.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">SiSBP of</span><span style="font-family:AdvTT454a7a89,serif;font-size:6.4pt"> b</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">160 mmHg and</span></p>
<p style="top:136.7pt;left:222.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">mean SiDBP 90</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">140</span></p>
<p style="top:145.2pt;left:222.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">mmHg).</span></p>
<p style="top:102.4pt;left:383.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">waist circumference</span></p>
<p style="top:102.4pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">treated with MK-0736 7 mg</span></p>
<p style="top:110.9pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">did not have a signi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">cant</span></p>
<p style="top:119.5pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">difference in trough SiDBP</span></p>
<p style="top:128.1pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">compared to placebo (</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:6.4pt">&#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">2.4</span></p>
<p style="top:136.7pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">&#xb1; 8.1 mmHg vs</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:6.4pt"> &#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">0.2 &#xb1; 8.7</span></p>
<p style="top:145.2pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">mmHg,</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt"> p</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> = 0.157).</span></p>
<p style="top:153.8pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Participants treated with</span></p>
<p style="top:162.4pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">MK-0916 6 mg and</span></p>
<p style="top:170.9pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">MK-0736 2md did have</span></p>
<p style="top:179.5pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">signi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">cant reductions in</span></p>
<p style="top:188.0pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">SiDBP compared to placebo</span></p>
<p style="top:196.7pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">(</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:6.4pt">&#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">3.1 &#xb1; 7.9 mmHg,</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt"> p</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> =</span></p>
<p style="top:205.2pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">0.042;</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:6.4pt"> &#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">4.2 &#xb1; 7.3 mmHg,</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt"> p</span></p>
<p style="top:213.8pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">= 0.01). Participants treated</span></p>
<p style="top:222.3pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">with MK-0736 7 mg had a</span></p>
<p style="top:230.9pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">signi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">cant reduction in</span></p>
<p style="top:239.5pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">trough SiSBP compared to</span></p>
<p style="top:248.0pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">placebo (</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:6.4pt">&#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">4.2 &#xb1; 12.9</span></p>
<p style="top:256.6pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">mmHg vs 0.7 &#xb1; 12.2 mmHg,</span></p>
<p style="top:265.2pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">p</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> = 0.46), no other</span></p>
<p style="top:273.8pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">treatment doses were</span></p>
<p style="top:282.3pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">signi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">cantly different to</span></p>
<p style="top:290.9pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">placebo. Body weight was</span></p>
<p style="top:299.4pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">decreased in all treatment</span></p>
<p style="top:308.0pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">groups (MK-0916 6 mg</span></p>
<p style="top:316.6pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9+22,serif;font-size:6.4pt">&#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">1.2 kg &#xb1;1.8 mmHg,</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt"> p</span><span style="font-family:AdvTT454a7a89,serif;font-size:6.4pt"> b</span></p>
<p style="top:325.2pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">0.001; MK-0736 2 mg</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:6.4pt"> &#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">0.6</span></p>
<p style="top:333.7pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">kg &#xb1;1.8 mmHg, p = 0.003;</span></p>
<p style="top:342.3pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">MK-0736 7 mg</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:6.4pt"> &#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">0.9 kg</span></p>
<p style="top:350.9pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">&#xb1;2.0 mmHg, p</span><span style="font-family:AdvTT454a7a89,serif;font-size:6.4pt"> b</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> 0.001).</span></p>
<p style="top:359.4pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Waist circumference was</span></p>
<p style="top:368.0pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">signi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">cantly reduced in</span></p>
<p style="top:376.5pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">those treated with MK-0736</span></p>
<p style="top:385.1pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">2 mg (</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:6.4pt">&#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">1.9 &#xb1; 4.9 cm vs 1.2</span></p>
<p style="top:393.7pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">&#xb1; 6.1 cm, p</span><span style="font-family:AdvTT454a7a89,serif;font-size:6.4pt"> b</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> 0.001) and</span></p>
<p style="top:402.3pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">LDL-C and HDL-C was</span></p>
<p style="top:410.8pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">reduced in those treated</span></p>
<p style="top:419.4pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">with MK-0736 7 mg (</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:6.4pt">&#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">5.2</span></p>
<p style="top:428.0pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">mg/dL &#xb1;20.4 vs 5.7 mg/dL</span></p>
<p style="top:436.5pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">&#xb1;30.8,</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt"> p</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> = 0.005;</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:6.4pt"> &#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">1.8</span></p>
<p style="top:445.1pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">mg/dL &#xb1;6.7 vs 1.5 mg/dL</span></p>
<p style="top:453.6pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">&#xb1;5.0,</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt"> p</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> = 0.015). There</span></p>
<p style="top:462.3pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">were no other differences</span></p>
<p style="top:470.8pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">between treatment groups</span></p>
<p style="top:479.4pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">and no changes with any</span></p>
<p style="top:487.9pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">treatment to triglycerides.</span></p>
<p style="top:496.5pt;left:48.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Miyamoto</span></p>
<p style="top:505.1pt;left:54.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">et al.,</span></p>
<p style="top:513.6pt;left:54.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">2009</span></p>
<p style="top:496.5pt;left:88.8pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">MetS</span></p>
<p style="top:496.5pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Analysis of HSD11B1</span></p>
<p style="top:505.1pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">polymorphisms (+9410 T</span><span style="font-family:AdvTT454a7a89,serif;font-size:6.4pt"> N</span></p>
<p style="top:513.6pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">A; +17925C</span><span style="font-family:AdvTT454a7a89,serif;font-size:6.4pt"> N</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> T; +27447G</span></p>
<p style="top:522.2pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT454a7a89,serif;font-size:6.4pt">N</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> C) in participants meeting</span></p>
<p style="top:530.8pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">criteria for metabolic</span></p>
<p style="top:539.4pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">syndrome (Japanese</span></p>
<p style="top:547.9pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">criteria), controls and an</span></p>
<p style="top:556.5pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">intermediate group (meet-</span></p>
<p style="top:565.0pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">ing criteria for neither meta-</span></p>
<p style="top:573.6pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">bolic syndrome nor control).</span></p>
<p style="top:582.2pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Participants provided blood</span></p>
<p style="top:590.8pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">samples, blood pressure</span></p>
<p style="top:599.3pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">measurements and anthro-</span></p>
<p style="top:607.9pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">pometric estimates.</span></p>
<p style="top:496.5pt;left:222.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">431 participants with</span></p>
<p style="top:505.1pt;left:222.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">metabolic syndrome (age</span></p>
<p style="top:513.6pt;left:222.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">67.6 &#xb1; 9.5 years), 777</span></p>
<p style="top:522.2pt;left:222.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">control participants (age</span></p>
<p style="top:530.8pt;left:222.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">59.5 &#xb1; 11.5 years) and 1797</span></p>
<p style="top:539.4pt;left:222.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">participants in intermediate</span></p>
<p style="top:547.9pt;left:222.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">group (68.0 &#xb1; 10.0 years).</span></p>
<p style="top:496.5pt;left:311.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Paired</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt"> t</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">-test, chi--</span></p>
<p style="top:505.1pt;left:311.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">square test, logistic</span></p>
<p style="top:513.6pt;left:311.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">regression</span></p>
<p style="top:496.5pt;left:383.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Associations of SNPs with</span></p>
<p style="top:505.1pt;left:383.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">metabolic syndrome</span></p>
<p style="top:496.5pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">There was a trend for</span></p>
<p style="top:505.1pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">association between</span></p>
<p style="top:513.6pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">+9410A allele and</span></p>
<p style="top:522.3pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">metabolic syndrome (OR 1.5</span></p>
<p style="top:530.8pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">(1.0</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">2.2),</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt"> p</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> = 0.041)</span></p>
<p style="top:539.4pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">however this was not</span></p>
<p style="top:547.9pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">signi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">cant after Bonferroni</span></p>
<p style="top:556.5pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">correction was applied.</span></p>
<p style="top:565.1pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">There were no signi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">cant</span></p>
<p style="top:573.6pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">associations seen with</span></p>
<p style="top:582.2pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">either +17925C</span><span style="font-family:AdvTT454a7a89,serif;font-size:6.4pt"> N</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> T;</span></p>
<p style="top:590.8pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">+27447G</span><span style="font-family:AdvTT454a7a89,serif;font-size:6.4pt"> N</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> C and metabolic</span></p>
<p style="top:599.4pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">syndrome.</span></p>
<p style="top:616.5pt;left:48.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Robitaille</span></p>
<p style="top:625.0pt;left:54.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">et al.,</span></p>
<p style="top:633.6pt;left:54.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">2004</span></p>
<p style="top:616.5pt;left:88.8pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">MetS</span></p>
<p style="top:616.5pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Analysis of 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">-HSD1</span></p>
<p style="top:625.0pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">genetic polymorphisms and</span></p>
<p style="top:633.6pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">association with metabolic</span></p>
<p style="top:642.2pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">syndrome. DNA was</span></p>
<p style="top:650.7pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">provided by participants for</span></p>
<p style="top:659.3pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">analysis as part of a larger</span></p>
<p style="top:667.9pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">study of 217</span></p>
<p style="top:676.5pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">French-Canadian men.</span></p>
<p style="top:616.5pt;left:222.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">36 participants with</span></p>
<p style="top:625.0pt;left:222.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">metabolic syndrome and 2</span></p>
<p style="top:633.6pt;left:222.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">controls, mean age 42.8 &#xb1;</span></p>
<p style="top:642.2pt;left:222.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">7.9 years, mean BMI 29.6 &#xb1;</span></p>
<p style="top:650.7pt;left:222.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">4.3.</span></p>
<p style="top:616.5pt;left:311.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Gene counting</span></p>
<p style="top:625.0pt;left:311.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">method</span></p>
<p style="top:616.5pt;left:383.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Frequency of 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">-HSD1</span></p>
<p style="top:625.0pt;left:383.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">genetic polymorphisms and</span></p>
<p style="top:633.6pt;left:383.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">association with metabolic</span></p>
<p style="top:642.2pt;left:383.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">syndrome</span></p>
<p style="top:616.5pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">There was no association</span></p>
<p style="top:625.0pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">between the variants and</span></p>
<p style="top:633.6pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">obesity, plasma or glucose</span></p>
<p style="top:642.2pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">insulin in the fasted state or</span></p>
<p style="top:650.7pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">response to an oral glucose</span></p>
<p style="top:659.3pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">tolerance test.</span></p>
<p style="top:685.0pt;left:48.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Alberti</span></p>
<p style="top:693.6pt;left:54.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">et al.,</span></p>
<p style="top:702.1pt;left:54.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">2007</span></p>
<p style="top:685.0pt;left:88.8pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">MetS and</span></p>
<p style="top:693.6pt;left:88.8pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">obesity</span></p>
<p style="top:685.0pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Analysis of 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">-HSD1</span></p>
<p style="top:693.6pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">expression in adipose tissue</span></p>
<p style="top:702.1pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">and association with</span></p>
<p style="top:710.7pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">metabolic syndrome and</span></p>
<p style="top:719.3pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">glucose intolerance. Samples</span></p>
<p style="top:685.0pt;left:222.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">62 obese participants, mean</span></p>
<p style="top:693.6pt;left:222.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">age bariatric group (n = 13)</span></p>
<p style="top:702.1pt;left:222.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">39.8 &#xb1; 9.87 years, mean age</span></p>
<p style="top:710.7pt;left:222.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">periumbilical biopsy group</span></p>
<p style="top:719.3pt;left:222.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">(n = 49) 45.6 &#xb1; 11.4. 10</span></p>
<p style="top:685.0pt;left:311.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Paired</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt"> t</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">-tests, two</span></p>
<p style="top:693.6pt;left:311.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">sample</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt"> t</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">-test,</span></p>
<p style="top:702.1pt;left:311.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Pearson&apos;s correlation,</span></p>
<p style="top:710.7pt;left:311.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">multiple regression</span></p>
<p style="top:719.3pt;left:311.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">analysis, ANOVA,</span></p>
<p style="top:685.0pt;left:383.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Expression of 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">-HSD1 in</span></p>
<p style="top:693.6pt;left:383.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">SAT &amp; VAT, expression of</span></p>
<p style="top:702.1pt;left:383.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">-HSD1 mRNA, MetS</span></p>
<p style="top:710.7pt;left:383.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">related biochemical</span></p>
<p style="top:719.3pt;left:383.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">variables</span></p>
<p style="top:685.0pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Expression of 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">-HSD1</span></p>
<p style="top:693.6pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">mRNA higher in VAT than</span></p>
<p style="top:702.1pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">SAT in 77% of subjects (2.06</span></p>
<p style="top:710.7pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">&#xb1; 0.92 vs 1.39 &#xb1; 0.82).</span></p>
<p style="top:719.3pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Obese participants with</span></p>
<p style="top:732.3pt;left:484.8pt;line-height:6.4pt"><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">(continued on next page)</span></p>
<p style="top:37.7pt;left:557.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">7</span></p>
<p style="top:37.7pt;left:199.2pt;line-height:6.4pt"><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">S. Gregory et al. / Metabolism Clinical and Experimental 108 (2020) 154246</span></p>


<p style="top:57.7pt;left:33.7pt;line-height:6.4pt"><span style="font-family:AdvTT28000ce1.B,serif;font-size:6.4pt">Table 1</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> (</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">continued</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">)</span></p>
<p style="top:72.2pt;left:39.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Study</span></p>
<p style="top:80.8pt;left:39.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">(Author,</span></p>
<p style="top:89.3pt;left:39.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">date)</span></p>
<p style="top:72.2pt;left:80.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Disease</span></p>
<p style="top:72.2pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Study design</span></p>
<p style="top:72.2pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Participants</span></p>
<p style="top:72.2pt;left:302.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Statistical analysis</span></p>
<p style="top:72.2pt;left:374.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Outcome measures</span></p>
<p style="top:72.2pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Description of</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt"> &#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">ndings</span></p>
<p style="top:102.4pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">were collected during</span></p>
<p style="top:110.9pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">planned bariatric surgery</span></p>
<p style="top:119.5pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">(VAT &amp; SAT,</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt"> n</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> = 13), or via</span></p>
<p style="top:128.1pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">periumbilical biopsy (SAT,</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt"> n</span></p>
<p style="top:136.7pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">= 49). Participants were</span></p>
<p style="top:145.2pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">grouped by</span></p>
<p style="top:153.8pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">presence/absence of</span></p>
<p style="top:162.4pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">metabolic syndrome</span></p>
<p style="top:170.9pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">(NCEP-ATP III criteria).</span></p>
<p style="top:102.4pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">males, 52 females.</span></p>
<p style="top:102.4pt;left:302.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">logistic regression</span></p>
<p style="top:102.4pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">metabolic syndrome had</span></p>
<p style="top:110.9pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">higher levels of 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">-HSD1</span></p>
<p style="top:119.5pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">expression in SAT (1.8 &#xb1; 1.5</span></p>
<p style="top:128.1pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">vs 1.0 &#xb1; 0.4, p</span><span style="font-family:AdvTT454a7a89,serif;font-size:6.4pt"> b</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> 0.01)</span></p>
<p style="top:136.7pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">compared to those with</span></p>
<p style="top:145.2pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">obesity but without</span></p>
<p style="top:153.8pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">metabolic syndrome.</span></p>
<p style="top:162.4pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">-HSD1 expression in SAT</span></p>
<p style="top:170.9pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">correlated positively with</span></p>
<p style="top:179.5pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">fasting glucose(</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">r</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> = 0.487,</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt"> p</span></p>
<p style="top:188.0pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT454a7a89,serif;font-size:6.4pt">b</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> 0.0001), triglycerides (</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">r</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> =</span></p>
<p style="top:196.7pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">0.318,</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt"> p</span><span style="font-family:AdvTT454a7a89,serif;font-size:6.4pt"> b</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> 0.05) and urinary</span></p>
<p style="top:205.2pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">free cortisol (</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">r</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> = 0.397, p</span><span style="font-family:AdvTT454a7a89,serif;font-size:6.4pt"> b</span></p>
<p style="top:213.8pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">0.01), and negatively with</span></p>
<p style="top:222.3pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">HDL cholesterol (</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">r</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> =</span></p>
<p style="top:230.9pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9+22,serif;font-size:6.4pt">&#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">0.392, p</span><span style="font-family:AdvTT454a7a89,serif;font-size:6.4pt"> b</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> 0.01). There was</span></p>
<p style="top:239.5pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">no correlation between</span></p>
<p style="top:248.0pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">-HSD1 expression in SAT</span></p>
<p style="top:256.6pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">and waist circumference,</span></p>
<p style="top:265.2pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">BMI, fasting insulin and</span></p>
<p style="top:273.8pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">blood pressure. Fasting</span></p>
<p style="top:282.3pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">glucose and urinary free</span></p>
<p style="top:290.9pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">cortisol were independently</span></p>
<p style="top:299.4pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">related to SAT 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">-HSD1</span></p>
<p style="top:308.0pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">expression (beta = 0.460, p</span></p>
<p style="top:316.6pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT454a7a89,serif;font-size:6.4pt">b</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> 0.0001; beta = 0.423,</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt"> p</span><span style="font-family:AdvTT454a7a89,serif;font-size:6.4pt"> b</span></p>
<p style="top:325.2pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">0.001). Obese subjects in the</span></p>
<p style="top:333.7pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">third tertile of SAT 11&#xdf;HSD1</span></p>
<p style="top:342.3pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">expression had a higher risk</span></p>
<p style="top:350.9pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">of type 2 diabetes: (OR 9.6,</span></p>
<p style="top:359.4pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">95% CI 1.0</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">88.6;</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt"> p</span><span style="font-family:AdvTT454a7a89,serif;font-size:6.4pt"> b</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> 0.05)</span></p>
<p style="top:368.0pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">and metabolic syndrome</span></p>
<p style="top:376.5pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">(OR 8.0, 95% CI, 1.7</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">36.7;</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt"> p</span><span style="font-family:AdvTT454a7a89,serif;font-size:6.4pt"> b</span></p>
<p style="top:385.1pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">0.01) when compared to the</span></p>
<p style="top:393.7pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">rst tertile.</span></p>
<p style="top:402.3pt;left:39.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Baudrand</span></p>
<p style="top:410.8pt;left:45.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">et al.,</span></p>
<p style="top:419.4pt;left:45.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">2010</span></p>
<p style="top:402.3pt;left:80.0pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">MetS and</span></p>
<p style="top:410.8pt;left:80.0pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">obesity</span></p>
<p style="top:402.3pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Analysis of 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">-HSD1</span></p>
<p style="top:410.8pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">expression in VAT, SAT and</span></p>
<p style="top:419.4pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">liver in morbidly obese</span></p>
<p style="top:428.0pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">participants to establish</span></p>
<p style="top:436.5pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">presence of correlations</span></p>
<p style="top:445.1pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">with clinical,</span></p>
<p style="top:453.6pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">anthropometric, and</span></p>
<p style="top:462.3pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">biochemical values. Samples</span></p>
<p style="top:470.8pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">(blood and biopsy) collected</span></p>
<p style="top:479.4pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">during surgery from all</span></p>
<p style="top:487.9pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">participants. Participants</span></p>
<p style="top:496.5pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">were de</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">ned as having MetS</span></p>
<p style="top:505.1pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">using NCEP-ATP III criteria.</span></p>
<p style="top:402.3pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">49 participants with morbid</span></p>
<p style="top:410.8pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">obesity undergoing bariatric</span></p>
<p style="top:419.4pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">surgery, 42.1 &#xb1; 10.1 years,</span></p>
<p style="top:428.0pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">29% male, BMI 42.1 &#xb1; 6.1,</span></p>
<p style="top:436.5pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">63% had metabolic</span></p>
<p style="top:445.1pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">syndrome.</span></p>
<p style="top:402.3pt;left:302.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Mann-Whitney,</span></p>
<p style="top:410.8pt;left:302.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Spearman correlation,</span></p>
<p style="top:419.4pt;left:302.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">generalised linear</span></p>
<p style="top:428.0pt;left:302.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">model</span></p>
<p style="top:402.3pt;left:374.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Expression of 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">-HSD1 in</span></p>
<p style="top:410.8pt;left:374.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">liver VAT and SAT,</span></p>
<p style="top:419.4pt;left:374.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">correlation of expression</span></p>
<p style="top:428.0pt;left:374.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">with clinical,</span></p>
<p style="top:436.5pt;left:374.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">anthropometric and</span></p>
<p style="top:445.1pt;left:374.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">biochemical variables</span></p>
<p style="top:402.3pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">There were no differences in</span></p>
<p style="top:410.8pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">-HSD1 expression</span></p>
<p style="top:419.4pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">between participants with</span></p>
<p style="top:428.0pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">and without metabolic</span></p>
<p style="top:436.5pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">syndrome. Hepatic</span></p>
<p style="top:445.1pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">-HSD1 correlated</span></p>
<p style="top:453.7pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">positively with fasting</span></p>
<p style="top:462.3pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">glucose (</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">r</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> = 0.29,</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt"> p</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> = 0.05)</span></p>
<p style="top:470.8pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">and ALT (</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">r</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> = 0.36, p = 0.01)</span></p>
<p style="top:479.4pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">and negatively with BMI (</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">r</span></p>
<p style="top:488.0pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">=</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:6.4pt"> &#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">0.32, p = 0.05). VAT</span></p>
<p style="top:496.5pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">-HSD1 correlated</span></p>
<p style="top:505.1pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">positively with fasting</span></p>
<p style="top:513.6pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">plasma insulin (r = 0.48, p</span></p>
<p style="top:522.3pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">= 0.005), ALT (r = 0.36,</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt"> p</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> =</span></p>
<p style="top:530.8pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">0.02), total cholesterol (</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">r</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> =</span></p>
<p style="top:539.4pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">0.37, p = 0.02) and LDL</span></p>
<p style="top:547.9pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">cholesterol (r = 0.36,</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt"> p</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> =</span></p>
<p style="top:556.5pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">0.03). There were no</span></p>
<p style="top:565.1pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">correlations seen with</span></p>
<p style="top:573.6pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">obstructive sleep apnoea,</span></p>
<p style="top:582.2pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">presence of gallstone</span></p>
<p style="top:590.8pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">disease or fatty liver and no</span></p>
<p style="top:599.4pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">correlations between</span></p>
<p style="top:607.9pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">biochemical variables and</span></p>
<p style="top:616.5pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">SAT levels.</span></p>
<p style="top:625.0pt;left:39.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Devang</span></p>
<p style="top:633.6pt;left:45.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">et al.,</span></p>
<p style="top:642.2pt;left:45.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">2017</span></p>
<p style="top:625.0pt;left:80.0pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Type 2</span></p>
<p style="top:633.6pt;left:80.0pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">diabetes and</span></p>
<p style="top:642.2pt;left:80.0pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">MetS</span></p>
<p style="top:625.0pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Target SNP association study</span></p>
<p style="top:633.6pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">(rs12086634 and rs846910)</span></p>
<p style="top:642.2pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">with type 2 diabetes and</span></p>
<p style="top:650.7pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">metabolic syndrome in a</span></p>
<p style="top:659.3pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">South Indian population.</span></p>
<p style="top:667.9pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Participants provided blood</span></p>
<p style="top:676.5pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">for genetic and biochemistry</span></p>
<p style="top:685.0pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">analysis as well as BMI,</span></p>
<p style="top:693.6pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">waist circumference and</span></p>
<p style="top:702.1pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">mid-arm circumference.</span></p>
<p style="top:625.0pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">616 South Indian partici-</span></p>
<p style="top:633.6pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">pants with either type 2 dia-</span></p>
<p style="top:642.2pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">betes (criteria of American</span></p>
<p style="top:650.7pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Diabetes Association,</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt"> n</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> =</span></p>
<p style="top:659.3pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">207), or metabolic syn-</span></p>
<p style="top:667.9pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">drome (criteria for South</span></p>
<p style="top:676.5pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Asian population of Interna-</span></p>
<p style="top:685.0pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">tional Diabetes Federation,</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt"> n</span></p>
<p style="top:693.6pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">= 101) or neither (control</span></p>
<p style="top:702.1pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">group). Mean age ranged</span></p>
<p style="top:710.7pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">from 49.28 to 51.74 years,</span></p>
<p style="top:719.3pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">sex of participants was not</span></p>
<p style="top:727.9pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">provided.</span></p>
<p style="top:625.0pt;left:302.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Pearson&apos;s k2, two</span></p>
<p style="top:633.6pt;left:302.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">sample</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt"> t</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">-test, logistic</span></p>
<p style="top:642.2pt;left:302.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">regression</span></p>
<p style="top:625.0pt;left:374.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Associations of rs12086634</span></p>
<p style="top:633.6pt;left:374.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">and rs846910</span></p>
<p style="top:642.1pt;left:374.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">polymorphisms with</span></p>
<p style="top:650.7pt;left:374.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">diagnostic groups</span></p>
<p style="top:625.0pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">HSD11B1 rs12086634 G</span></p>
<p style="top:633.6pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">allele associated with</span></p>
<p style="top:642.1pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">increased risk of T2D (OR =</span></p>
<p style="top:650.7pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">1.91, 95% CI-1.33</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">2.76,</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt"> P</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> =</span></p>
<p style="top:659.3pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">0.0005) and increased risk</span></p>
<p style="top:667.9pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">of metabolic syndrome,</span></p>
<p style="top:676.4pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">odds ratio 2.37, 95% CI</span></p>
<p style="top:685.0pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">1.39</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">4.05,</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt"> p</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> = 0.0015 (and</span></p>
<p style="top:693.6pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">metabolic syndrome OR =</span></p>
<p style="top:702.1pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">2.37, 95% CI-1.39</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">4.05,</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt"> P</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> =</span></p>
<p style="top:710.7pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">0.0015) compared to control</span></p>
<p style="top:719.2pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">group. HSD11B1 rs846910 A</span></p>
<p style="top:727.9pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">allele associated with</span></p>
<p style="top:37.7pt;left:33.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">8</span></p>
<p style="top:37.7pt;left:190.4pt;line-height:6.4pt"><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">S. Gregory et al. / Metabolism Clinical and Experimental 108 (2020) 154246</span></p>


<p style="top:57.7pt;left:42.5pt;line-height:6.4pt"><span style="font-family:AdvTT28000ce1.B,serif;font-size:6.4pt">Table 1</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> (</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">continued</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">)</span></p>
<p style="top:72.2pt;left:48.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Study</span></p>
<p style="top:80.8pt;left:48.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">(Author,</span></p>
<p style="top:89.3pt;left:48.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">date)</span></p>
<p style="top:72.2pt;left:88.8pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Disease</span></p>
<p style="top:72.2pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Study design</span></p>
<p style="top:72.2pt;left:222.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Participants</span></p>
<p style="top:72.2pt;left:311.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Statistical analysis</span></p>
<p style="top:72.2pt;left:383.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Outcome measures</span></p>
<p style="top:72.2pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Description of</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt"> &#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">ndings</span></p>
<p style="top:102.4pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">increased risk of T2DM (OR</span></p>
<p style="top:110.9pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">= 1.62, 95% CI-1.02</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">2.57,</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt"> P</span></p>
<p style="top:119.5pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">= 0.03)</span></p>
<p style="top:128.1pt;left:48.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Feig et al.,</span></p>
<p style="top:136.7pt;left:54.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">2011</span></p>
<p style="top:128.1pt;left:88.8pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Type 2</span></p>
<p style="top:136.7pt;left:88.8pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">diabetes and</span></p>
<p style="top:145.2pt;left:88.8pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">MetS</span></p>
<p style="top:128.1pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Evaluation of MK-0916 in</span></p>
<p style="top:136.7pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">treatment of type 2 diabetes</span></p>
<p style="top:145.2pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">and metabolic syndrome.</span></p>
<p style="top:153.8pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Participants were</span></p>
<p style="top:162.4pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">randomised to placebo,</span></p>
<p style="top:170.9pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">MK-0916 0.5 mg, MK-0916</span></p>
<p style="top:179.5pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">2 mg or MK-0916 6 mg, once</span></p>
<p style="top:188.0pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">daily taken orally for 12</span></p>
<p style="top:196.7pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">weeks.</span></p>
<p style="top:128.1pt;left:222.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">154 participants with type 2</span></p>
<p style="top:136.7pt;left:222.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">diabetes and metabolic</span></p>
<p style="top:145.2pt;left:222.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">syndrome (according to</span></p>
<p style="top:153.8pt;left:222.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">published diagnostic</span></p>
<p style="top:162.4pt;left:222.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">criteria), aged 18</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">65, 54%</span></p>
<p style="top:170.9pt;left:222.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">male.</span></p>
<p style="top:128.1pt;left:311.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">ANCOVA</span></p>
<p style="top:128.1pt;left:383.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Fasting plasma glucose</span></p>
<p style="top:136.7pt;left:383.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">(primary), A1C, 2-h</span></p>
<p style="top:145.2pt;left:383.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">postprandial glucose, body</span></p>
<p style="top:153.8pt;left:383.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">weight, waist</span></p>
<p style="top:162.4pt;left:383.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">circumference, lipids and</span></p>
<p style="top:170.9pt;left:383.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">blood pressure.</span></p>
<p style="top:128.1pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">There were no signi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">cant</span></p>
<p style="top:136.7pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">differences between any of</span></p>
<p style="top:145.2pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">the groups in fasting plasma</span></p>
<p style="top:153.8pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">glucose or 2 h post-prandial</span></p>
<p style="top:162.4pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">glucose (</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">p</span><span style="font-family:AdvTT454a7a89,serif;font-size:6.4pt"> N</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> 0.05).</span></p>
<p style="top:170.9pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Participants treated with</span></p>
<p style="top:179.5pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">MK-0916 6 mg had a</span></p>
<p style="top:188.0pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">signi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">cant reduction in A1C</span></p>
<p style="top:196.7pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">(</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:6.4pt">&#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">0.08%,</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt"> p</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> = 0.049), body</span></p>
<p style="top:205.2pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">weight (</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:6.4pt">&#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">2.2 kg, p</span><span style="font-family:AdvTT454a7a89,serif;font-size:6.4pt"> b</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> 0.001),</span></p>
<p style="top:213.8pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">systolic blood pressure</span></p>
<p style="top:222.3pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">(</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:6.4pt">&#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">4.6 mmHg, p</span><span style="font-family:AdvTT454a7a89,serif;font-size:6.4pt"> b</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> 0.001),</span></p>
<p style="top:230.9pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">diastolic blood pressure</span></p>
<p style="top:239.5pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">(</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:6.4pt">&#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">3.1 mmHg, p = 0.001)</span></p>
<p style="top:248.0pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">and increases in LDL (5.7%,</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt"> p</span></p>
<p style="top:256.6pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">= 0.041) compared to</span></p>
<p style="top:265.2pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">placebo. There were no</span></p>
<p style="top:273.8pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">signi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">cant changes with any</span></p>
<p style="top:282.3pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">other doses, and no</span></p>
<p style="top:290.9pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">signi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">cant changes to</span></p>
<p style="top:299.4pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">insulin (fed or fasted), waist</span></p>
<p style="top:308.0pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">circumference, HDL-C or</span></p>
<p style="top:316.6pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">triglycerides.</span></p>
<p style="top:325.2pt;left:48.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Valsamakis</span></p>
<p style="top:333.7pt;left:54.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">et al.,</span></p>
<p style="top:342.3pt;left:54.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">2004</span></p>
<p style="top:325.2pt;left:88.8pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Type 2</span></p>
<p style="top:333.7pt;left:88.8pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">diabetes</span></p>
<p style="top:342.3pt;left:88.8pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">mellitus and</span></p>
<p style="top:350.9pt;left:88.8pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">obesity</span></p>
<p style="top:325.2pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Analysis of 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">-HSD1</span></p>
<p style="top:333.7pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">activity in patients, lean and</span></p>
<p style="top:342.3pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">obese, with type 2 diabetes</span></p>
<p style="top:350.9pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">mellitus. Participants</span></p>
<p style="top:359.4pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">provided anthropometric</span></p>
<p style="top:368.0pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">measurements, blood</span></p>
<p style="top:376.5pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">samples for biochemistry, 24</span></p>
<p style="top:385.1pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">h urine sample and a</span></p>
<p style="top:393.7pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">sub-group underwent</span></p>
<p style="top:402.3pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">abdominal MRI</span></p>
<p style="top:325.2pt;left:222.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">33 diabetics participants</span></p>
<p style="top:333.7pt;left:222.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">(mean age 44.2 &#xb1; 13 years,</span></p>
<p style="top:342.3pt;left:222.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">mean BMI 31.1 &#xb1; 7.5 kg/m</span><sup><span style="font-family:AdvTT5235d5a9,serif;font-size:4.5pt">2</span></sup><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">)</span></p>
<p style="top:350.9pt;left:222.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">and 38 healthy participants</span></p>
<p style="top:359.4pt;left:222.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">(mean age 41.4 &#xb1; 14 years,</span></p>
<p style="top:368.0pt;left:222.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">mean BMI 38.2 &#xb1; 12.8</span></p>
<p style="top:376.6pt;left:222.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">kg/m</span><sup><span style="font-family:AdvTT5235d5a9,serif;font-size:4.5pt">2</span></sup><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">)</span></p>
<p style="top:325.2pt;left:311.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Students</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt"> t</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">-test,</span></p>
<p style="top:333.8pt;left:311.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Mann-Whitney U</span></p>
<p style="top:325.2pt;left:383.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">-HSD1 activity</span></p>
<p style="top:325.2pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">There were no signi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">cant</span></p>
<p style="top:333.8pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">differences in 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">-HSD1</span></p>
<p style="top:342.3pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">activity between those with</span></p>
<p style="top:350.9pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">diabetes and controls.</span></p>
<p style="top:410.9pt;left:48.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Andrews</span></p>
<p style="top:419.4pt;left:54.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">et al.,</span></p>
<p style="top:428.0pt;left:54.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">2003</span></p>
<p style="top:410.9pt;left:88.8pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Diabetes</span></p>
<p style="top:410.9pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Evaluation of the</span></p>
<p style="top:419.4pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">mechanism of action of</span></p>
<p style="top:428.0pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">carbenoxolone on insulin</span></p>
<p style="top:436.5pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">and the effects of</span></p>
<p style="top:445.1pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">carbenoxolone in patients</span></p>
<p style="top:453.7pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">with type 2 diabetes.</span></p>
<p style="top:462.3pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Participants were</span></p>
<p style="top:470.8pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">randomised to placebo or</span></p>
<p style="top:479.4pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">carbenoxolone 100 mg for 7</span></p>
<p style="top:488.0pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">days, followed by a</span></p>
<p style="top:496.5pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">minimum 3 month wash out</span></p>
<p style="top:505.1pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">period leading to cross over</span></p>
<p style="top:513.6pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">of treatment. Participants</span></p>
<p style="top:522.3pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">were dosed orally every 8 h.</span></p>
<p style="top:410.9pt;left:222.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">12 participants were</span></p>
<p style="top:419.4pt;left:222.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">recruited, 6 with type 2</span></p>
<p style="top:428.0pt;left:222.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">diabetes and 6 healthy</span></p>
<p style="top:436.5pt;left:222.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">controls. All participants</span></p>
<p style="top:445.1pt;left:222.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">were male. Participants with</span></p>
<p style="top:453.7pt;left:222.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">diabetes were diagnosed</span><span style="font-family:AdvTT454a7a89,serif;font-size:6.4pt"> b</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">3</span></p>
<p style="top:462.3pt;left:222.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">years previously with type 2</span></p>
<p style="top:470.8pt;left:222.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">diabetes mellitus by WHO</span></p>
<p style="top:479.4pt;left:222.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">criteria and were not treated</span></p>
<p style="top:488.0pt;left:222.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">apart from with diet.</span></p>
<p style="top:496.5pt;left:222.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Healthy controls had no</span></p>
<p style="top:505.1pt;left:222.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">diabetes and were matched</span></p>
<p style="top:513.6pt;left:222.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">diabetes group in age,</span></p>
<p style="top:522.3pt;left:222.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">weight, height, BMI and</span></p>
<p style="top:530.8pt;left:222.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">blood pressure</span></p>
<p style="top:410.8pt;left:311.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Paired and unpaired</span></p>
<p style="top:419.4pt;left:311.6pt;line-height:6.4pt"><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">t</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">-tests, multiple</span></p>
<p style="top:428.0pt;left:311.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">regression.</span></p>
<p style="top:410.8pt;left:383.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Glucose production and</span></p>
<p style="top:419.4pt;left:383.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">glycogenolysis</span></p>
<p style="top:410.8pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Glucose production from</span></p>
<p style="top:419.4pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">12.00</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">12.30 was</span></p>
<p style="top:428.0pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">signi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">cantly lower in</span></p>
<p style="top:436.5pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">diabetic subjects on</span></p>
<p style="top:445.1pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">carbenoxolone compared to</span></p>
<p style="top:453.6pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">placebo (</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">p</span><span style="font-family:AdvTT454a7a89,serif;font-size:6.4pt"> b</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> 0.05). There</span></p>
<p style="top:462.3pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">was no difference at other</span></p>
<p style="top:470.8pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">time points. Glycogenolysis</span></p>
<p style="top:479.4pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">from 12.00</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">12.30 was also</span></p>
<p style="top:487.9pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">signi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">cantly lower in</span></p>
<p style="top:496.5pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">diabetic subjects on</span></p>
<p style="top:505.1pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">carbenoxolone compared to</span></p>
<p style="top:513.6pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">placebo (</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">p</span><span style="font-family:AdvTT454a7a89,serif;font-size:6.4pt"> b</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> 0.01). There</span></p>
<p style="top:522.2pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">was no difference at other</span></p>
<p style="top:530.8pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">time points. There was no</span></p>
<p style="top:539.4pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">difference between glucose</span></p>
<p style="top:547.9pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">disposal or gluconeogenesis</span></p>
<p style="top:556.5pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">for either treatment or</span></p>
<p style="top:565.0pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">diagnostic group.</span></p>
<p style="top:573.6pt;left:48.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Heise et al.,</span></p>
<p style="top:582.2pt;left:54.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">2014</span></p>
<p style="top:573.6pt;left:88.8pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Type 2</span></p>
<p style="top:582.2pt;left:88.8pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">diabetes</span></p>
<p style="top:573.6pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Evaluation of RO5093151</span></p>
<p style="top:582.2pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">(RO-151) and RO5027383</span></p>
<p style="top:590.8pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">(RO-383) as adjunctive</span></p>
<p style="top:599.3pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">treatments to metformin for</span></p>
<p style="top:607.9pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">patients with type 2</span></p>
<p style="top:616.5pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">diabetes. Participants were</span></p>
<p style="top:625.0pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">randomised to placebo,</span></p>
<p style="top:633.6pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">RO-151 5 mg twice daily,</span></p>
<p style="top:642.1pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">RO-151 200 mg twice daily,</span></p>
<p style="top:650.7pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">RO-383 50 mg four times</span></p>
<p style="top:659.3pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">daily or RO-383 200 mg four</span></p>
<p style="top:667.9pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">times daily orally for 28</span></p>
<p style="top:676.4pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">days.</span></p>
<p style="top:573.6pt;left:222.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">110 participants with type 2</span></p>
<p style="top:582.2pt;left:222.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">diabetes, age 37</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">65, male</span></p>
<p style="top:590.8pt;left:222.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">and female.</span></p>
<p style="top:573.6pt;left:311.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">ANOVA</span></p>
<p style="top:573.6pt;left:383.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Mean daily blood glucose,</span></p>
<p style="top:582.2pt;left:383.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">fasting plasma glucose,</span></p>
<p style="top:590.8pt;left:383.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">HbA</span><span style="font-family:AdvTT5235d5a9,serif;font-size:4.5pt">1c</span></p>
<p style="top:573.6pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Treatment with RO-151 and</span></p>
<p style="top:582.2pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">RO-383 showed no</span></p>
<p style="top:590.8pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">difference on mean daily</span></p>
<p style="top:599.4pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">blood glucose and fasting</span></p>
<p style="top:607.9pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">plasma glucose compared to</span></p>
<p style="top:616.5pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">placebo, and no signi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">cant</span></p>
<p style="top:625.0pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">changes in HbA</span><span style="font-family:AdvTT5235d5a9,serif;font-size:4.5pt">1c</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">, glucose or</span></p>
<p style="top:633.6pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">insulin compared to placebo.</span></p>
<p style="top:642.2pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Participants treated with</span></p>
<p style="top:650.7pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">RO-151 200 mg had a</span></p>
<p style="top:659.3pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">signi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">cant change in</span></p>
<p style="top:667.9pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">cholesterol compared to</span></p>
<p style="top:676.5pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">placebo (</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:6.4pt">&#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">5 (</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:6.4pt">&#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">11,2) vs 5</span></p>
<p style="top:685.0pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">(</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:6.4pt">&#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">1, 13),</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt"> p</span><span style="font-family:AdvTT454a7a89,serif;font-size:6.4pt"> b</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> 0.05), LDL (</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:6.4pt">&#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">6</span></p>
<p style="top:693.6pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">(</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:6.4pt">&#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">14,3) vs 9 (0,19), p</span><span style="font-family:AdvTT454a7a89,serif;font-size:6.4pt"> b</span></p>
<p style="top:702.1pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">0.05), Apolipoprotein B (15</span></p>
<p style="top:710.7pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">(8, 23) vs 23 (16.30), p</span><span style="font-family:AdvTT454a7a89,serif;font-size:6.4pt"> b</span></p>
<p style="top:719.3pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">0.05) and reduction in body</span></p>
<p style="top:732.4pt;left:484.8pt;line-height:6.4pt"><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">(continued on next page)</span></p>
<p style="top:37.7pt;left:557.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">9</span></p>
<p style="top:37.7pt;left:199.2pt;line-height:6.4pt"><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">S. Gregory et al. / Metabolism Clinical and Experimental 108 (2020) 154246</span></p>


<p style="top:57.7pt;left:33.7pt;line-height:6.4pt"><span style="font-family:AdvTT28000ce1.B,serif;font-size:6.4pt">Table 1</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> (</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">continued</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">)</span></p>
<p style="top:72.2pt;left:39.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Study</span></p>
<p style="top:80.8pt;left:39.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">(Author,</span></p>
<p style="top:89.3pt;left:39.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">date)</span></p>
<p style="top:72.2pt;left:80.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Disease</span></p>
<p style="top:72.2pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Study design</span></p>
<p style="top:72.2pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Participants</span></p>
<p style="top:72.2pt;left:302.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Statistical analysis</span></p>
<p style="top:72.2pt;left:374.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Outcome measures</span></p>
<p style="top:72.2pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Description of</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt"> &#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">ndings</span></p>
<p style="top:102.4pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">weight (data extracted from</span></p>
<p style="top:110.9pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">graph: day 27: 1.68 kg vs</span></p>
<p style="top:119.5pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9+22,serif;font-size:6.4pt">&#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">0.28 kg, p</span><span style="font-family:AdvTT454a7a89,serif;font-size:6.4pt"> b</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> 0.05).</span></p>
<p style="top:128.1pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Participants treated with</span></p>
<p style="top:136.7pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">RO-838 200 mg had</span></p>
<p style="top:145.2pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">signi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">cant changes to</span></p>
<p style="top:153.8pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">triglycerides (40 (22, 60) vs</span></p>
<p style="top:162.4pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">12 (</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:6.4pt">&#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">3, 29), p</span><span style="font-family:AdvTT454a7a89,serif;font-size:6.4pt"> b</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> 0.05), VLDL</span></p>
<p style="top:170.9pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">(25 (5, 48) vs</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:6.4pt"> &#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">13 (</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:6.4pt">&#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">27, 3),</span></p>
<p style="top:179.5pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">p</span><span style="font-family:AdvTT454a7a89,serif;font-size:6.4pt"> b</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> 0.05) and Apolipoprotein</span></p>
<p style="top:188.1pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">C III (32 (19, 45) vs 15</span></p>
<p style="top:196.7pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">(5,27), p</span><span style="font-family:AdvTT454a7a89,serif;font-size:6.4pt"> b</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> 0.05)</span></p>
<p style="top:205.2pt;left:39.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Jang et al.,</span></p>
<p style="top:213.8pt;left:45.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">2007</span></p>
<p style="top:205.2pt;left:80.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Type 2</span></p>
<p style="top:213.8pt;left:80.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">diabetes</span></p>
<p style="top:205.2pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Analysis of 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">-HSD1 and</span></p>
<p style="top:213.8pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">-HSD2 mRNA expression</span></p>
<p style="top:222.3pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">in skeletal muscle of diabetic</span></p>
<p style="top:230.9pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">participants compared to</span></p>
<p style="top:239.5pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">controls. Participants fasted</span></p>
<p style="top:248.0pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">overnight for 10 h prior to</span></p>
<p style="top:256.6pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">collection of blood samples.</span></p>
<p style="top:265.2pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Body composition</span></p>
<p style="top:273.8pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">measurements collected</span></p>
<p style="top:282.3pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">(body weight, BMI and</span></p>
<p style="top:290.9pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">waist-to-hip ratio). Muscle</span></p>
<p style="top:299.4pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">tissue collected via biopsy of</span></p>
<p style="top:308.0pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">vastus lateralis under</span></p>
<p style="top:316.6pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">sedation.</span></p>
<p style="top:205.2pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">24 participants, type 2</span></p>
<p style="top:213.8pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">diabetes (n = 12) or age %</span></p>
<p style="top:222.3pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">sex matched controls (</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">n</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> =</span></p>
<p style="top:230.9pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">12), aged 57.8 &#xb1; 3.27 years</span></p>
<p style="top:239.5pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">(controls) and 58.3 &#xb1; 1.58</span></p>
<p style="top:248.0pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">years (diabetic), 50% male.</span></p>
<p style="top:205.2pt;left:302.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Repeated measures</span></p>
<p style="top:213.8pt;left:302.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">ANOVA, Pearson</span></p>
<p style="top:222.3pt;left:302.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">correlation, unpaired</span></p>
<p style="top:230.9pt;left:302.9pt;line-height:6.4pt"><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">t</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">-test</span></p>
<p style="top:205.2pt;left:374.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Expression of 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">-HSD1,</span></p>
<p style="top:213.8pt;left:374.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">-HSD2 mRNA and</span></p>
<p style="top:222.3pt;left:374.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">enzyme activity.</span></p>
<p style="top:205.2pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">There was no difference in</span></p>
<p style="top:213.8pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">-HSD1 expression</span></p>
<p style="top:222.3pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">between diabetic and</span></p>
<p style="top:230.9pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">control subjects (19.59 &#xb1;</span></p>
<p style="top:239.5pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">0.18 versus 19.52 &#xb1; 0.23</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt"> p</span></p>
<p style="top:248.0pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">= 0.838). 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">-HSD1</span></p>
<p style="top:256.6pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">expression was 2.7 fold</span></p>
<p style="top:265.2pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">higher in skeletal muscle</span></p>
<p style="top:273.8pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">compared to 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">-HSD2</span></p>
<p style="top:282.3pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">expression (19.55 &#xb1; 0.14 vs</span></p>
<p style="top:290.9pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">20.98 &#xb1; 0.28,</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt"> p</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> = 0.006).</span></p>
<p style="top:299.4pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Basal 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">-HSD1</span></p>
<p style="top:308.0pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">oxo-reductase activity in</span></p>
<p style="top:316.6pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">intact skeletal muscle was</span></p>
<p style="top:325.2pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">signi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">cantly lower in</span></p>
<p style="top:333.7pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">diabetic subjects compared</span></p>
<p style="top:342.3pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">to controls (11.4 &#xb1; 2.5% per</span></p>
<p style="top:350.9pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">200 mg muscle/24 h VS 18.5</span></p>
<p style="top:359.4pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">&#xb1; 2.2% per 200 mg</span></p>
<p style="top:368.0pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">muscle/24 h, p = 0.041).</span></p>
<p style="top:376.5pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">11&#xdf;-HSD1 dehydrogenase</span></p>
<p style="top:385.1pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">activity was signi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">cantly</span></p>
<p style="top:393.7pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">higher in the diabetic group</span></p>
<p style="top:402.3pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">compared to controls (5.3 &#xb1;</span></p>
<p style="top:410.8pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">0.6% per 3 mg protein VS 3.3</span></p>
<p style="top:419.4pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">&#xb1; 0.3% per 3 mg protein).</span></p>
<p style="top:428.0pt;left:39.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Nair et al.,</span></p>
<p style="top:436.5pt;left:45.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">2004</span></p>
<p style="top:428.0pt;left:80.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Type 2</span></p>
<p style="top:436.5pt;left:80.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">diabetes</span></p>
<p style="top:428.0pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Analysis of 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">-HSD1 SNPs</span></p>
<p style="top:436.5pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">and association with type 2</span></p>
<p style="top:445.1pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">diabetes mellitus in a Pima</span></p>
<p style="top:453.6pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Indian population. Partici-</span></p>
<p style="top:462.3pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">pants provided body com-</span></p>
<p style="top:470.8pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">position measurements and</span></p>
<p style="top:479.4pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">blood samples for genetic</span></p>
<p style="top:488.0pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">analysis.</span></p>
<p style="top:428.0pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">800 Pima Indians</span></p>
<p style="top:428.0pt;left:302.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">General linear</span></p>
<p style="top:436.5pt;left:302.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">regression models</span></p>
<p style="top:428.0pt;left:374.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Associations between SNP</span></p>
<p style="top:436.5pt;left:374.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">polymorphisms and type 2</span></p>
<p style="top:445.1pt;left:374.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">diabetes, insulin resistance</span></p>
<p style="top:453.7pt;left:374.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">and obesity</span></p>
<p style="top:428.0pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">SNP1 (</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">n</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> = 706) and SNP5 (</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">n</span></p>
<p style="top:436.5pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">= 839) were both</span></p>
<p style="top:445.1pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">signi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">cantly associated with</span></p>
<p style="top:453.7pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">type 2 diabetes mellitus.</span></p>
<p style="top:462.3pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">This was seen in the additive</span></p>
<p style="top:470.8pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">models (SNP1: OR 1.64</span></p>
<p style="top:479.4pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">(1.11</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">2.38),</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt"> p</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> = 0.01;</span></p>
<p style="top:488.0pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">SNP5: OR 1.34 (1.05</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">1.72),</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt"> p</span></p>
<p style="top:496.5pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">= 0.02) and the recessive</span></p>
<p style="top:505.1pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">models (SNP1:OR 1.72</span></p>
<p style="top:513.6pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">(1.14</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">2.56), p = 0.01;</span></p>
<p style="top:522.3pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">SNP5: OR 1.79 (1.14</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">2.8), p</span></p>
<p style="top:530.8pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">= 0.01). Both SNPs were</span></p>
<p style="top:539.4pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">signi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">cantly associated with</span></p>
<p style="top:547.9pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">glucose uptake rates (SNP1:</span></p>
<p style="top:556.5pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">p</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> = 0.03; SNP5: p = 0.04)</span></p>
<p style="top:565.1pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">after adjusting for relevant</span></p>
<p style="top:573.6pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">covariates of age, sex, fat</span></p>
<p style="top:582.2pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">percentage and nuclear</span></p>
<p style="top:590.8pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">family membership. SNP1</span></p>
<p style="top:599.4pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">was also associated with</span></p>
<p style="top:607.9pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">fasting insulin (</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">p</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> = 0.002),</span></p>
<p style="top:616.5pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">30-min plasma insulin (p =</span></p>
<p style="top:625.0pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">0.002) and 2-h plasma</span></p>
<p style="top:633.6pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">insulin (p = 0.03) after a 75</span></p>
<p style="top:642.2pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">g oral glucose tolerance test,</span></p>
<p style="top:650.7pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">as well as fasting insulin (p</span></p>
<p style="top:659.3pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">= 0.02) and early insulin</span></p>
<p style="top:667.9pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">secretion (</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">p</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> = 0.003). There</span></p>
<p style="top:676.5pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">were no signi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">cant</span></p>
<p style="top:685.0pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">associations between either</span></p>
<p style="top:693.6pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">SNP and age, percentage</span></p>
<p style="top:702.1pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">body fat, fasting glucose,</span></p>
<p style="top:710.7pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">30-min glucose, 2-h glucose,</span></p>
<p style="top:719.3pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">glucose disposal rate and</span></p>
<p style="top:727.9pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">hepatic insulin sensitivity.</span></p>
<p style="top:37.7pt;left:33.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">10</span></p>
<p style="top:37.7pt;left:190.4pt;line-height:6.4pt"><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">S. Gregory et al. / Metabolism Clinical and Experimental 108 (2020) 154246</span></p>


<p style="top:57.7pt;left:41.4pt;line-height:6.4pt"><span style="font-family:AdvTT28000ce1.B,serif;font-size:6.4pt">Table 1</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> (</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">continued</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">)</span></p>
<p style="top:72.2pt;left:47.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Study</span></p>
<p style="top:80.8pt;left:47.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">(Author,</span></p>
<p style="top:89.3pt;left:47.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">date)</span></p>
<p style="top:72.2pt;left:87.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Disease</span></p>
<p style="top:72.2pt;left:132.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Study design</span></p>
<p style="top:72.2pt;left:221.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Participants</span></p>
<p style="top:72.2pt;left:310.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Statistical analysis</span></p>
<p style="top:72.2pt;left:382.2pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Outcome measures</span></p>
<p style="top:72.2pt;left:471.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Description of</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt"> &#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">ndings</span></p>
<p style="top:102.4pt;left:47.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Rosenstock</span></p>
<p style="top:110.9pt;left:53.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">et al.,</span></p>
<p style="top:119.5pt;left:53.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">2010</span></p>
<p style="top:102.4pt;left:87.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Diabetes</span></p>
<p style="top:102.4pt;left:132.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Evaluation of INCB13739 in</span></p>
<p style="top:110.9pt;left:132.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">treatment of type 2 diabetes.</span></p>
<p style="top:119.5pt;left:132.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Participants were</span></p>
<p style="top:128.1pt;left:132.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">randomised to placebo,</span></p>
<p style="top:136.7pt;left:132.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">INCB13729 5 mg,</span></p>
<p style="top:145.2pt;left:132.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">INCB13739 15 mg,</span></p>
<p style="top:153.8pt;left:132.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">INCB13739 50 mg,</span></p>
<p style="top:162.4pt;left:132.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">INCB13739 100 mg, or</span></p>
<p style="top:170.9pt;left:132.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">INCB13739 200 mg, for 12</span></p>
<p style="top:179.5pt;left:132.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">weeks in addition to</span></p>
<p style="top:188.0pt;left:132.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">ongoing metformin</span></p>
<p style="top:196.7pt;left:132.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">monotherapy.</span></p>
<p style="top:102.4pt;left:221.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">302 participants with type 2</span></p>
<p style="top:110.9pt;left:221.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">diabetes, BMI between 25</span></p>
<p style="top:119.5pt;left:221.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">and 45 kg/m</span><sup><span style="font-family:AdvTT5235d5a9,serif;font-size:4.5pt">2</span></sup><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">, A1C between</span></p>
<p style="top:128.1pt;left:221.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">7 and 11%, aged 18</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">75 years</span></p>
<p style="top:136.7pt;left:221.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">and taking metformin on a</span></p>
<p style="top:145.2pt;left:221.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">stable dose for at least 10</span></p>
<p style="top:153.8pt;left:221.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">weeks.</span></p>
<p style="top:102.4pt;left:310.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Linear model</span></p>
<p style="top:102.4pt;left:382.2pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">A1C, fasting plasma glucose,</span></p>
<p style="top:110.9pt;left:382.2pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">lipid pro</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">les, proportion of</span></p>
<p style="top:119.5pt;left:382.2pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">patients achieving A1C</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:6.4pt"> &#x2264;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> 7%,</span></p>
<p style="top:128.1pt;left:382.2pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">HOMA-IR, weight, blood</span></p>
<p style="top:136.7pt;left:382.2pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">pressure and proportion of</span></p>
<p style="top:145.2pt;left:382.2pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">patients needing rescue</span></p>
<p style="top:153.8pt;left:382.2pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">therapy.</span></p>
<p style="top:102.4pt;left:471.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Participants treated with</span></p>
<p style="top:110.9pt;left:471.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">INCB13739 100 mg and</span></p>
<p style="top:119.5pt;left:471.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">INCB13739 200 mg had</span></p>
<p style="top:128.1pt;left:471.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">signi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">cant reductions in A1C</span></p>
<p style="top:136.7pt;left:471.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">(</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:6.4pt">&#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">0.47%, p</span><span style="font-family:AdvTT454a7a89,serif;font-size:6.4pt"> b</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> 0.05;</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:6.4pt"> &#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">0.56%,</span></p>
<p style="top:145.2pt;left:471.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">p</span><span style="font-family:AdvTT454a7a89,serif;font-size:6.4pt"> b</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> 0.01). 25% of participants</span></p>
<p style="top:153.8pt;left:471.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">in 100 mg and 200 mg</span></p>
<p style="top:162.4pt;left:471.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">groups achieved A1C at 12</span></p>
<p style="top:170.9pt;left:471.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">weeks of equal to or below</span></p>
<p style="top:179.5pt;left:471.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">7%, compared to 9.5% in</span></p>
<p style="top:188.0pt;left:471.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">placebo group. Participants</span></p>
<p style="top:196.7pt;left:471.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">treated with INCB13739 200</span></p>
<p style="top:205.2pt;left:471.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">mg had signi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">cantly lower</span></p>
<p style="top:213.8pt;left:471.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">fasting plasma glucose</span></p>
<p style="top:222.3pt;left:471.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">(</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:6.4pt">&#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">11.5 &#xb1; 6.2 mg/dL, p</span><span style="font-family:AdvTT454a7a89,serif;font-size:6.4pt"> b</span></p>
<p style="top:230.9pt;left:471.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">0.01, LS mean difference of</span></p>
<p style="top:239.5pt;left:471.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9+22,serif;font-size:6.4pt">&#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">24.1 mg/dL, p</span><span style="font-family:AdvTT454a7a89,serif;font-size:6.4pt"> b</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> 0.01) and</span></p>
<p style="top:248.0pt;left:471.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">HOMA-IR (</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:6.4pt">&#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">1.32, p</span><span style="font-family:AdvTT454a7a89,serif;font-size:6.4pt"> b</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> 0.05)</span></p>
<p style="top:256.6pt;left:471.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">compared to placebo but no</span></p>
<p style="top:265.2pt;left:471.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">signi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">cant changes in other</span></p>
<p style="top:273.8pt;left:471.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">treatment groups.</span></p>
<p style="top:282.3pt;left:471.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Participants treated with</span></p>
<p style="top:290.9pt;left:471.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">INCB13739 15 mg,</span></p>
<p style="top:299.4pt;left:471.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">INCB13739 100 mg and</span></p>
<p style="top:308.0pt;left:471.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">INCB13739 200 mg had</span></p>
<p style="top:316.6pt;left:471.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">signi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">cant decreases in body</span></p>
<p style="top:325.2pt;left:471.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">weight (</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:6.4pt">&#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">0.6 kg, p</span><span style="font-family:AdvTT454a7a89,serif;font-size:6.4pt"> b</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> 0.05;</span></p>
<p style="top:333.7pt;left:471.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9+22,serif;font-size:6.4pt">&#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">1.1 kg, p</span><span style="font-family:AdvTT454a7a89,serif;font-size:6.4pt"> b</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> 0.05;</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:6.4pt"> &#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">0.9 kg, p</span></p>
<p style="top:342.3pt;left:471.3pt;line-height:6.4pt"><span style="font-family:AdvTT454a7a89,serif;font-size:6.4pt">b</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> 0.05). Participants with</span></p>
<p style="top:350.9pt;left:471.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Adult Treatment Panel III</span></p>
<p style="top:359.4pt;left:471.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">de</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">ned hyperlipidaemia</span></p>
<p style="top:368.0pt;left:471.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">treated with INCB13739 100</span></p>
<p style="top:376.5pt;left:471.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">mg showed signi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">cant</span></p>
<p style="top:385.1pt;left:471.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">reduction in cholesterol</span></p>
<p style="top:393.7pt;left:471.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">(</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:6.4pt">&#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">16 mg/dL,</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:6.4pt"> &#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">6%, p</span><span style="font-family:AdvTT454a7a89,serif;font-size:6.4pt"> b</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> 0.05),</span></p>
<p style="top:402.3pt;left:471.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">LDL (</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:6.4pt">&#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">17 mg/dL,</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:6.4pt"> &#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">10%, p</span><span style="font-family:AdvTT454a7a89,serif;font-size:6.4pt"> b</span></p>
<p style="top:410.8pt;left:471.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">0.05) and triglycerides (</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:6.4pt">&#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">74</span></p>
<p style="top:419.4pt;left:471.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">mg/dL,</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:6.4pt"> &#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">16%, p</span><span style="font-family:AdvTT454a7a89,serif;font-size:6.4pt"> b</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> 0.05)</span></p>
<p style="top:428.0pt;left:471.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">however no other treatment</span></p>
<p style="top:436.5pt;left:471.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">groups had any signi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">cant</span></p>
<p style="top:445.1pt;left:471.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">differences to placebo. There</span></p>
<p style="top:453.6pt;left:471.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">were no changes to HDL,</span></p>
<p style="top:462.3pt;left:471.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">free fatty acids, systolic or</span></p>
<p style="top:470.8pt;left:471.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">diastolic blood pressure. The</span></p>
<p style="top:479.4pt;left:471.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">number of patients</span></p>
<p style="top:488.0pt;left:471.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">requiring rescue therapy did</span></p>
<p style="top:496.5pt;left:471.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">not differ between groups.</span></p>
<p style="top:505.1pt;left:47.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Sandeep</span></p>
<p style="top:513.6pt;left:53.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">et al.,</span></p>
<p style="top:522.3pt;left:53.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">2004</span></p>
<p style="top:505.1pt;left:87.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Diabetes and</span></p>
<p style="top:513.6pt;left:87.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">cognition</span></p>
<p style="top:505.1pt;left:132.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Evaluation of carbenoxolone</span></p>
<p style="top:513.6pt;left:132.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">on cognitive function in</span></p>
<p style="top:522.3pt;left:132.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">healthy elderly men and</span></p>
<p style="top:530.8pt;left:132.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">cognitive function and</span></p>
<p style="top:539.4pt;left:132.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">metabolic control in type 2</span></p>
<p style="top:547.9pt;left:132.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">diabetes. Participants were</span></p>
<p style="top:556.5pt;left:132.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">randomised to placebo or</span></p>
<p style="top:565.1pt;left:132.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">carbenoxolone 100 mg in a</span></p>
<p style="top:573.6pt;left:132.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">crossover trial. Participants</span></p>
<p style="top:582.2pt;left:132.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">completed cognitive</span></p>
<p style="top:590.8pt;left:132.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">assessments at the end of</span></p>
<p style="top:599.4pt;left:132.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">each phase of treatment in</span></p>
<p style="top:607.9pt;left:132.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">both groups.</span></p>
<p style="top:505.1pt;left:221.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">10 healthy volunteers and</span></p>
<p style="top:513.6pt;left:221.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">12 participants with</span></p>
<p style="top:522.3pt;left:221.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">diabetes.</span></p>
<p style="top:505.1pt;left:310.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Wilcoxon matched</span></p>
<p style="top:513.6pt;left:310.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">pair test, ANOVA,</span></p>
<p style="top:522.3pt;left:310.5pt;line-height:6.4pt"><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">t</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">-test</span></p>
<p style="top:505.1pt;left:382.2pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Verbal</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt"> &#xfb02;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">uency, visual</span></p>
<p style="top:513.6pt;left:382.2pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">memory, verbal memory,</span></p>
<p style="top:522.3pt;left:382.2pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">non-verbal reasoning,</span></p>
<p style="top:530.8pt;left:382.2pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">attention, processing speed,</span></p>
<p style="top:539.4pt;left:382.2pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">anxiety and depression,</span></p>
<p style="top:547.9pt;left:382.2pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">HbA</span><span style="font-family:AdvTT5235d5a9,serif;font-size:4.5pt">1c</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> levels (diabetes group</span></p>
<p style="top:556.5pt;left:382.2pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">only)</span></p>
<p style="top:505.1pt;left:471.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">In the healthy individuals</span></p>
<p style="top:513.6pt;left:471.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">carbenoxolone signi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">cantly</span></p>
<p style="top:522.3pt;left:471.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">increased verbal</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt"> &#xfb02;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">uency</span></p>
<p style="top:530.8pt;left:471.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">scores (44.2 &#xb1; 10.6 vs 40.6</span></p>
<p style="top:539.4pt;left:471.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">&#xb1; 12.4,</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt"> p</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> = 0.006). No effect</span></p>
<p style="top:547.9pt;left:471.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">on visual or verbal memory,</span></p>
<p style="top:556.5pt;left:471.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">non-verbal reasoning,</span></p>
<p style="top:565.1pt;left:471.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">attention nor processing</span></p>
<p style="top:573.6pt;left:471.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">speed. No signi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">cant effects</span></p>
<p style="top:582.2pt;left:471.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">on mood metrics.</span></p>
<p style="top:590.8pt;left:471.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">In T2DM group,</span></p>
<p style="top:599.4pt;left:471.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">carbenoxolone had no effect</span></p>
<p style="top:607.9pt;left:471.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">on HBA</span><span style="font-family:AdvTT5235d5a9,serif;font-size:4.5pt">1c</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">, total cholesterol</span></p>
<p style="top:616.5pt;left:471.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">or HDL cholesterol. There</span></p>
<p style="top:625.0pt;left:471.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">were signi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">cant</span></p>
<p style="top:633.6pt;left:471.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">improvements on Auditory</span></p>
<p style="top:642.2pt;left:471.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Verbal Learning Test (58.8 &#xb1;</span></p>
<p style="top:650.7pt;left:471.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">5.2 vs 55.2 &#xb1; 8.0,</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt"> p</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> =</span></p>
<p style="top:659.3pt;left:471.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">0.005). There was no effect</span></p>
<p style="top:667.9pt;left:471.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">on verbal</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt"> &#xfb02;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">uency, Raven&apos;s</span></p>
<p style="top:676.5pt;left:471.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">matrices not digit symbol</span></p>
<p style="top:685.0pt;left:471.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">substitution test.</span></p>
<p style="top:693.6pt;left:47.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Shukla</span></p>
<p style="top:702.1pt;left:53.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">et al.,</span></p>
<p style="top:710.7pt;left:53.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">2019</span></p>
<p style="top:693.6pt;left:87.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Type 2</span></p>
<p style="top:702.1pt;left:87.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">diabetes</span></p>
<p style="top:710.7pt;left:87.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">mellitus</span></p>
<p style="top:693.6pt;left:132.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Analysis of 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">-HSD1</span></p>
<p style="top:702.1pt;left:132.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">activity in participants with</span></p>
<p style="top:710.7pt;left:132.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">type 2 diabetes mellitus</span></p>
<p style="top:719.3pt;left:132.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">compared to age, gender</span></p>
<p style="top:693.6pt;left:221.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">60 participants, 30 with type</span></p>
<p style="top:702.1pt;left:221.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">2 diabetes mellitus and 30</span></p>
<p style="top:710.7pt;left:221.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">age (diabetes 46 years,</span></p>
<p style="top:719.3pt;left:221.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">controls 40 years), gender</span></p>
<p style="top:693.6pt;left:310.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Students</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt"> t-</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">test,</span></p>
<p style="top:702.1pt;left:310.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">one-way and two-way</span></p>
<p style="top:710.7pt;left:310.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">ANOVA, Mann</span></p>
<p style="top:719.3pt;left:310.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Whitney</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt"> U</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> test,</span></p>
<p style="top:693.6pt;left:382.2pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Delta cortisol (surrogate of</span></p>
<p style="top:702.1pt;left:382.2pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">-HSD1 activity)</span></p>
<p style="top:693.6pt;left:471.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Diabetic participants had</span></p>
<p style="top:702.1pt;left:471.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">higher levels of 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">-HSD1</span></p>
<p style="top:710.7pt;left:471.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">activity compared to</span></p>
<p style="top:719.3pt;left:471.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">controls (12.29 &#xb1; 10.65 vs</span></p>
<p style="top:732.4pt;left:483.7pt;line-height:6.4pt"><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">(continued on next page)</span></p>
<p style="top:37.7pt;left:554.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">11</span></p>
<p style="top:37.7pt;left:199.2pt;line-height:6.4pt"><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">S. Gregory et al. / Metabolism Clinical and Experimental 108 (2020) 154246</span></p>


<p style="top:57.7pt;left:33.7pt;line-height:6.4pt"><span style="font-family:AdvTT28000ce1.B,serif;font-size:6.4pt">Table 1</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> (</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">continued</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">)</span></p>
<p style="top:72.2pt;left:39.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Study</span></p>
<p style="top:80.8pt;left:39.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">(Author,</span></p>
<p style="top:89.3pt;left:39.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">date)</span></p>
<p style="top:72.2pt;left:80.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Disease</span></p>
<p style="top:72.2pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Study design</span></p>
<p style="top:72.2pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Participants</span></p>
<p style="top:72.2pt;left:302.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Statistical analysis</span></p>
<p style="top:72.2pt;left:374.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Outcome measures</span></p>
<p style="top:72.2pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Description of</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt"> &#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">ndings</span></p>
<p style="top:102.4pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">and BMI matched controls.</span></p>
<p style="top:110.9pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Participants were treated</span></p>
<p style="top:119.5pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">with 1 mg dexamethasone</span></p>
<p style="top:128.1pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">on the night prior to testing</span></p>
<p style="top:136.7pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">and fasting baseline serum</span></p>
<p style="top:145.2pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">cortisol and glucose samples</span></p>
<p style="top:153.8pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">taken prior to participants</span></p>
<p style="top:162.4pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">being given cortisone</span></p>
<p style="top:170.9pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">acetate (25 mg, oral), with</span></p>
<p style="top:179.5pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">second serum cortisol</span></p>
<p style="top:188.1pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">sample taken after dosing.</span></p>
<p style="top:102.4pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">(no breakdown given) and</span></p>
<p style="top:110.9pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">BMI (diabetes 25.25,</span></p>
<p style="top:119.5pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">controls 24.65) matched</span></p>
<p style="top:128.1pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">controls.</span></p>
<p style="top:102.4pt;left:302.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Wilcoxon Signed</span></p>
<p style="top:110.9pt;left:302.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Rank, Pearson and</span></p>
<p style="top:119.5pt;left:302.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Spearmen test,</span></p>
<p style="top:128.1pt;left:302.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">multiple regression</span></p>
<p style="top:102.4pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">6.68 &#xb1; 7.24,</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt"> p</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> = 0.022).</span></p>
<p style="top:110.9pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">When split by age this</span></p>
<p style="top:119.5pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">difference was only seen in</span></p>
<p style="top:128.1pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">those under 35 (13 vs 5.4</span></p>
<p style="top:136.7pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt">&#x3bc;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">g/dL, p = 0.005).</span></p>
<p style="top:145.2pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">-HSD1 activity was also</span></p>
<p style="top:153.8pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">signi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">cantly higher in those</span></p>
<p style="top:162.4pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">with diabetes who exercises</span></p>
<p style="top:170.9pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">compared to controls (15.1</span></p>
<p style="top:179.5pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">vs 6.2</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt"> &#x3bc;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">g/dL,</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt"> p</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> = 0.004) with</span></p>
<p style="top:188.0pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">no differences between</span></p>
<p style="top:196.7pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">diabetic participants and</span></p>
<p style="top:205.2pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">control participants with</span></p>
<p style="top:213.8pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">sedentary or intermediate</span></p>
<p style="top:222.3pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">physical activity levels.</span></p>
<p style="top:230.9pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">11&#xdf;-HSD1 activity was</span></p>
<p style="top:239.5pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">signi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">cantly higher in</span></p>
<p style="top:248.0pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">diabetic participants</span></p>
<p style="top:256.6pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">compared to controls when</span></p>
<p style="top:265.2pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">calorie intake was</span></p>
<p style="top:273.8pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">1900</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">2200 (12 vs 8.2</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt">&#x3bc;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">g/dL,</span></p>
<p style="top:282.3pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">p = 0.03), with no</span></p>
<p style="top:290.9pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">signi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">cant differences seen</span></p>
<p style="top:299.4pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">at higher or lower calorie</span></p>
<p style="top:308.0pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">intake. The lowest BMI</span></p>
<p style="top:316.6pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">group (</span><span style="font-family:AdvTT454a7a89,serif;font-size:6.4pt">b</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">23) also saw</span></p>
<p style="top:325.2pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">signi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">cantly higher</span></p>
<p style="top:333.7pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">11&#xdf;-HSD1 activity for</span></p>
<p style="top:342.3pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">diabetic participants</span></p>
<p style="top:350.9pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">compared to controls (14.2</span></p>
<p style="top:359.4pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">vs 8.9</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt">&#x3bc;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">g/dL,</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt"> p</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> = 0.017), with</span></p>
<p style="top:368.0pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">no differences between</span></p>
<p style="top:376.5pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">normal and overweight</span></p>
<p style="top:385.1pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">groups on BMI.</span></p>
<p style="top:393.7pt;left:39.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">De</span></p>
<p style="top:402.3pt;left:45.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Quervain</span></p>
<p style="top:410.8pt;left:45.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">et al.,</span></p>
<p style="top:419.4pt;left:45.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">2004</span></p>
<p style="top:393.7pt;left:80.0pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Alzheimer&apos;s</span></p>
<p style="top:402.3pt;left:80.0pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">disease</span></p>
<p style="top:393.7pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Genome wide association</span></p>
<p style="top:402.3pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">study for association of 11</span></p>
<p style="top:410.8pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">glucocorticoid related genes</span></p>
<p style="top:419.4pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">in patients with Alzheimer&apos;s</span></p>
<p style="top:428.0pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">disease and control subjects.</span></p>
<p style="top:436.5pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Participants provided blood</span></p>
<p style="top:445.1pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">for genetic analysis.</span></p>
<p style="top:393.7pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">814 participants (351</span></p>
<p style="top:402.3pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">patients with AD, 463</span></p>
<p style="top:410.8pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">controls), mean age of AD</span></p>
<p style="top:419.4pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">onset was 67 &#xb1; 9 years,</span></p>
<p style="top:428.0pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">MMSE of patients 20 &#xb1; 6,</span></p>
<p style="top:436.5pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">40% of patients were male,</span></p>
<p style="top:445.1pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">mean age of controls 68 &#xb1; 9</span></p>
<p style="top:453.6pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">years, MMSE on controls 29</span></p>
<p style="top:462.3pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">&#xb1; 1, 47% of controls were</span></p>
<p style="top:470.8pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">male.</span></p>
<p style="top:393.7pt;left:302.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Set association</span></p>
<p style="top:402.3pt;left:302.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">method</span></p>
<p style="top:393.7pt;left:374.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Association of 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">-HSD1</span></p>
<p style="top:402.3pt;left:374.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">gene with Alzheimer&apos;s</span></p>
<p style="top:410.8pt;left:374.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">disease</span></p>
<p style="top:393.7pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Of the 11 genes tested, only</span></p>
<p style="top:402.3pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">APOE and HSD11B1 were</span></p>
<p style="top:410.8pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">signi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">cantly associated with</span></p>
<p style="top:419.4pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">risk for Alzheimer&apos;s disease</span></p>
<p style="top:428.0pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">(p = 0.006). The rare A</span></p>
<p style="top:436.5pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">allele of HSD11B1</span></p>
<p style="top:445.1pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">(rs846911) was present in</span></p>
<p style="top:453.6pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">2.9% of AD patients</span></p>
<p style="top:462.3pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">compared to 0.5% of controls</span></p>
<p style="top:470.8pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">(</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">p</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> = 0.008).</span></p>
<p style="top:479.4pt;left:39.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Marek</span></p>
<p style="top:487.9pt;left:45.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">et al.,</span></p>
<p style="top:496.5pt;left:45.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">2014</span></p>
<p style="top:479.4pt;left:80.0pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Mild to</span></p>
<p style="top:487.9pt;left:80.0pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">moderate</span></p>
<p style="top:496.5pt;left:80.0pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Alzheimer&apos;s</span></p>
<p style="top:505.1pt;left:80.0pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">disease</span></p>
<p style="top:479.4pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Evaluation of ABT-384 in</span></p>
<p style="top:487.9pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">treatment of mild to</span></p>
<p style="top:496.5pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">moderate Alzheimer&apos;s</span></p>
<p style="top:505.1pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">disease. Participants were</span></p>
<p style="top:513.6pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">randomised to placebo,</span></p>
<p style="top:522.2pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">ABT-384 10 mg, ABT-384 50</span></p>
<p style="top:530.8pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">mg or donepezil 10 mg once</span></p>
<p style="top:539.4pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">daily taken orally for 12</span></p>
<p style="top:547.9pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">weeks.</span></p>
<p style="top:479.4pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Participants met criteria for</span></p>
<p style="top:487.9pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">probable AD and were aged</span></p>
<p style="top:496.5pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">55</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">90 years, with an MMSE</span></p>
<p style="top:505.1pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">score of 10</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">24 at screening.</span></p>
<p style="top:513.6pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">327 participants were</span></p>
<p style="top:522.3pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">screened and 267</span></p>
<p style="top:530.8pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">randomised.</span></p>
<p style="top:479.4pt;left:302.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">ANCOVA, mixed</span></p>
<p style="top:488.0pt;left:302.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">effects maximum</span></p>
<p style="top:496.5pt;left:302.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">likelihood repeated</span></p>
<p style="top:505.1pt;left:302.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">measures model</span></p>
<p style="top:479.4pt;left:374.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">ADAS-Cog, MMSE, CIBIS,</span></p>
<p style="top:488.0pt;left:374.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">NPI, ADCS-ADL</span></p>
<p style="top:479.4pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Study was prematurely</span></p>
<p style="top:488.0pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">discontinued due to lack of</span></p>
<p style="top:496.5pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">ef</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">cacy. There was no</span></p>
<p style="top:505.1pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">signi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">cant difference on</span></p>
<p style="top:513.6pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">ADAS-Cog for either</span></p>
<p style="top:522.3pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">ABT-384 dose compared to</span></p>
<p style="top:530.8pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">placebo (LS mean change</span></p>
<p style="top:539.4pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">from baseline =</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:6.4pt"> &#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">0.35,</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt"> p</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> =</span></p>
<p style="top:547.9pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">0.72 (10 mg) and LS mean</span></p>
<p style="top:556.5pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">change from baseline =</span></p>
<p style="top:565.1pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9+22,serif;font-size:6.4pt">&#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">0.51,</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt"> p</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> = 0.67 (50 mg)).</span></p>
<p style="top:573.6pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Both doses of ABT-384</span></p>
<p style="top:582.2pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">showed worse performance</span></p>
<p style="top:590.8pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">on ADAS-Cog at both Week</span></p>
<p style="top:599.4pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">4 and Week 8, and no</span></p>
<p style="top:607.9pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">comparable difference at</span></p>
<p style="top:616.5pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">week 12. There were no</span></p>
<p style="top:625.0pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">change to any secondary</span></p>
<p style="top:633.6pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">outcome measures with</span></p>
<p style="top:642.2pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">ABT-384 treatment. There</span></p>
<p style="top:650.7pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">was a signi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">cant</span></p>
<p style="top:659.3pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">improvement on ADAS-Cog</span></p>
<p style="top:667.9pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">compared to placebo for</span></p>
<p style="top:676.5pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">donepezil (LS mean change</span></p>
<p style="top:685.0pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">from baseline =</span><span style="font-family:AdvTT5235d5a9+22,serif;font-size:6.4pt"> &#x2212;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">3.06, p =</span></p>
<p style="top:693.6pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">0.02).</span></p>
<p style="top:702.1pt;left:39.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Smit et al.,</span></p>
<p style="top:710.7pt;left:45.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">2007</span></p>
<p style="top:702.1pt;left:80.0pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Alzheimer&apos;s</span></p>
<p style="top:710.7pt;left:80.0pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">disease</span></p>
<p style="top:702.1pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Analysis of HSD11B1</span></p>
<p style="top:710.7pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">polymorphism and</span></p>
<p style="top:719.3pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">diagnosis of Alzheimer&apos;s</span></p>
<p style="top:727.9pt;left:124.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">disease. Participants</span></p>
<p style="top:702.1pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">6105 participants from the</span></p>
<p style="top:710.7pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Rotterdam study and 403</span></p>
<p style="top:719.3pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">participants from the Frail</span></p>
<p style="top:727.9pt;left:213.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Old men study.</span></p>
<p style="top:702.1pt;left:302.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Cox proportional</span></p>
<p style="top:710.7pt;left:302.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">hazards models,</span></p>
<p style="top:719.3pt;left:302.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">adjusted for age and</span></p>
<p style="top:727.9pt;left:302.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">sex</span></p>
<p style="top:702.1pt;left:374.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">HSD11B1 83557insA and</span></p>
<p style="top:710.7pt;left:374.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">dementia incidence</span></p>
<p style="top:702.1pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">34.6% of the study</span></p>
<p style="top:710.7pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">population were</span></p>
<p style="top:719.3pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">heterozygous carriers of</span></p>
<p style="top:727.9pt;left:463.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">HSD11B1 85,577insA and</span></p>
<p style="top:37.7pt;left:33.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">12</span></p>
<p style="top:37.7pt;left:190.4pt;line-height:6.4pt"><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">S. Gregory et al. / Metabolism Clinical and Experimental 108 (2020) 154246</span></p>


<p style="top:172.4pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">had higher levels of 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">-HSD1 SAT expression and higher levels of 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">-</span></p>
<p style="top:182.8pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">HSD1 mRNA activity compared to obese participants without MetS [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">51</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">].</span></p>
<p style="top:193.3pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">A second study found no differences in hepatic expression of 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">-HSD1</span></p>
<p style="top:203.7pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">in obese participants with and without MetS [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">52</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">]. Both studies utilised</span></p>
<p style="top:214.2pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">the National Cholesterol Education Program&apos;s Adult Treatment Panel</span></p>
<p style="top:224.6pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">III (NCEP-ATP III) criteria to classify MetS [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">53</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">]. The studies differed in</span></p>
<p style="top:235.1pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">obesity levels, with only 13 of the 62 participants undergoing bariatric</span></p>
<p style="top:245.6pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">surgery in the</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt"> &#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">rst [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">51</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">] compared to all 49 undergoing bariatric surgery</span></p>
<p style="top:256.1pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">in the second [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">52</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">]. This makes it dif</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">cult to draw direct comparisons be-</span></p>
<p style="top:266.5pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">tween the effect of MetS, in addition to obesity, in these studies.</span></p>
<p style="top:287.4pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT94c8263f.I,serif;font-size:8.0pt">3.1.3. Metabolic syndrome</span></p>
<p style="top:297.9pt;left:54.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">Two studies reported on MetS alone, although it should be acknowl-</span></p>
<p style="top:308.3pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">edged that obesity is a component diagnosis of MetS. In a study of 36</span></p>
<p style="top:318.8pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">French-Canadian men with MetS and two control participants, re-</span></p>
<p style="top:329.2pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">searchers found no signi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">cant associations between 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">-HSD1 poly-</span></p>
<p style="top:339.7pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">morphisms and markers of MetS [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">54</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">]. A study in a Japanese cohort</span></p>
<p style="top:350.2pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">investigated three HSD11B1 polymorphisms (+9410 T</span><span style="font-family:AdvTT454a7a89,serif;font-size:8.0pt"> N</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt"> A; +17925C</span></p>
<p style="top:360.7pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT454a7a89,serif;font-size:8.0pt">N</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt"> T; +27447G</span><span style="font-family:AdvTT454a7a89,serif;font-size:8.0pt"> N</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt"> C) in participants meeting criteria for metabolic syn-</span></p>
<p style="top:371.1pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">drome (</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:8.0pt">n</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt"> = 31), controls (</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:8.0pt">n</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt"> = 777) and an intermediate group meeting</span></p>
<p style="top:381.6pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">criteria for neither metabolic syndrome nor control group (1797) [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">55</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">].</span></p>
<p style="top:392.1pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">Whilst there was an initial trend for association between the +9410A</span></p>
<p style="top:402.5pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">allele and metabolic syndrome this was not statistically signi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">cant</span></p>
<p style="top:413.0pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">after Bonferroni correction was applied, and there was no association</span></p>
<p style="top:423.4pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">seen between the other two polymorphisms and metabolic syndrome</span></p>
<p style="top:433.9pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">in this population.</span></p>
<p style="top:454.8pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT94c8263f.I,serif;font-size:8.0pt">3.1.4. Metabolic syndrome and diabetes</span></p>
<p style="top:465.2pt;left:54.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">One genome wide association study (GWAS) investigated genetics</span></p>
<p style="top:475.7pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">in both diabetes and MetS compared to controls without either disease.</span></p>
<p style="top:486.2pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">The GWAS reported on HSD11B1 single nucleotide polymorphisms</span></p>
<p style="top:496.7pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">(SNPs) in this population. Nearly a quarter of participants with type 2</span></p>
<p style="top:507.1pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">diabetes or MetS carried one of the two identi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">ed HSD11B1 SNPs</span></p>
<p style="top:517.6pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">(rs12086634 and rs846910) compared to 12</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:8.0pt">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">13% of the control popula-</span></p>
<p style="top:528.0pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">tion [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">56</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">]. There were no participants included in the study who had co-</span></p>
<p style="top:538.5pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">morbid MetS and diabetes.</span></p>
<p style="top:559.4pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT94c8263f.I,serif;font-size:8.0pt">3.1.5. Diabetes</span></p>
<p style="top:569.9pt;left:54.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">Studies looked at 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">-HSD1 expression and activity, as well as 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">-</span></p>
<p style="top:580.3pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">HSD1 SNPs in participants with type 2 diabetes. There were no differences</span></p>
<p style="top:590.8pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">seen in 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">-HSD1 expression between patients and controls [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">57</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">]. There</span></p>
<p style="top:601.3pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">were higher levels of 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">-HSD1 activity in both studies that investigated</span></p>
<p style="top:611.7pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">this [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">57</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">,</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">58</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">], with activity particularly high in participants under 35, those</span></p>
<p style="top:622.2pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">with a BMI under 23, those with daily calori</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">c intake between and those</span></p>
<p style="top:632.7pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">who are physically active [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">58</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">]. In a study of Pima Indians two SNPs (SNP1</span></p>
<p style="top:643.1pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">and SNP5) were signi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">cantly associated with type 2 diabetes mellitus and</span></p>
<p style="top:653.6pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">insulin resistance but not obesity [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">59</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">], suggesting an interesting area for</span></p>
<p style="top:664.0pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">future research to understand how these genes in</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb02;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">uence the develop-</span></p>
<p style="top:674.5pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">ment of type 2 diabetes in this population.</span></p>
<p style="top:695.4pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT94c8263f.I,serif;font-size:8.0pt">3.1.6. Alzheimer&apos;s disease</span></p>
<p style="top:705.9pt;left:54.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">An analysis of 814 participants recruited from memory clinics, 351 of</span></p>
<p style="top:716.3pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">whom had a diagnosis of AD, found that of 11 studied genes, only APOE</span></p>
<p style="top:726.8pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">and HSD11B1 were signi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">cantly associated with risk for AD. In particu-</span></p>
<p style="top:737.3pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">lar the rare A allele (rs846911) was present in a signi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">cantly higher</span></p>
<p style="top:172.4pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">proportion of AD patients (2.9%) compared to controls (0.5%) [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">60</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">].</span></p>
<p style="top:182.8pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">This allele is found in the promotor region for HSD11B1, at 2037 base</span></p>
<p style="top:193.3pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">pairs upstream from the start codon. In a larger sample taken from the</span></p>
<p style="top:203.7pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">Rotterdam study (</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:8.0pt">n</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt"> = 6105) there was no association between another</span></p>
<p style="top:214.2pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">SNP of interest, HSD11B1 83,557insA, and dementia incidence [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">61</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">]. It is</span></p>
<p style="top:224.6pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">of interest that the HSD11B1 gene was the only gene other than APOE to</span></p>
<p style="top:235.1pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">be associated with AD and would be worth replicating in the Rotterdam</span></p>
<p style="top:245.6pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">study as a larger population would allow us to draw</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt"> &#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">rmer conclusions.</span></p>
<p style="top:274.4pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT94c8263f.I,serif;font-size:8.0pt">3.1.7. Summary of tissue and gene expression study</span><span style="font-family:AdvTT94c8263f.I+fb,serif;font-size:8.0pt"> &#xfb01;</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:8.0pt">ndings</span></p>
<p style="top:284.8pt;left:322.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">Overall studies found higher levels of 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">-HSD1 expression in obese</span></p>
<p style="top:295.3pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">compared to non-obese participants. Two studies extended this to in-</span></p>
<p style="top:305.7pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">clude obese participants with MetS and these results were inconclusive.</span></p>
<p style="top:316.2pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">There was some evidence for changes to 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">-HSD1 activity in diabetes.</span></p>
<p style="top:326.6pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">There were mixed results for 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">-HSD1 polymorphisms and diabetes or</span></p>
<p style="top:337.1pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">MetS, whilst two studies investigating genetic associations with AD</span></p>
<p style="top:347.6pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">found the rs846911 SNP was associated with AD risk but the HSD11B1</span></p>
<p style="top:358.0pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">85,557insA SNP was not.</span></p>
<p style="top:386.8pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT94c8263f.I,serif;font-size:8.0pt">3.2. Interventional studies</span></p>
<p style="top:407.7pt;left:322.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">All studies of 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">-HSD1 inhibitors in humans reported below are</span></p>
<p style="top:418.2pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">from phase II testing. No compounds were identi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">ed in phase III testing</span></p>
<p style="top:428.6pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">and none have been licensed for treatment to date.</span></p>
<p style="top:457.4pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT94c8263f.I,serif;font-size:8.0pt">3.2.1. Diabetes</span></p>
<p style="top:467.9pt;left:322.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">INCB13739 or placebo was given at multiple dosages to patients</span></p>
<p style="top:478.3pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">with type 2 diabetes. In this study the primary outcome measure of</span></p>
<p style="top:488.8pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">HbA</span><span style="font-family:AdvTT5235d5a9,serif;font-size:5.6pt">1c</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt"> levels were reduced with the two highest doses of INCB13739</span></p>
<p style="top:499.3pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">compared to placebo. Secondary outcome measures also showed signif-</span></p>
<p style="top:509.8pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">icant changes, with reductions of fasting plasma glucose, HOMA-IR and</span></p>
<p style="top:520.2pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">body weight [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">62</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">].</span></p>
<p style="top:530.7pt;left:322.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">RO-151 or RO-838 were given concomitantly with metformin to pa-</span></p>
<p style="top:541.1pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">tients with type 2 diabetes. This study found no changes in the co-</span></p>
<p style="top:551.6pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">primary outcomes of mean daily plasma glucose or fasting plasma glu-</span></p>
<p style="top:562.0pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">cose, but did show reductions in body weight, a secondary outcome,</span></p>
<p style="top:572.5pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">at the highest treatment dose of both compounds [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">63</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">].</span></p>
<p style="top:582.9pt;left:322.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">One trial was identi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">ed on the</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092"> clinicaltrials.gov</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt"> website that had</span></p>
<p style="top:593.4pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">been terminated due to poor recruitment, and no papers could be iden-</span></p>
<p style="top:603.9pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">ti</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">ed reporting further on this compound in humans. The trial was a</span></p>
<p style="top:614.4pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">phase II trial designed to test P2202 for people with type 2 diabetes in-</span></p>
<p style="top:624.8pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">adequately controlled with a stable dose of metformin or sulfonylurea</span></p>
<p style="top:635.3pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">or both (</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">ClincalTrials.gov</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt"> Identi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">er: NCT01674348).</span></p>
<p style="top:664.0pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT94c8263f.I,serif;font-size:8.0pt">3.2.2. Metabolic syndrome and diabetes</span></p>
<p style="top:674.5pt;left:322.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">The compound MK-0916 was trialled in participants with co-morbid</span></p>
<p style="top:684.9pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">type 2 diabetes and MetS. The co-primary outcome measures for this</span></p>
<p style="top:695.4pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">study were fasting plasma glucose and 2-h post prandial glucose, with</span></p>
<p style="top:705.9pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">no differences in either outcome between treatment with MK-0916</span></p>
<p style="top:716.3pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">and placebo group. On secondary outcome measures at the highest</span></p>
<p style="top:726.8pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">dose of MK-0916 there were reductions in HbA</span><span style="font-family:AdvTT5235d5a9,serif;font-size:5.6pt">1c</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">, body weight, systolic</span></p>
<p style="top:737.3pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">and diastolic blood pressure and increases in LDL cholesterol [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">64</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">].</span></p>
<p style="top:57.7pt;left:42.5pt;line-height:6.4pt"><span style="font-family:AdvTT28000ce1.B,serif;font-size:6.4pt">Table 1</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> (</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">continued</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">)</span></p>
<p style="top:72.2pt;left:48.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Study</span></p>
<p style="top:80.8pt;left:48.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">(Author,</span></p>
<p style="top:89.3pt;left:48.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">date)</span></p>
<p style="top:72.2pt;left:88.8pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Disease</span></p>
<p style="top:72.2pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Study design</span></p>
<p style="top:72.2pt;left:222.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Participants</span></p>
<p style="top:72.2pt;left:311.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Statistical analysis</span></p>
<p style="top:72.2pt;left:383.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Outcome measures</span></p>
<p style="top:72.2pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Description of</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt"> &#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">ndings</span></p>
<p style="top:102.4pt;left:133.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">provided blood samples.</span></p>
<p style="top:102.4pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">4.8% were homozygous</span></p>
<p style="top:110.9pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">carriers. There was no</span></p>
<p style="top:119.5pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">association between carriers</span></p>
<p style="top:128.1pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">and non-carriers for</span></p>
<p style="top:136.7pt;left:472.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">incidence of dementia.</span></p>
<p style="top:37.7pt;left:554.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">13</span></p>
<p style="top:37.7pt;left:199.2pt;line-height:6.4pt"><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">S. Gregory et al. / Metabolism Clinical and Experimental 108 (2020) 154246</span></p>


<p style="top:57.3pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT94c8263f.I,serif;font-size:8.0pt">3.2.3. Obesity</span></p>
<p style="top:67.7pt;left:45.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">MK-0736 was trialled to treat co-morbid obesity and hypertension,</span></p>
<p style="top:78.2pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">with no changes seen between compound and placebo on the primary</span></p>
<p style="top:88.6pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">outcome of systolic blood pressure. On secondary outcome measures</span></p>
<p style="top:99.1pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">there was a decrease in body weight, LDL and HDL cholesterol following</span></p>
<p style="top:109.6pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">treatment with the highest dose of MK-0736 [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">65</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">], however all second-</span></p>
<p style="top:120.0pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">ary outcomes were regarded as non-signi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">cant by the study&apos;s authors.</span></p>
<p style="top:130.5pt;left:45.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">Whilst not an 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">-HSD1 inhibitor, a study of salicylate, a lipophilic</span></p>
<p style="top:141.0pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">monohydroxybenzoic acid, as a treatment for obesity showed a reduc-</span></p>
<p style="top:151.5pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">tion in adipose 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">-HSD1 mRNA levels although without changes to</span></p>
<p style="top:161.9pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">any anthropometric or biochemical parameters [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">66</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">].</span></p>
<p style="top:193.3pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT94c8263f.I,serif;font-size:8.0pt">3.2.4. Alzheimer&apos;s disease</span></p>
<p style="top:203.7pt;left:45.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">One interventional study enrolled mild-to-moderate AD participants</span></p>
<p style="top:214.2pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">to trial ABT-384. The primary endpoint of this phase II study was change</span></p>
<p style="top:224.6pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">from baseline on the Alzheimer&apos;s Disease Assessment Scale-Cognitive</span></p>
<p style="top:235.1pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">Subscale (ADAS-Cog). There were no differences seen between ABT-384</span></p>
<p style="top:245.6pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">and placebo on either the primary outcome or any of the secondary out-</span></p>
<p style="top:256.1pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">comes, which included the Mini Mental State Examination (MMSE) and</span></p>
<p style="top:266.5pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">activities of daily living [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">67</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">]. This trial included an active donepezil arm</span></p>
<p style="top:57.3pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">as well as a placebo arm, and results showed that patients treated with</span></p>
<p style="top:67.7pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">donepezil performed better on the ADAS-Cog compared to placebo.</span></p>
<p style="top:78.2pt;left:313.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">A phase II trial sponsored by Actinogen Medical Ltd. ongoing at the</span></p>
<p style="top:88.6pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">time of review investigated Xanamem</span><span style="font-family:AdvTT5235d5a9+21,serif;font-size:8.0pt">&#x2122;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt"> in mild-to-moderate AD [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">68</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">].</span></p>
<p style="top:99.1pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">This trial has since reported no differences seen between Xanamem and</span></p>
<p style="top:109.6pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">placebo on either the primary outcomes (ADAS-Cog and the Alzheimer&apos;s</span></p>
<p style="top:120.0pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">Disease composite score (ADCOMS)) or any of the secondary outcomes,</span></p>
<p style="top:130.5pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">which included the MMSE. Ongoing compound development is now</span></p>
<p style="top:141.0pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">investigating higher doses of the compound [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">69</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">].</span></p>
<p style="top:161.9pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT94c8263f.I,serif;font-size:8.0pt">3.2.5. Summary of interventional study</span><span style="font-family:AdvTT94c8263f.I+fb,serif;font-size:8.0pt"> &#xfb01;</span><span style="font-family:AdvTT94c8263f.I,serif;font-size:8.0pt">ndings</span></p>
<p style="top:172.4pt;left:313.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">INCB13739 successfully reduced HbA</span><span style="font-family:AdvTT5235d5a9,serif;font-size:5.6pt">1c</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">, fasting plasma glucose and</span></p>
<p style="top:182.9pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">HOMA-IR levels in people with type 2 diabetes, however there is no infor-</span></p>
<p style="top:193.3pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">mation available on the continued development of this compound. The</span></p>
<p style="top:203.8pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">other type 2 diabetes studies did not meet primary endpoints but did</span></p>
<p style="top:214.2pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">meet secondary endpoints including reduced body weight, reduced</span></p>
<p style="top:224.7pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">HbA</span><span style="font-family:AdvTT5235d5a9,serif;font-size:5.6pt">1c</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt"> and reduced LDL cholesterol. It is interesting that HbA</span><span style="font-family:AdvTT5235d5a9,serif;font-size:5.6pt">1c</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt"> levels</span></p>
<p style="top:235.1pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">were reduced in many studies and this may be an endpoint worth consid-</span></p>
<p style="top:245.6pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">ering as a primary outcome for future studies. There was no discernible</span></p>
<p style="top:256.1pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">bene</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">t of using 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">-HSD1 inhibitors as an adjunct therapy to metformin</span></p>
<p style="top:266.5pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">for patients with type 2 diabetes. Although two phase II trials have taken</span></p>
<p style="top:295.0pt;left:33.7pt;line-height:6.4pt"><span style="font-family:AdvTT28000ce1.B,serif;font-size:6.4pt">Table 2</span></p>
<p style="top:303.5pt;left:33.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Risk of bias assessment for each included study.Studies in bold indicate studies assessed as having a low risk of bias.</span></p>
<p style="top:318.1pt;left:39.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Study</span></p>
<p style="top:326.7pt;left:39.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">(Author,</span></p>
<p style="top:335.2pt;left:39.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">date)</span></p>
<p style="top:318.1pt;left:102.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Risk of bias</span></p>
<p style="top:326.7pt;left:102.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">assessment</span></p>
<p style="top:318.1pt;left:142.0pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Information on assessment</span></p>
<p style="top:348.3pt;left:39.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Alberti et al., 2007</span></p>
<p style="top:348.3pt;left:102.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Moderate</span></p>
<p style="top:348.3pt;left:142.0pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">No information on numbers of participants considered for enrolment or power calculations and no pre-published protocols.</span></p>
<p style="top:356.9pt;left:39.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Andrews et al.,</span></p>
<p style="top:365.4pt;left:45.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">2003</span></p>
<p style="top:356.9pt;left:102.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Moderate</span></p>
<p style="top:356.9pt;left:142.0pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Inadequate information on randomisation, concealment and blinding, no pre-published protocol or registration</span></p>
<p style="top:374.0pt;left:39.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Baudrand et al.,</span></p>
<p style="top:382.6pt;left:45.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">2010</span></p>
<p style="top:374.0pt;left:102.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Moderate</span></p>
<p style="top:374.0pt;left:142.0pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">No information on numbers of participants considered for enrolment or power calculations and no pre-published protocols.</span></p>
<p style="top:391.1pt;left:39.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Crowley et al.,</span></p>
<p style="top:399.7pt;left:45.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">2019</span></p>
<p style="top:391.1pt;left:102.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Moderate</span></p>
<p style="top:391.1pt;left:142.0pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">No information on numbers of participants considered for enrolment or power calculations and no pre-published protocols.</span></p>
<p style="top:408.2pt;left:39.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">De Quervain et al.,</span></p>
<p style="top:416.9pt;left:45.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">2004</span></p>
<p style="top:408.2pt;left:102.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Moderate</span></p>
<p style="top:408.2pt;left:142.0pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">No information on power calculations and no pre-published protocols.</span></p>
<p style="top:425.4pt;left:39.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Desbriere et al.,</span></p>
<p style="top:434.0pt;left:45.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">2006</span></p>
<p style="top:425.4pt;left:102.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Moderate</span></p>
<p style="top:425.4pt;left:142.0pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">No information on numbers of participants considered for enrolment or power calculations and no pre-published protocols.</span></p>
<p style="top:442.5pt;left:39.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Devang et al., 2017</span></p>
<p style="top:442.5pt;left:102.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Moderate</span></p>
<p style="top:442.5pt;left:142.0pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">No information on numbers of participants considered for enrolment or power calculations and no pre-published protocols.</span></p>
<p style="top:451.1pt;left:39.7pt;line-height:6.4pt"><span style="font-family:AdvTT28000ce1.B,serif;font-size:6.4pt">Feig et al</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">,</span><span style="font-family:AdvTT28000ce1.B,serif;font-size:6.4pt"> 2011</span></p>
<p style="top:451.1pt;left:102.9pt;line-height:6.4pt"><span style="font-family:AdvTT28000ce1.B,serif;font-size:6.4pt">Low</span></p>
<p style="top:451.1pt;left:142.0pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Clearly described the randomisation and blinding process, numbers of participants included at each analysis stage with clear reasons for</span></p>
<p style="top:459.7pt;left:142.0pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">differences in numbers, adopted a well-accepted primary outcome, and were registered on</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> clinicaltrials.gov</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> prior to starting</span></p>
<p style="top:468.2pt;left:39.7pt;line-height:6.4pt"><span style="font-family:AdvTT28000ce1.B,serif;font-size:6.4pt">Heise et al</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">,</span><span style="font-family:AdvTT28000ce1.B,serif;font-size:6.4pt"> 2014</span></p>
<p style="top:468.2pt;left:102.9pt;line-height:6.4pt"><span style="font-family:AdvTT28000ce1.B,serif;font-size:6.4pt">Low</span></p>
<p style="top:468.2pt;left:142.0pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Clearly described the randomisation and blinding process, numbers of participants included at each analysis stage with clear reasons for</span></p>
<p style="top:476.8pt;left:142.0pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">differences in numbers, adopted a well-accepted primary outcome, and were registered on</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> clinicaltrials.gov</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> prior to starting</span></p>
<p style="top:485.4pt;left:39.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Jang et al., 2007</span></p>
<p style="top:485.4pt;left:102.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Moderate</span></p>
<p style="top:485.4pt;left:142.0pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">No information on numbers of participants considered for enrolment or power calculations and no pre-published protocols.</span></p>
<p style="top:494.0pt;left:39.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Lindsay et al., 2003</span></p>
<p style="top:494.0pt;left:102.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Moderate</span></p>
<p style="top:494.0pt;left:142.0pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Participant recruitment was via media and community recruiters so dif</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">cult to judge representativeness of population, no power calculation</span></p>
<p style="top:502.5pt;left:142.0pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">or pre-published protocol</span></p>
<p style="top:511.1pt;left:39.7pt;line-height:6.4pt"><span style="font-family:AdvTT28000ce1.B,serif;font-size:6.4pt">Marek et al</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">,</span><span style="font-family:AdvTT28000ce1.B,serif;font-size:6.4pt"> 2014</span></p>
<p style="top:511.1pt;left:102.9pt;line-height:6.4pt"><span style="font-family:AdvTT28000ce1.B,serif;font-size:6.4pt">Low</span></p>
<p style="top:511.1pt;left:142.0pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Clearly described the randomisation and blinding process, numbers of participants included at each analysis stage with clear reasons for</span></p>
<p style="top:519.6pt;left:142.0pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">differences in numbers, adopted a well-accepted primary outcome, and were registered on</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> clinicaltrials.gov</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> prior to starting</span></p>
<p style="top:528.2pt;left:39.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Mariniello et al.,</span></p>
<p style="top:536.8pt;left:45.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">2006</span></p>
<p style="top:528.2pt;left:102.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Moderate</span></p>
<p style="top:528.2pt;left:142.0pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">No information on numbers of participants considered for enrolment or power calculations and no pre-published protocols.</span></p>
<p style="top:545.4pt;left:39.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Miyamoto et al.,</span></p>
<p style="top:553.9pt;left:45.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">2009</span></p>
<p style="top:545.4pt;left:102.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Moderate</span></p>
<p style="top:545.4pt;left:142.0pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">No information on numbers of participants considered for enrolment or power calculations and no pre-published protocols.</span></p>
<p style="top:562.5pt;left:39.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Munoz et al., 2009</span></p>
<p style="top:562.5pt;left:102.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Moderate</span></p>
<p style="top:562.5pt;left:142.0pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">No information on numbers of participants considered for enrolment or power calculations and no pre-published protocols.</span></p>
<p style="top:571.1pt;left:39.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Nair et al., 2004</span></p>
<p style="top:571.1pt;left:102.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Moderate</span></p>
<p style="top:571.1pt;left:142.0pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">No information on numbers of participants considered for enrolment or power calculations and no pre-published protocols.</span></p>
<p style="top:579.6pt;left:39.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Nixon et al., 2012</span></p>
<p style="top:579.6pt;left:102.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Moderate</span></p>
<p style="top:579.6pt;left:142.0pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">No pre-published protocol</span></p>
<p style="top:588.2pt;left:39.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Rask et al., 2002</span></p>
<p style="top:588.2pt;left:102.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Moderate</span></p>
<p style="top:588.2pt;left:142.0pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">No information on power calculation or pre-published protocol</span></p>
<p style="top:596.7pt;left:39.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Robitaille et al.,</span></p>
<p style="top:605.3pt;left:45.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">2004</span></p>
<p style="top:596.7pt;left:102.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Moderate</span></p>
<p style="top:596.7pt;left:142.0pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">No information on numbers of participants considered for enrolment or power calculations and no pre-published protocols.</span></p>
<p style="top:613.9pt;left:39.7pt;line-height:6.4pt"><span style="font-family:AdvTT28000ce1.B,serif;font-size:6.4pt">Rosenstock et al</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">,</span></p>
<p style="top:622.5pt;left:45.7pt;line-height:6.4pt"><span style="font-family:AdvTT28000ce1.B,serif;font-size:6.4pt">2010</span></p>
<p style="top:613.9pt;left:102.9pt;line-height:6.4pt"><span style="font-family:AdvTT28000ce1.B,serif;font-size:6.4pt">Low</span></p>
<p style="top:613.9pt;left:142.0pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Clearly described the randomisation and blinding process, numbers of participants included at each analysis stage with clear reasons for</span></p>
<p style="top:622.5pt;left:142.0pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">differences in numbers, adopted a well-accepted primary outcome, and were registered on</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> clinicaltrials.gov</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> prior to starting</span></p>
<p style="top:631.0pt;left:39.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Sandeep et al.,</span></p>
<p style="top:639.6pt;left:45.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">2004</span></p>
<p style="top:631.0pt;left:102.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Moderate</span></p>
<p style="top:631.0pt;left:142.0pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Inadequate information on randomisation, concealment and blinding, no pre-published protocol</span></p>
<p style="top:648.2pt;left:39.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Sandeep et al.,</span></p>
<p style="top:656.7pt;left:45.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">2005</span></p>
<p style="top:648.2pt;left:102.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Moderate</span></p>
<p style="top:648.2pt;left:142.0pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Inadequate information on randomisation, concealment and blinding, no pre-published protocol</span></p>
<p style="top:665.3pt;left:39.7pt;line-height:6.4pt"><span style="font-family:AdvTT28000ce1.B,serif;font-size:6.4pt">Shah et al</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">,</span><span style="font-family:AdvTT28000ce1.B,serif;font-size:6.4pt"> 2011</span></p>
<p style="top:665.3pt;left:102.9pt;line-height:6.4pt"><span style="font-family:AdvTT28000ce1.B,serif;font-size:6.4pt">Low</span></p>
<p style="top:665.3pt;left:142.0pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Clearly described the randomisation and blinding process, numbers of participants included at each analysis stage with clear reasons for</span></p>
<p style="top:673.9pt;left:142.0pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">differences in numbers, adopted a well-accepted primary outcome, and were registered on</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> clinicaltrials.gov</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt"> prior to starting</span></p>
<p style="top:682.5pt;left:39.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Shao et al., 2016</span></p>
<p style="top:682.5pt;left:102.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Moderate</span></p>
<p style="top:682.5pt;left:142.0pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">No information on numbers of participants considered for enrolment or power calculations and no pre-published protocols.</span></p>
<p style="top:691.0pt;left:39.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Shukla et al., 2019</span></p>
<p style="top:691.0pt;left:102.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Moderate</span></p>
<p style="top:691.0pt;left:142.0pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">No information on numbers of participants considered for enrolment or power calculations and no pre-published protocols.</span></p>
<p style="top:699.6pt;left:39.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Smit et al., 2007</span></p>
<p style="top:699.6pt;left:102.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Moderate</span></p>
<p style="top:699.6pt;left:142.0pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">No information on power calculation or pre-published protocol</span></p>
<p style="top:708.2pt;left:39.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Wake et al., 2003</span></p>
<p style="top:708.2pt;left:102.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Moderate</span></p>
<p style="top:708.2pt;left:142.0pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">No information on numbers of participants considered for enrolment or power calculations and no pre-published protocols.</span></p>
<p style="top:716.7pt;left:39.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Valsamakis et al.,</span></p>
<p style="top:725.3pt;left:45.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">2004</span></p>
<p style="top:716.7pt;left:102.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Moderate</span></p>
<p style="top:716.7pt;left:142.0pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">No information on numbers of participants considered for enrolment or power calculations and no pre-published protocols.</span></p>
<p style="top:733.8pt;left:39.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Zha et al., 2009</span></p>
<p style="top:733.8pt;left:102.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Moderate</span></p>
<p style="top:733.8pt;left:142.0pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">No information on numbers of participants considered for enrolment or power calculations and no pre-published protocols.</span></p>
<p style="top:37.7pt;left:33.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">14</span></p>
<p style="top:37.7pt;left:190.4pt;line-height:6.4pt"><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">S. Gregory et al. / Metabolism Clinical and Experimental 108 (2020) 154246</span></p>


<p style="top:57.3pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">place of 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">-HSD1 inhibitors in mild-to-moderate AD, neither were suc-</span></p>
<p style="top:67.7pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">cessful. Both studies suggest changes to dosage, albeit in different direc-</span></p>
<p style="top:78.2pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">tions, with Marek et al. [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">67</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">] suggesting a trial with</span><span style="font-family:AdvTT454a7a89,serif;font-size:8.0pt"> b</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">100% inhibition and</span></p>
<p style="top:88.6pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">Actinogen Medical Ltd. working on higher dose studies [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">69</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">].</span></p>
<p style="top:109.6pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT94c8263f.I,serif;font-size:8.0pt">3.3. Carbenoxolone</span></p>
<p style="top:130.5pt;left:54.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">Carbenoxolone was included in the review as a non-speci</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">c 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">-</span></p>
<p style="top:141.0pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">HSD inhibitor and is reported separately for clarity. Three studies looked</span></p>
<p style="top:151.5pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">at the effects of carbenoxolone in humans, with one paper reporting on</span></p>
<p style="top:161.9pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">diabetes, one on diabetes and cognition, and one on obesity.</span></p>
<p style="top:172.4pt;left:54.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">Treatment of type 2 diabetics with carbenoxolone led to reduced</span></p>
<p style="top:182.8pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">glucose production and lower glycogenolysis in a 30-min midday pe-</span></p>
<p style="top:193.3pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">riod, with no difference at other time points and no difference in glucose</span></p>
<p style="top:203.7pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">disposal or gluconeogenesis compared to placebo [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">70</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">]. Carbenoxolone</span></p>
<p style="top:214.2pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">signi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">cantly improved verbal</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt"> &#xfb02;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">uency scores in healthy men and verbal</span></p>
<p style="top:224.6pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">memory scores in diabetic men compared to placebo, with no other</span></p>
<p style="top:235.1pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">changes to cognition, depression, or anxiety and no changes to HbA</span><span style="font-family:AdvTT5235d5a9,serif;font-size:5.6pt">1c</span></p>
<p style="top:245.6pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">levels [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">71</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">]. The use of carbenoxolone in obesity found no changes be-</span></p>
<p style="top:256.1pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">tween treatment and placebo on glucose or insulin concentrations, glu-</span></p>
<p style="top:266.5pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">cose infusion rate, glucose disposal, or glucose production rates [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">72</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">].</span></p>
<p style="top:277.0pt;left:54.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">Carbenoxolone does not have a clear treatment bene</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">t emerging</span></p>
<p style="top:287.4pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">from these trials, with no effect on obesity, changes at one time point</span></p>
<p style="top:297.9pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">only in diabetes, and limited bene</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">ts in cognition, speci</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">cally verbal</span></p>
<p style="top:308.3pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">memory and verbal</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt"> &#xfb02;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">uency.</span></p>
<p style="top:329.3pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT94c8263f.I,serif;font-size:8.0pt">3.4. Areas with no research to date</span></p>
<p style="top:350.2pt;left:54.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">No articles were identi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">ed reporting on PD, cancer, depression, anxi-</span></p>
<p style="top:360.7pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">ety, PTSD, schizophrenia, and bipolar disorder. Whilst there is a body of</span></p>
<p style="top:371.1pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">work looking at 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">-HSD1 in depression, anxiety, and PTSD in preclinical</span></p>
<p style="top:381.6pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">models, there were no papers identi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">ed in a human population, and none</span></p>
<p style="top:392.1pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">in either preclinical or human in the diagnoses of schizophrenia, bipolar</span></p>
<p style="top:402.5pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">disorder, or PD, investigating 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">-HSD1. Cushing&apos;s syndrome (CS) was</span></p>
<p style="top:413.0pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">deliberately not included as this is a disease where cortisol levels are clin-</span></p>
<p style="top:423.4pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">ically abnormal, whereas all diseases included in the review have changes</span></p>
<p style="top:433.9pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">to cortisol levels that are typically below the upper limits of normal.</span></p>
<p style="top:454.8pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT94c8263f.I,serif;font-size:8.0pt">3.5. Risk of bias assessments</span></p>
<p style="top:475.7pt;left:54.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">Papers included in the review were assessed for risk of bias and all</span></p>
<p style="top:486.2pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">were assessed as low or moderate risk. Low risk studies described</span></p>
<p style="top:496.7pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">randomisation and blinding processes, clearly de</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">ned primary out-</span></p>
<p style="top:507.1pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">comes and were registered or had published protocols prior to initia-</span></p>
<p style="top:517.6pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">tion. Moderate risk studies tended to lack information on number of</span></p>
<p style="top:528.1pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">participants considered for enrolment, power calculations, method of</span></p>
<p style="top:538.5pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">allocation or concealment, blinding (where appropriate) and pre-</span></p>
<p style="top:549.0pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">published protocols. There was limited opportunity to compare be-</span></p>
<p style="top:559.4pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">tween the studies, even within a diagnostic</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt"> &#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">eld where there was</span></p>
<p style="top:569.9pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">often heterogeneity in inclusion criteria and primary outcome selection.</span></p>
<p style="top:580.3pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">There remains a lack of replication studies from which to draw</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt"> &#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">rm con-</span></p>
<p style="top:590.8pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">clusions. Further information on which papers were assessed at each</span></p>
<p style="top:601.3pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">level is provided in</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092"> Table 2</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">.</span></p>
<p style="top:622.2pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT28000ce1.B,serif;font-size:8.0pt">4. Discussion</span></p>
<p style="top:643.1pt;left:54.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">Studies reporting on 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">-HSD1 expression or inhibitors identify</span></p>
<p style="top:653.6pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">some promising areas for further research, but also highlight areas</span></p>
<p style="top:664.0pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">where potential therapeutic bene</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">t is still not well understood.</span></p>
<p style="top:674.5pt;left:54.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">Overall results suggest increased levels of 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">-HSD1 expression or</span></p>
<p style="top:684.9pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">activity in obesity. Results are mixed for 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">-HSD1 expression and</span></p>
<p style="top:695.4pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">-HSD1 genetic in</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb02;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">uence in MetS, diabetes and AD, with further re-</span></p>
<p style="top:705.9pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">search in more homogenous populations required. Trials of 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">-HSD1</span></p>
<p style="top:716.3pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">inhibitors have also had mixed success to date, with only one study</span></p>
<p style="top:726.8pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">meeting its primary outcome. Similarly, treatment with carbenoxolone</span></p>
<p style="top:737.3pt;left:42.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">has shown mixed results to date with some changes to cognition and</span></p>
<p style="top:57.3pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">glucose production, but no effects on obesity or other parameters of</span></p>
<p style="top:67.7pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">interest in diabetic participants.</span></p>
<p style="top:78.2pt;left:322.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">Many of the studies included look at comorbidities between MetS,</span></p>
<p style="top:88.6pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">diabetes and obesity. Trials including participants with such co-</span></p>
<p style="top:99.1pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">morbid diseases are important as they commonly co-occur in patients.</span></p>
<p style="top:109.6pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">However, it is also possible that some of the signals are lost in noise</span></p>
<p style="top:120.0pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">when multiple diseases are expressed at once, and it is therefore dif</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">-</span></p>
<p style="top:130.5pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">cult to determine the exact effects of 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">-HSD1 inhibitors.</span></p>
<p style="top:141.0pt;left:322.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">Much of the research to date has developed from promising preclin-</span></p>
<p style="top:151.4pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">ical studies, with 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">-HSD1 inhibitors successfully trialled in diabetes</span></p>
<p style="top:161.9pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">[</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">73</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:8.0pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">80</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">], MetS [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">81</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:8.0pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">86</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">], obesity [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">87</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:8.0pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">90</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">], AD [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">91</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:8.0pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">94</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">], and PTSD [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">95</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">].</span></p>
<p style="top:172.4pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">Challenges in translation of</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt"> &#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">ndings from preclinical studies to clinical</span></p>
<p style="top:182.8pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">trials are well acknowledged with recommendations for more rigorous</span></p>
<p style="top:193.3pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">preclinical trial designs suggested [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">96</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">]. All preclinical studies cited in-</span></p>
<p style="top:203.7pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">duced the diseases in murine models. Differences in development and</span></p>
<p style="top:214.2pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">expression of the disease between induced and naturally occurring</span></p>
<p style="top:224.6pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">(particularly in AD) may be one part of the translational challenge.</span></p>
<p style="top:235.1pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">More attention should be paid to this translational gap.</span></p>
<p style="top:245.6pt;left:322.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">The papers included in this review often included heterogeneous</span></p>
<p style="top:256.1pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">groups of participants, which limits the interpretability of some of the</span></p>
<p style="top:266.5pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">results. Studies on obesity used various de</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">nitions of obesity and het-</span></p>
<p style="top:277.0pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">erogeneous inclusion criteria. Observational studies often did not report</span></p>
<p style="top:287.4pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">on numbers of participants screened compared to those included or re-</span></p>
<p style="top:297.9pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">cruitment methods making it dif</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">cult to con</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">rm how generalizable the</span></p>
<p style="top:308.3pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">ndings would be to the population the participants were drawn from.</span></p>
<p style="top:318.8pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">Most studies did include participants with a mean BMI that would be clas-</span></p>
<p style="top:329.2pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">si</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">ed as obese by the World Health Organisation [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">97</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">], however some in-</span></p>
<p style="top:339.7pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">cluded participants who would be categorised as overweight not obese.</span></p>
<p style="top:350.2pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">One of these studies was run in China where there is a reduced cut off rec-</span></p>
<p style="top:360.7pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">ommended for obesity and therefore this study appropriately recruited</span></p>
<p style="top:371.1pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">obese participants in the context of the country wide BMI normative</span></p>
<p style="top:381.6pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">values [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">98</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">]. Both trials using an 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">-HSD1 inhibitor in AD enrolled partic-</span></p>
<p style="top:392.0pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">ipants on the basis on a clinical diagnosis, rather than a biomarker as is be-</span></p>
<p style="top:402.5pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">coming increasingly common in AD care and research [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">99</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">]. There are</span></p>
<p style="top:412.9pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">known variations between clinical diagnosis and histopathological diag-</span></p>
<p style="top:423.4pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">nosis on autopsy [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">100</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">] and therefore without a biomarker it is dif</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">cult</span></p>
<p style="top:433.8pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">to be certain these studies included people with a de</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">nite AD. An 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">-</span></p>
<p style="top:444.3pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">HSD1 PET tracer has recently been developed and tested successfully in</span></p>
<p style="top:454.8pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">humans for the</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt"> &#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">rst time [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">101</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">]. This development will allow further ex-</span></p>
<p style="top:465.2pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">ploration the presence and pattern of 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">-HSD1 in the human brain</span></p>
<p style="top:475.7pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">and better study these inhibitors in diseases such as AD. It is important</span></p>
<p style="top:486.2pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">for the research community to identify the most appropriate markers of</span></p>
<p style="top:496.7pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">-HSD1 expression and activity to then allow harmonisation across</span></p>
<p style="top:507.1pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">study protocols bringing ease of comparability between study results.</span></p>
<p style="top:517.6pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">Identi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">cation of participants with abnormal HPA axis function within</span></p>
<p style="top:528.0pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">these disease classes may also be important to move towards a strati</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">ed</span></p>
<p style="top:538.5pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">medicine approach, whereby the 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">-HSD1 inhibitors are trialled in</span></p>
<p style="top:548.9pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">those with a known cortisol abnormality.</span></p>
<p style="top:559.4pt;left:322.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">Whilst CS was out of scope for this review, refractory CS may be</span></p>
<p style="top:569.9pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">an emerging area of interest 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">-HSD1 inhibitor treatment. There</span></p>
<p style="top:580.3pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">is one ongoing phase I/II trial in Japan assessing the safety and ef</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">-</span></p>
<p style="top:590.8pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">cacy of an unnamed 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">-HSD1 inhibitor in refractory and subclinical</span></p>
<p style="top:601.3pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">CS, with a primary outcome of glucose AUC after 24 weeks of once a</span></p>
<p style="top:611.7pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">day treatment [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">102</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">]. This developing area of research will inform</span></p>
<p style="top:622.2pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">whether people with refractory CS could bene</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">t from 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">-HSD1 in-</span></p>
<p style="top:632.6pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">hibitor treatment. There may also be cardiac indications for these in-</span></p>
<p style="top:643.1pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">hibitors based on work with mineralocorticoid receptor (MR) and GR</span></p>
<p style="top:653.5pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">antagonists. Preclinical studies and clinical studies of mineralocorti-</span></p>
<p style="top:664.0pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">coid receptor (MR) antagonists suggest that atherosclerosis and</span></p>
<p style="top:674.4pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">heart failure may be a future therapeutic avenue for exploration</span></p>
<p style="top:684.9pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">[</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">103</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">]. Activation of both (GR) and MR have been associated with car-</span></p>
<p style="top:695.4pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">diac development and cardiac pathology [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">104</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">]. MR antagonists are</span></p>
<p style="top:705.9pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">already developed as effective heart failure treatments [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">105</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">] how-</span></p>
<p style="top:716.3pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">ever there are side effects such as hyperkalaemia which cannot be</span></p>
<p style="top:726.8pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">tolerated by patients who would bene</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">t from alternative therapeu-</span></p>
<p style="top:737.2pt;left:310.5pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">tic options [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">106</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">]. These treatments work by preventing MR activity</span></p>
<p style="top:37.7pt;left:554.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">15</span></p>
<p style="top:37.7pt;left:199.2pt;line-height:6.4pt"><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">S. Gregory et al. / Metabolism Clinical and Experimental 108 (2020) 154246</span></p>


<p style="top:57.3pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">in cardiomyocytes and macrophages [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">103</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">]. Our review focused on</span></p>
<p style="top:67.7pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">diseases in which 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">-HSD1 could be implicated and targeted for</span></p>
<p style="top:78.2pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">treatment and as such excluded fetal medicine, however it is impor-</span></p>
<p style="top:88.6pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">tant to highlight this as an emerging area of therapeutic interest.</span></p>
<p style="top:99.1pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">-HSD1 is found in fetal membranes (including amnion epithelial</span></p>
<p style="top:109.6pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">cells,</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt"> &#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">broblasts and chorion trophoblasts) [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">107</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">], with expression</span></p>
<p style="top:120.0pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">increasing with gestational age [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">108</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">]. It is also known that both</span></p>
<p style="top:130.5pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">-HSD1 and cortisol increase at the time of partuition [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">108</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">]. For</span></p>
<p style="top:141.0pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">a recent review of the potential therapeutic use of 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">-HSD1 inhibi-</span></p>
<p style="top:151.5pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">tors in preterm birth see Wang et al. [</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">109</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">]. The areas of refractory CS,</span></p>
<p style="top:161.9pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">cardiac medicine and fetal medicine all demonstrate future avenues</span></p>
<p style="top:172.4pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">of exploration for 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">-HSD1 inhibitors.</span></p>
<p style="top:182.8pt;left:45.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">Finally, the involvement of the HPA axis in the mechanism of ac-</span></p>
<p style="top:193.3pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">tion of disease pathology remains unclear in many diseases. It is not</span></p>
<p style="top:203.7pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">yet understood if the disease leads to HPA disruption or vice versa.</span></p>
<p style="top:214.2pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">Whilst it is interesting that cortisol levels are increased in many dis-</span></p>
<p style="top:224.6pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">ease processes, treatment to lower cortisol may not have an impact</span></p>
<p style="top:235.1pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">on the underlying disease if cortisol levels are only a correlative ef-</span></p>
<p style="top:245.6pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">fect and not a critical component of the causative pathway. More</span></p>
<p style="top:256.1pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">studies in animals should look at the evolution of disease with long</span></p>
<p style="top:266.5pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">term cortisol (corticosterone in rodents) measures taken to track</span></p>
<p style="top:277.0pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">when increases occur. Similarly, in humans larger and longer cohort</span></p>
<p style="top:287.4pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">studies are required to understand when cortisol increases relative</span></p>
<p style="top:297.9pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">to disease onset. Only once the results of these studies are available</span></p>
<p style="top:308.3pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">will true understanding of whether management of cortisol levels</span></p>
<p style="top:318.8pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">is able to change the course of a disease. 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">-HSD1 inhibitors may</span></p>
<p style="top:329.2pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">also provide an interesting therapeutic avenue to explore the manip-</span></p>
<p style="top:339.7pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">ulation and modulation of cortisol levels outside of HPA axis activity.</span></p>
<p style="top:350.2pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">Whilst the HPA axis controls circulating glucocorticoid levels, 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">-</span></p>
<p style="top:360.6pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">HSD1 can act to increase glucocorticoid levels within cells and tis-</span></p>
<p style="top:371.1pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">sues from intrinsically inert metabolites. The use of 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">-HSD1 inhib-</span></p>
<p style="top:381.6pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">itors to therapeutically lower these levels may therefore provide a</span></p>
<p style="top:392.0pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">role independent of the HPA axis. This, alongside the evidence iden-</span></p>
<p style="top:402.5pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">ti</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">ed from this review, highlights 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">-HSD1 inhibitors are impor-</span></p>
<p style="top:412.9pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">tant</span></p>
<p style="top:412.9pt;left:55.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">therapeutics</span></p>
<p style="top:412.9pt;left:110.1pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">to</span></p>
<p style="top:412.9pt;left:124.3pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">further</span></p>
<p style="top:412.9pt;left:157.9pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">develop</span></p>
<p style="top:412.9pt;left:194.8pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">and</span></p>
<p style="top:412.9pt;left:215.4pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">study</span></p>
<p style="top:412.9pt;left:243.1pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">in</span></p>
<p style="top:412.9pt;left:257.0pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">disease</span></p>
<p style="top:423.4pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">populations.</span></p>
<p style="top:444.3pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT28000ce1.B,serif;font-size:8.0pt">5. Conclusions</span></p>
<p style="top:465.2pt;left:45.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">Inhibition of 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">-HSD1 remains a promising area for multiple</span></p>
<p style="top:475.7pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">diseases, particularly diabetes, metabolic syndrome, obesity, and</span></p>
<p style="top:486.2pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">AD. The translation from animal models to human clinical trials has</span></p>
<p style="top:496.7pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">to date been challenging and the underlying mechanistic involve-</span></p>
<p style="top:507.1pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">ment of the HPA-axis in the course of the identi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">ed human diseases</span></p>
<p style="top:517.6pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">needs to be better understood to ensure that inhibition of 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:8.0pt">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">-HSD1</span></p>
<p style="top:528.0pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">results in therapeutic and clinically meaningful outcomes. Further,</span></p>
<p style="top:538.5pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">future studies should look at optimising the compounds that move</span></p>
<p style="top:548.9pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">to human testing, identifying appropriate clinically useful endpoints</span></p>
<p style="top:559.4pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">when designing protocols, and identifying the appropriate patient</span></p>
<p style="top:569.8pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">population for inclusion in the studies based on evidence of abnor-</span></p>
<p style="top:580.3pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">malities in cortisol metabolism.</span></p>
<p style="top:590.8pt;left:45.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">Supplementary data to this article can be found online at</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092"> https://doi.</span></p>
<p style="top:601.3pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt;color:#2e3092">org/10.1016/j.metabol.2020.154246</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">.</span></p>
<p style="top:622.2pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT28000ce1.B,serif;font-size:8.0pt">Funding</span></p>
<p style="top:643.1pt;left:45.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">This work was funded by Actinogen Medical Ltd.</span></p>
<p style="top:664.0pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT28000ce1.B,serif;font-size:8.0pt">CRediT authorship contribution statement</span></p>
<p style="top:684.9pt;left:45.7pt;line-height:8.0pt"><span style="font-family:AdvTT28000ce1.B,serif;font-size:8.0pt">Sarah Gregory:</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt"> Conceptualization, Methodology, Software, Formal</span></p>
<p style="top:695.4pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">analysis, Data curation, Writing - original draft, Project administration.</span></p>
<p style="top:705.8pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT28000ce1.B,serif;font-size:8.0pt">David Hill:</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt"> Formal analysis, Writing - review &amp; editing.</span><span style="font-family:AdvTT28000ce1.B,serif;font-size:8.0pt"> Ben Grey:</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt"> For-</span></p>
<p style="top:716.3pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">mal analysis, Writing - review &amp; editing.</span><span style="font-family:AdvTT28000ce1.B,serif;font-size:8.0pt"> William Ketelbey:</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt"> Conceptual-</span></p>
<p style="top:726.8pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">ization, Writing - review &amp; editing.</span><span style="font-family:AdvTT28000ce1.B,serif;font-size:8.0pt"> Tamara Miller:</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt"> Conceptualization,</span></p>
<p style="top:737.3pt;left:33.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">Writing - review &amp; editing.</span><span style="font-family:AdvTT28000ce1.B,serif;font-size:8.0pt"> Graciela Muniz-Terrera:</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt"> Writing - review</span></p>
<p style="top:57.3pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">&amp; editing.</span><span style="font-family:AdvTT28000ce1.B,serif;font-size:8.0pt"> Craig W. Ritchie:</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt"> Conceptualization, Writing - review &amp;</span></p>
<p style="top:67.7pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">editing, Supervision, Funding acquisition.</span></p>
<p style="top:88.7pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT28000ce1.B,serif;font-size:8.0pt">Declaration of competing interest</span></p>
<p style="top:109.6pt;left:313.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">BK and TM are employees of Actinogen Medical Ltd., CWR is a mem-</span></p>
<p style="top:120.0pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">ber of the advisory board for Actinogen Medical Ltd. SG was funded by</span></p>
<p style="top:130.5pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">Actinogen Medical Ltd. to complete this systematic review. The remain-</span></p>
<p style="top:141.0pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">ing authors have no con</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:8.0pt">&#xfb02;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">icts of interest.</span></p>
<p style="top:161.9pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT28000ce1.B,serif;font-size:8.0pt">Acknowledgments</span></p>
<p style="top:182.9pt;left:313.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">The authors would like to thank the University of Edinburgh librar-</span></p>
<p style="top:193.3pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">ian team for their support in accessing Covidence.</span></p>
<p style="top:214.2pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT28000ce1.B,serif;font-size:8.0pt">Contributions of authors</span></p>
<p style="top:235.1pt;left:313.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">SG designed the protocol, search strategy, completed the search,</span></p>
<p style="top:245.6pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">screened papers, extracted data and drafted the manuscript. DH sup-</span></p>
<p style="top:256.1pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">ported with the search, screening and data extraction, as well as drafting</span></p>
<p style="top:266.5pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">of the manuscript. BG supported with data extraction. CWR supported</span></p>
<p style="top:277.0pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">with the protocol design and search strategy, acted as the independent re-</span></p>
<p style="top:287.5pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">viewer for article inclusion if required and supported with drafting of the</span></p>
<p style="top:297.9pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">manuscript. BK and TM reviewed and provided comment on the protocol</span></p>
<p style="top:308.4pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:8.0pt">and manuscript. GMT supported with drafting of the manuscript.</span></p>
<p style="top:328.8pt;left:301.7pt;line-height:8.0pt"><span style="font-family:AdvTT28000ce1.B,serif;font-size:8.0pt">References</span></p>
<p style="top:348.0pt;left:308.8pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[1]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Longstaff A. Neuroscience. New York: London Gardland Science; 2011.</span></p>
<p style="top:356.0pt;left:308.8pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[2]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Juruena MF, et al. Atypical depression and non-atypical depression: is HPA axis</span></p>
<p style="top:363.9pt;left:320.2pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">function a biomarker? A systematic review. J Affect Disord 2018;233(Sp. Iss. SI):</span></p>
<p style="top:371.9pt;left:320.2pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">45</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">67.</span></p>
<p style="top:379.9pt;left:308.8pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[3]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Murri MB, et al. HPA axis and aging in depression: systematic review and meta-</span></p>
<p style="top:387.8pt;left:320.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">analysis. Psychoneuroendocrinology 2014;41:46</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">62.</span></p>
<p style="top:395.8pt;left:308.8pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[4]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Murri MB, et al. The HPA axis in bipolar disorder: systematic review and meta-</span></p>
<p style="top:403.8pt;left:320.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">analysis. Psychoneuroendocrinology 2016;63:327</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">42.</span></p>
<p style="top:411.8pt;left:308.8pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[5]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Mahajan DM, London SN. Mifepristone (RU486): a review. Fertil Steril 1997;68(6):</span></p>
<p style="top:419.8pt;left:319.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">967</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">76.</span></p>
<p style="top:427.7pt;left:308.8pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[6]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Soria V, et al. Targeting hypothalamic-pituitary-adrenal axis hormones and sex ste-</span></p>
<p style="top:435.7pt;left:319.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">roids for improving cognition in major mood disorders and schizophrenia: a sys-</span></p>
<p style="top:443.6pt;left:319.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">tematic review and narrative synthesis. Psychoneuroendocrinology 2018;93:8</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">19.</span></p>
<p style="top:451.6pt;left:308.8pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[7]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Watson S, et al. A randomized trial to examine the effect of mifepristone on neuro-</span></p>
<p style="top:459.6pt;left:319.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">psychological performance and mood in patients with bipolar depression. Biol Psy-</span></p>
<p style="top:467.5pt;left:319.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">chiatry 2012;72(11):943</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">9.</span></p>
<p style="top:475.5pt;left:308.8pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[8]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Young AH, et al. Improvements in neurocognitive function and mood following ad-</span></p>
<p style="top:483.5pt;left:319.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">junctive</span></p>
<p style="top:483.5pt;left:350.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">treatment</span></p>
<p style="top:483.5pt;left:386.8pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">with</span></p>
<p style="top:483.5pt;left:407.2pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">mifepristone</span></p>
<p style="top:483.5pt;left:451.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">(RU-486)</span></p>
<p style="top:483.5pt;left:486.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">in</span></p>
<p style="top:483.5pt;left:498.8pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">bipolar</span></p>
<p style="top:483.5pt;left:526.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">disorder.</span></p>
<p style="top:491.5pt;left:319.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">Neuropsychopharmacology 2004;29(8):1538</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">45.</span></p>
<p style="top:499.4pt;left:308.8pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[9]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Gallagher P, et al. Effects of adjunctive mifepristone (RU-486) administration on</span></p>
<p style="top:507.4pt;left:320.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">neurocognitive function and symptoms in schizophrenia. Biol Psychiatry 2005;57</span></p>
<p style="top:515.4pt;left:320.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">(2):155</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">61.</span></p>
<p style="top:523.3pt;left:305.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[10]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Belanoff JK, et al. Rapid reversal of psychotic depression using mifepristone. J Clin</span></p>
<p style="top:531.3pt;left:319.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">Psychopharmacol 2001;21:516</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">21.</span></p>
<p style="top:539.3pt;left:305.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[11]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Schatzberg AF. Anna-Monika Award Lecture, DGPPN Kongress, 2013: the role of</span></p>
<p style="top:547.3pt;left:320.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">the hypothalamic-pituitary-adrenal (HPA) axis in the pathogenesis of psychotic</span></p>
<p style="top:555.2pt;left:320.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">major depression. World J Biol Psychiatry 2015;16:2</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">11.</span></p>
<p style="top:563.2pt;left:305.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[12]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Blasey CM, et al. Ef</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt;color:#2e3092">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">cacy and safety of mifepristone for the treatment of psychotic</span></p>
<p style="top:571.2pt;left:319.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">depression. J Clin Psychopharmacol 2011;31:436</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">40.</span></p>
<p style="top:579.1pt;left:305.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[13]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Block T, et al. Mifepristone plasma level and glucocorticoid receptor antagonism as-</span></p>
<p style="top:587.1pt;left:319.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">sociated</span></p>
<p style="top:587.1pt;left:349.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">with</span></p>
<p style="top:587.1pt;left:368.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">response</span></p>
<p style="top:587.1pt;left:400.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">in</span></p>
<p style="top:587.1pt;left:412.2pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">patients</span></p>
<p style="top:587.1pt;left:441.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">with</span></p>
<p style="top:587.1pt;left:460.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">psychotic</span></p>
<p style="top:587.1pt;left:494.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">depression.</span></p>
<p style="top:587.1pt;left:533.8pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">J</span></p>
<p style="top:587.1pt;left:541.2pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">Clin</span></p>
<p style="top:595.0pt;left:319.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">Psychopharmacol 2017;37(5):505</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">11.</span></p>
<p style="top:603.0pt;left:305.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[14]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Csernansky JG, et al. Plasma cortisol and progression of dementia in subjects with</span></p>
<p style="top:611.0pt;left:319.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">Alzheimer-type dementia. Am J Psychiatry 2006;163(12):2164</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">9.</span></p>
<p style="top:619.0pt;left:305.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[15]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Pietrzak RH, et al. Plasma cortisol, brain amyloid-&#xdf;, and cognitive decline in pre-</span></p>
<p style="top:627.0pt;left:320.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">clinical Alzheimer</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2019;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">s disease: a 6-year prospective cohort study. Biol Psychiat Cogn</span></p>
<p style="top:634.9pt;left:320.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">Neurosci Neuroimaging 2017;2:45</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">52.</span></p>
<p style="top:642.9pt;left:305.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[16]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Li G, et al. Salivary cortisol and memory function in human aging. Neurobiol Aging</span></p>
<p style="top:650.9pt;left:319.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">2006;27:1705</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">14.</span></p>
<p style="top:658.8pt;left:305.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[17]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Karlamangla AS, et al. Urinary cortisol excretion as a predictor of incident cognitive</span></p>
<p style="top:666.8pt;left:319.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">impairment. Neurobiol Aging 2005;26:80</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">4.</span></p>
<p style="top:674.8pt;left:305.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[18]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Udeh-Momoh CT, et al. Cortisol, amyloid-</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt;color:#2e3092">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">, and reserve predicts Alzheimer</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2019;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">s disease</span></p>
<p style="top:682.7pt;left:320.0pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">progression for cognitively normal older adults. J Alzheimers Dis 2019;70:551</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">60.</span></p>
<p style="top:690.7pt;left:305.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[19]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Canet G, et al. Central role of glucocorticoid receptors in Alzheimer</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2019;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">s disease and</span></p>
<p style="top:698.7pt;left:320.0pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">depression. Front Neurosci 2018;12(73).</span></p>
<p style="top:706.7pt;left:305.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[20]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Costa CM, et al. Levels of cortisol and neurotrophic factor brain-derived in</span></p>
<p style="top:714.6pt;left:320.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">Parkinson</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2019;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">s disease. Neurosci Lett 2019;708(134359).</span></p>
<p style="top:722.6pt;left:305.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[21]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Soares NM, et al. Cortisol levels, motor, cognitive and behavioral symptoms in</span></p>
<p style="top:730.5pt;left:319.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">Parkinson</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2019;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">s disease: a systematic review. J Neural Transm 2019;126(3):</span></p>
<p style="top:738.5pt;left:319.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">219</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">32.</span></p>
<p style="top:37.7pt;left:33.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">16</span></p>
<p style="top:37.7pt;left:190.4pt;line-height:6.4pt"><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">S. Gregory et al. / Metabolism Clinical and Experimental 108 (2020) 154246</span></p>


<p style="top:56.1pt;left:46.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[22]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> de Kloet CS, et al. Assessment of HPA-axis function in posttraumatic stress disorder:</span></p>
<p style="top:64.1pt;left:60.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">pharmacological and non-pharmacological challenge tests, a review. J Psychiatr Res</span></p>
<p style="top:72.0pt;left:60.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">2006;40(6):550</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">67.</span></p>
<p style="top:80.0pt;left:46.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[23]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Meewisse M-L, et al. Cortisol and post-traumatic stress disorder in adults - system-</span></p>
<p style="top:87.9pt;left:60.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">atic review and meta-analysis. Br J Psychiatry 2007;191:387</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">92.</span></p>
<p style="top:95.9pt;left:46.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[24]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Nicolson NA, Ponnamperuma T. Gender moderates diurnal cortisol in relation to</span></p>
<p style="top:103.9pt;left:61.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">trauma</span></p>
<p style="top:103.9pt;left:89.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">and</span></p>
<p style="top:103.9pt;left:107.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">PTSD</span></p>
<p style="top:103.9pt;left:129.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">symptoms:</span></p>
<p style="top:103.9pt;left:169.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">a</span></p>
<p style="top:103.9pt;left:179.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">study</span></p>
<p style="top:103.9pt;left:202.8pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">in</span></p>
<p style="top:103.9pt;left:215.8pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">Sri</span></p>
<p style="top:103.9pt;left:230.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">Lankan</span></p>
<p style="top:103.9pt;left:258.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">adolescents.</span></p>
<p style="top:111.9pt;left:61.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">Psychoneuroendocrinology 2019;104:122</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">31.</span></p>
<p style="top:119.8pt;left:46.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[25]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Dekel S, et al. Cortisol and PTSD symptoms among male and female high-exposure</span></p>
<p style="top:127.8pt;left:60.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">9-11 survivors. J Trauma Stress 2013;26:621</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">5.</span></p>
<p style="top:135.8pt;left:46.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[26]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Shah JL, Malla AK. Much ado about much: stress, dynamic biomarkers and HPA axis</span></p>
<p style="top:143.7pt;left:60.8pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">dysregulation along the trajectory to psychosis. Schizophr Res 2015;162(1</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">3):</span></p>
<p style="top:151.7pt;left:60.8pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">253</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">60.</span></p>
<p style="top:159.7pt;left:46.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[27]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Karanikas E, Garyfallos G. Role of cortisol in patients at risk for psychosis mental</span></p>
<p style="top:167.6pt;left:60.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">state and psychopathological correlates: a systematic review. Psychiatry Clin</span></p>
<p style="top:175.6pt;left:60.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">Neurosci 2015;69:268</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">82.</span></p>
<p style="top:183.6pt;left:46.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[28]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Hilbert K, Lueken U, Beesdo-Baum K. Neural structures, functioning and connectiv-</span></p>
<p style="top:191.6pt;left:60.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">ity in Generalized Anxiety Disorder and interaction with neuroendocrine systems:</span></p>
<p style="top:199.6pt;left:60.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">a systematic review. J Affect Disord 2014;158:114</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">26.</span></p>
<p style="top:207.5pt;left:46.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[29]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Garcez A, et al. Basal cortisol levels and metabolic syndrome: a systematic review</span></p>
<p style="top:215.5pt;left:60.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">and meta-analysis of observational studies. Psychoneuroendocrinology 2018;95:</span></p>
<p style="top:223.4pt;left:60.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">50</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">62.</span></p>
<p style="top:231.4pt;left:46.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[30]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Rodriguez ACI, et al. Hypothalamic-pituitary-adrenal axis dysregulation and corti-</span></p>
<p style="top:239.4pt;left:60.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">sol activity in obesity: a systematic review. Psychoneuroendocrinology 2015;62:</span></p>
<p style="top:247.3pt;left:60.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">301</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">18.</span></p>
<p style="top:255.3pt;left:46.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[31]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Hackett RA, Steptoe A, Kumari M. Association of diurnal patterns in salivary cortisol</span></p>
<p style="top:263.3pt;left:60.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">with type 2 diabetes in the Whitehall II study. J Clin Endocrinol Metabol 2014;99</span></p>
<p style="top:271.3pt;left:60.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">(12):4625</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">31.</span></p>
<p style="top:279.2pt;left:46.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[32]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Hackett RA, et al. Diurnal cortisol patterns, future diabetes, and impaired glucose</span></p>
<p style="top:287.2pt;left:60.8pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">metabolism in the Whitehall II cohort study. J Clin Endocrinol Metabol 2016;101</span></p>
<p style="top:295.2pt;left:60.8pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">(2):619</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">25.</span></p>
<p style="top:303.1pt;left:46.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[33]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Schoorlemmer RM, et al. Relationships between cortisol level, mortality and</span></p>
<p style="top:311.1pt;left:61.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">chronic diseases in older persons. Clin Endocrinol (Oxf) 2009;71(6):779</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">86.</span></p>
<p style="top:319.1pt;left:46.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[34]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Reynolds RM, et al. Morning cortisol levels and cognitive abilities in people with</span></p>
<p style="top:327.1pt;left:60.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">type 2 diabetes: the Edinburgh type 2 diabetes study. Diabetes Care 2010;33(4):</span></p>
<p style="top:335.0pt;left:60.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">714</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">20.</span></p>
<p style="top:343.0pt;left:46.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[35]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Seckl JR, Walker BR. Minireview: 11 beta-hydroxysteroid dehydrogenase type 1 - a</span></p>
<p style="top:351.0pt;left:60.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">tissue-speci</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt;color:#2e3092">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">c ampli</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt;color:#2e3092">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">er of glucocorticoid action. Endocrinology 2001;142(4):</span></p>
<p style="top:358.9pt;left:60.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">1371</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">6.</span></p>
<p style="top:366.9pt;left:46.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[36]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Wyrwoll CS, Holmes MC, Seckl JR. 11 beta-Hydroxysteroid dehydrogenases and the</span></p>
<p style="top:374.9pt;left:60.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">brain: from zero to hero, a decade of progress. Front Neuroendocrinol 2011;32(3):</span></p>
<p style="top:382.8pt;left:60.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">265</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">86.</span></p>
<p style="top:390.8pt;left:46.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[37]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Tomlinson JW, Stewart PM. Mechanisms of disease: selective inhibition of 11 beta-</span></p>
<p style="top:398.8pt;left:60.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">hydroxysteroid dehydrogenase type 1 as a novel treatment for the metabolic syn-</span></p>
<p style="top:406.8pt;left:60.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">drome. Nat Clin Pract Endocrinol Metab 2005;1(2):92</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">9.</span></p>
<p style="top:414.7pt;left:46.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[38]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Gathercole LL, et al. 11 beta-hydroxysteroid dehydrogenase 1: translational and</span></p>
<p style="top:422.7pt;left:61.0pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">therapeutic aspects. Endocr Rev 2013;34(4):525</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">55.</span></p>
<p style="top:430.6pt;left:46.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[39]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Higgins JPT, et al. The Cochrane Collaboration</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2019;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">s tool for assessing risk of bias in</span></p>
<p style="top:438.6pt;left:61.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">randomised trials. BMJ 2011;343:1</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">9.</span></p>
<p style="top:446.6pt;left:46.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[40] NIH-NIoH. Quality Assessment Tool for Observational Cohort and Cross-Sectional</span></p>
<p style="top:454.6pt;left:60.8pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">Studies. [cited 2019 March]; Available from:</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> https://www.nhlbi.nih.gov/health-</span></p>
<p style="top:462.6pt;left:60.8pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">topics/study-quality-assessment-tools</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">; 2014.</span></p>
<p style="top:470.5pt;left:46.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[41]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Valsamakis G, et al. 11beta-hydroxysteroid dehydrogenase type 1 activity in lean</span></p>
<p style="top:478.5pt;left:60.8pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">and obese males with type 2 diabetes mellitus. J Clin Endocrinol Metabol 2004;</span></p>
<p style="top:486.5pt;left:60.8pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">89(9):4755</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">61.</span></p>
<p style="top:494.4pt;left:46.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[42]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Shao SY, Zhang XJ, Zhang MX. Inhibition of 11 beta-hydroxysteroid dehydrogenase</span></p>
<p style="top:502.4pt;left:60.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">type 1 ameliorates obesity-related insulin resistance. Biochem Biophys Res</span></p>
<p style="top:510.4pt;left:60.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">Commun 2016;478(1):474</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">a480.</span></p>
<p style="top:518.3pt;left:46.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[43]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Desbriere R, et al. 11 beta-hydroxysteroid dehydrogenase type 1 mRNA is in-</span></p>
<p style="top:526.3pt;left:61.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">creased in both visceral and subcutaneous adipose tissue of obese patients. Obesity</span></p>
<p style="top:534.3pt;left:61.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">2006;14(5):794</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">8.</span></p>
<p style="top:542.3pt;left:46.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[44]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Mariniello B, et al. Adipose tissue 11 beta-hydroxysteroid dehydrogenase type 1</span></p>
<p style="top:550.2pt;left:60.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">expression in obesity and Cushing</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2019;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">s syndrome. Eur J Endocrinol 2006;155(3):</span></p>
<p style="top:558.2pt;left:60.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">435</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">41.</span></p>
<p style="top:566.1pt;left:46.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[45]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Munoz R, et al. 11 beta-hydroxysteroid dehydrogenase type 1 is overexpressed in</span></p>
<p style="top:574.1pt;left:60.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">subcutaneous adipose tissue of morbidly obese patients. Obes Surg 2009;19(6):</span></p>
<p style="top:582.1pt;left:60.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">764</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">70.</span></p>
<p style="top:590.1pt;left:46.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[46]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Wake DJ, et al. Local and systemic impact of transcriptional up-regulation of</span></p>
<p style="top:598.1pt;left:61.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue in human obesity.</span></p>
<p style="top:606.0pt;left:61.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">J Clin Endocrinol Metabol 2003;88(8):3983</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">8.</span></p>
<p style="top:614.0pt;left:46.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[47]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Zha JM, et al. Comparison of gene transcription between subcutaneous and visceral</span></p>
<p style="top:622.0pt;left:60.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">adipose tissue in Chinese adults. Endocr J 2009;56(8):935</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">44.</span></p>
<p style="top:629.9pt;left:46.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[48]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Crowley RK, et al. Increased central adiposity and decreased subcutaneous adipose tis-</span></p>
<p style="top:637.9pt;left:60.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">sue 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt;color:#2e3092">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">-hydroxysteroid dehydrogenase type 1 are associated with deterioration in</span></p>
<p style="top:645.8pt;left:60.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">glucose tolerance-a longitudinal cohort study. Clin Endocrinol (Oxf) 2019;91(1):</span></p>
<p style="top:653.8pt;left:60.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">72</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">81.</span></p>
<p style="top:661.8pt;left:46.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[49]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Rask E, et al. Tissue-speci</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt;color:#2e3092">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">c changes in peripheral cortisol metabolism in obese</span></p>
<p style="top:669.8pt;left:61.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">women: increased adipose 11beta-hydroxysteroid dehydrogenase type 1 activity.</span></p>
<p style="top:677.8pt;left:61.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">J Clin Endocrinol Metabol 2002;87(7):3330</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">6.</span></p>
<p style="top:685.7pt;left:46.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[50]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Lindsay RS, et al. Subcutaneous adipose 11beta-hydroxysteroid dehydrogenase</span></p>
<p style="top:693.7pt;left:61.2pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">type 1 activity and messenger ribonucleic acid levels are associated with adiposity</span></p>
<p style="top:701.6pt;left:61.2pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">and insulinemia in Pima Indians and Caucasians. J Clin Endocrinol Metabol 2003;88</span></p>
<p style="top:709.6pt;left:61.2pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">(6):2738</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">44.</span></p>
<p style="top:717.6pt;left:46.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[51]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Alberti L, et al. Type 2 diabetes and metabolic syndrome are associated with in-</span></p>
<p style="top:725.6pt;left:61.0pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">creased expression of 11 beta-hydroxysteroid dehydrogenase 1 in obese subjects.</span></p>
<p style="top:733.5pt;left:61.0pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">Int J Obes (Lond) 2007;31(12):1826</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">31.</span></p>
<p style="top:56.1pt;left:314.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[52]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Baudrand R, et al. Overexpression of 11 beta-hydroxysteroid dehydrogenase type 1</span></p>
<p style="top:64.1pt;left:328.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">in hepatic and visceral adipose tissue is associated with metabolic disorders in</span></p>
<p style="top:72.0pt;left:328.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">morbidly obese patients. Obes Surg 2010;20(1):77</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">83.</span></p>
<p style="top:80.0pt;left:314.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[53]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Grundy SM, et al. Diagnosis and management of the metabolic syndrome: an</span></p>
<p style="top:87.9pt;left:329.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">American Heart Association/National Heart, Lung, and Blood Institute Scienti</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt;color:#2e3092">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">c</span></p>
<p style="top:95.9pt;left:329.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">Statement. Circulation 2005;112:2735</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">52.</span></p>
<p style="top:103.9pt;left:314.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[54]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Robitaille J, et al. Molecular screening of the 11 beta-HSD1 gene in men character-</span></p>
<p style="top:111.8pt;left:328.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">ized by the metabolic syndrome. Obes Res 2004;12(10):1570</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">5.</span></p>
<p style="top:119.9pt;left:314.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[55]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Miyamoto Y, et al. Association study of 11 beta-hydroxysteroid dehydrogenase</span></p>
<p style="top:127.8pt;left:329.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">type 1 gene polymorphisms and metabolic syndrome in urban Japanese cohort. Di-</span></p>
<p style="top:135.8pt;left:329.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">abetes Res Clin Pract 2009;85(2):132</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">8.</span></p>
<p style="top:143.7pt;left:314.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[56]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Devang N, et al. Association of HSD11B1 gene polymorphisms with type 2 diabetes</span></p>
<p style="top:151.7pt;left:328.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">and metabolic syndrome in South Indian population. Diabetes Res Clin Pract 2017;</span></p>
<p style="top:159.7pt;left:328.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">131:142</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">8.</span></p>
<p style="top:167.6pt;left:314.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[57]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Jang C, et al. Altered activity of 11 beta-hydroxysteroid dehydrogenase types 1 and</span></p>
<p style="top:175.6pt;left:328.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">2 in skeletal muscle confers metabolic protection in subjects with type 2 diabetes. J</span></p>
<p style="top:183.6pt;left:328.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">Clin Endocrinol Metabol 2007;92(8):3314</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">20.</span></p>
<p style="top:191.6pt;left:314.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[58]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Shukla R, et al. 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt;color:#2e3092">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> hydroxysteroid dehydrogenase</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092"> &#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> 1 activity in type 2 diabetes</span></p>
<p style="top:199.6pt;left:328.8pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">mellitus: a comparative study. BMC Endocr Disord 2019:19(15).</span></p>
<p style="top:207.5pt;left:314.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[59]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Nair S, et al. 11beta-Hydroxysteroid dehydrogenase Type 1: genetic polymor-</span></p>
<p style="top:215.5pt;left:328.8pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">phisms are associated with Type 2 diabetes in Pima Indians independently of</span></p>
<p style="top:223.4pt;left:328.8pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">obesity and expression in adipocyte and muscle. Diabetologia 2004;47(6):</span></p>
<p style="top:231.4pt;left:328.8pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">1088</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">95.</span></p>
<p style="top:239.4pt;left:314.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[60]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> de Quervain DJF, et al. Glucocorticoid-related genetic susceptibility for Alzheimer</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2019;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">s</span></p>
<p style="top:247.4pt;left:328.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">disease. Hum Mol Genet 2004;13(1):47</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">52.</span></p>
<p style="top:255.3pt;left:314.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[61]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Smit P, et al. Lack of association of the 11-beta-hydroxysteroid dehydrogenase type</span></p>
<p style="top:263.3pt;left:328.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">1 gene 83,557insA and hexose-6-phosphate dehydrogenase gene R453Q polymor-</span></p>
<p style="top:271.3pt;left:328.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">phisms with body composition, adrenal androgen production, blood pressure, glu-</span></p>
<p style="top:279.2pt;left:328.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">cose metabolism, and dementia. J Clin Endocrinol Metabol 2007;92(1):359</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">62.</span></p>
<p style="top:287.2pt;left:314.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[62]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Rosenstock J, et al. The 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor</span></p>
<p style="top:295.2pt;left:329.0pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately</span></p>
<p style="top:303.1pt;left:329.0pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">controlled by metformin monotherapy. Diabetes Care 2010;33(7):1516</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">22.</span></p>
<p style="top:311.1pt;left:314.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[63]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Heise T, et al. Safety, ef</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt;color:#2e3092">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">cacy and weight effect of two 11&#xdf;-HSD1 inhibitors in met-</span></p>
<p style="top:319.1pt;left:328.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">formin-treated patients with type 2 diabetes. Diabetes Obes Metab 2014;16:</span></p>
<p style="top:327.1pt;left:328.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">1070</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">7.</span></p>
<p style="top:335.0pt;left:314.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[64]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Feig PU, et al. Effects of an 11 beta-hydroxysteroid dehydrogenase type 1 inhibitor,</span></p>
<p style="top:343.0pt;left:328.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">MK-0916, in patients with type 2 diabetes mellitus and metabolic syndrome. Dia-</span></p>
<p style="top:351.0pt;left:328.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">betes Obes Metab 2011;13(6):498</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">504.</span></p>
<p style="top:358.9pt;left:314.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[65]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Shah S, et al. Ef</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt;color:#2e3092">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">cacy and safety of the selective 11 beta-HSD-1 inhibitors MK-0736</span></p>
<p style="top:366.9pt;left:328.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">and MK-0916 in overweight and obese patients with hypertension. J Am Soc</span></p>
<p style="top:374.9pt;left:328.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">Hypertens 2011;5(3):166</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">76.</span></p>
<p style="top:382.8pt;left:314.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[66]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Nixon M, et al. Salicylate downregulates 11 beta-HSD1 expression in adipose tissue</span></p>
<p style="top:390.8pt;left:328.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">in obese mice and in humans, mediating insulin sensitization. Diabetes 2012;61</span></p>
<p style="top:398.8pt;left:328.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">(4):790</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">6.</span></p>
<p style="top:406.8pt;left:314.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[67]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Marek GJ, et al. Ef</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt;color:#2e3092">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">cacy and safety evaluation of HSD-1 inhibitor ABT-384 in</span></p>
<p style="top:414.7pt;left:329.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">Alzheimer</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2019;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">s disease. Alzheimers Dement 2014;10(5):S364</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">73.</span></p>
<p style="top:422.7pt;left:314.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[68]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Webster SP, et al. Selection and early clinical evaluation of the brain-penetrant 11</span></p>
<p style="top:430.6pt;left:328.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1) inhibitor UE2343</span></p>
<p style="top:438.6pt;left:328.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">(Xanamem (TM)). Br J Pharmacol 2017;174(5):396</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">408.</span></p>
<p style="top:446.6pt;left:314.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[69]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Ltd, A.M.. Phase II Alzheimer&apos;s Disease Trial</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092"> &#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Results; 2019.</span></p>
<p style="top:454.6pt;left:314.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[70]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Andrews RC, Rooyackers O, Walker BR. Effects of the 11beta-hydroxysteroid dehy-</span></p>
<p style="top:462.6pt;left:328.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">drogenase inhibitor carbenoxolone on insulin sensitivity in men with type 2 diabe-</span></p>
<p style="top:470.5pt;left:328.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">tes. J Clin Endocrinol Metabol 2003;88(1):285</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">91.</span></p>
<p style="top:478.5pt;left:314.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[71]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Sandeep TC, et al. 11beta-hydroxysteroid dehydrogenase inhibition improves cog-</span></p>
<p style="top:486.5pt;left:328.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">nitive function in healthy elderly men and type 2 diabetics. Proc Natl Acad Sci U S A</span></p>
<p style="top:494.4pt;left:328.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">2004;101(17):6734</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">9.</span></p>
<p style="top:502.4pt;left:314.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[72]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Sandeep TC, et al. Increased in vivo regeneration of cortisol in adipose tissue in</span></p>
<p style="top:510.4pt;left:329.0pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">human obesity and effects of the 11beta-hydroxysteroid dehydrogenase type 1 in-</span></p>
<p style="top:518.3pt;left:329.0pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">hibitor carbenoxolone. Diabetes 2005;54(3):872</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">9.</span></p>
<p style="top:526.3pt;left:314.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[73]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Wang Y, et al. 11 beta-hydroxysteroid dehydrogenase type 1 shRNA ameliorates</span></p>
<p style="top:534.3pt;left:328.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">glucocorticoid-induced insulin resistance and lipolysis in mouse abdominal adi-</span></p>
<p style="top:542.3pt;left:328.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">pose tissue. Am J Physiol Endocrinol Metab 2015;308(1):E84</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">95.</span></p>
<p style="top:550.2pt;left:314.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[74]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Byun SY, et al. A novel highly potent and selective 11 beta-hydroxysteroid dehy-</span></p>
<p style="top:558.2pt;left:328.8pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">drogenase type 1 inhibitor, UI-1499. Life Sci 2015;120:1</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">7.</span></p>
<p style="top:566.1pt;left:314.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[75]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Morgan SA, et al. 11 beta-hydroxysteroid dehydrogenase type 1 regulates gluco-</span></p>
<p style="top:574.1pt;left:328.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">corticoid-induced insulin resistance in skeletal muscle. Diabetes 2009;58(11):</span></p>
<p style="top:582.1pt;left:328.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">2506</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">15.</span></p>
<p style="top:590.1pt;left:314.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[76]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Sundbom M, et al. Inhibition of 11 beta HSD1 with the S-phenylethylaminothiazolone</span></p>
<p style="top:598.1pt;left:328.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">BVT116429 increases adiponectin concentrations and improves glucose homeostasis</span></p>
<p style="top:606.0pt;left:328.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">in diabetic KKAy mice. BMC Pharmacol 2008;8:3.</span></p>
<p style="top:614.0pt;left:314.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[77]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Veniant MM, et al. Discovery of a potent, orally active 11 beta-hydroxysteroid de-</span></p>
<p style="top:622.0pt;left:328.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">hydrogenase type 1 inhibitor for clinical study: identi</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt;color:#2e3092">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">cation of (S)-2-((1S,2S,4R)-</span></p>
<p style="top:629.9pt;left:328.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">bicyclo 2.2.1 heptan-2-ylamino)-5-isopropyl-5-methylthi azol-4(5H)-one (AMG</span></p>
<p style="top:637.9pt;left:328.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">221). J Med Chem 2010;53(11):4481</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">7.</span></p>
<p style="top:645.8pt;left:314.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[78]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Wan Z-K, et al. Discovery of HSD-621 as a potential agent for the treatment of type</span></p>
<p style="top:653.8pt;left:328.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">2 diabetes. ACS Med Chem Lett 2013;4(1):118</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">23.</span></p>
<p style="top:661.8pt;left:314.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[79]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Wan Z-K, et al. Ef</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt;color:#2e3092">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">cacious 11 beta-hydroxysteroid dehydrogenase type I inhib-</span></p>
<p style="top:669.8pt;left:328.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">itors in the diet-induced obesity mouse model. J Med Chem 2009;52(17):</span></p>
<p style="top:677.8pt;left:328.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">5449</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">61.</span></p>
<p style="top:685.7pt;left:314.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[80]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Zhang X, et al. 4-(Phenylsulfonamidomethyl) benzamides as potent and selective</span></p>
<p style="top:693.7pt;left:328.8pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">inhibitors of the 11 beta-hydroxysteroid dehydrogenase type 1 with ef</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt;color:#2e3092">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">cacy in di-</span></p>
<p style="top:701.6pt;left:328.8pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">abetic ob/ob mice. Bioorg Med Chem Lett 2009;19(15):4455</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">8.</span></p>
<p style="top:709.6pt;left:314.1pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[81]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Anil TM, et al. A novel 11 beta-hydroxysteroid dehydrogenase type1 inhibitor CNX-</span></p>
<p style="top:717.6pt;left:328.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">010-49 improves hyperglycemia, lipid pro</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt;color:#2e3092">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">le and reduces body weight in diet in-</span></p>
<p style="top:725.6pt;left:328.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">duced obese C57B6/J mice with a potential to provide cardio protective bene</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt;color:#2e3092">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">ts.</span></p>
<p style="top:733.5pt;left:328.6pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">BMC Pharmacol Toxicol 2014;15:43.</span></p>
<p style="top:37.7pt;left:554.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">17</span></p>
<p style="top:37.7pt;left:199.2pt;line-height:6.4pt"><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">S. Gregory et al. / Metabolism Clinical and Experimental 108 (2020) 154246</span></p>


<p style="top:56.1pt;left:37.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[82]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Feng Y, et al. Emodin, a natural product, selectively inhibits 11 beta-hydroxysteroid</span></p>
<p style="top:64.1pt;left:51.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">dehydrogenase type 1 and ameliorates metabolic disorder in diet-induced obese</span></p>
<p style="top:72.0pt;left:51.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">mice. Br J Pharmacol 2010;161(1):113</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">26.</span></p>
<p style="top:80.0pt;left:37.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[83]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Hermanowski-Vosatka A, et al. 11 beta-HSD1 inhibition ameliorates metabolic syn-</span></p>
<p style="top:87.9pt;left:51.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">drome and prevents progression of atherosclerosis in mice. J Exp Med 2005;202</span></p>
<p style="top:95.9pt;left:51.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">(4):517</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">27.</span></p>
<p style="top:103.9pt;left:37.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[84]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Hong SP, et al. A novel highly potent and selective 11 beta-hydroxysteroid dehy-</span></p>
<p style="top:111.9pt;left:52.0pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">drogenase type 1 inhibitor, INU-101. Eur J Pharmacol 2018;835:169</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">78.</span></p>
<p style="top:119.8pt;left:37.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[85]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Schnackenberg CG, et al. Chronic inhibition of 11 beta-hydroxysteroid dehydroge-</span></p>
<p style="top:127.8pt;left:51.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">nase type 1 activity decreases hypertension, insulin resistance, and hypertriglyc-</span></p>
<p style="top:135.8pt;left:51.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">eridemia in metabolic syndrome. Biomed Res Int 2013:427640.</span></p>
<p style="top:143.7pt;left:37.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[86]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Berthiaume M, et al. Depot-speci</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt;color:#2e3092">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">c modulation of rat intraabdominal adipose tis-</span></p>
<p style="top:151.7pt;left:51.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">sue lipid metabolism by pharmacological inhibition of 11 beta-hydroxysteroid de-</span></p>
<p style="top:159.7pt;left:51.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">hydrogenase type 1. Endocrinology 2007;148(5):2391</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">7.</span></p>
<p style="top:167.6pt;left:37.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[87]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Liu J, et al. Adipose tissue-targeted 11 beta-hydroxysteroid dehydrogenase type 1</span></p>
<p style="top:175.6pt;left:52.0pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">inhibitor protects against diet-induced obesity. Endocr J 2011;58(3):199</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">209.</span></p>
<p style="top:183.6pt;left:37.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[88]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Wang L, et al. BVT.2733, a selective 11 beta-hydroxysteroid dehydrogenase type 1</span></p>
<p style="top:191.6pt;left:51.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">inhibitor, attenuates obesity and in</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt;color:#2e3092">&#xfb02;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">ammation in diet-induced obese mice. PLoS</span></p>
<p style="top:199.6pt;left:51.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">One 2012;</span><span style="font-family:AdvTT28000ce1.B,serif;font-size:6.4pt;color:#2e3092">7</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">(7) [p. e40056].</span></p>
<p style="top:207.5pt;left:37.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[89]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Wang SJY, et al. Inhibition of 11 beta-hydroxysteroid dehydrogenase type 1 re-</span></p>
<p style="top:215.5pt;left:52.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">duces food intake and weight gain but maintains energy expenditure in diet-</span></p>
<p style="top:223.4pt;left:52.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">induced obese mice. Diabetologia 2006;49(6):1333</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">7.</span></p>
<p style="top:231.4pt;left:37.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[90]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Okazaki S, et al. HIS-388, a potent orally active 11beta-hydroxysteroid dehydroge-</span></p>
<p style="top:239.4pt;left:51.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">nase type 1 inhibitor, improves insulin resistance and glucose intolerance in obese</span></p>
<p style="top:247.3pt;left:51.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">and diabetes model mice. J Pharmacol Sci 2012;118(Suppl. 1):254P.</span></p>
<p style="top:255.3pt;left:37.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[91]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Sooy K, et al. Cognitive and disease-modifying effects of 11 beta-hydroxysteroid</span></p>
<p style="top:263.3pt;left:52.2pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">dehydrogenase type 1 inhibition in male Tg2576 mice, a model of Alzheimer</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2019;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">s dis-</span></p>
<p style="top:271.3pt;left:52.2pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">ease. Endocrinology 2015;156(12):4592</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">603.</span></p>
<p style="top:279.2pt;left:37.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[92]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Yau JLW, et al. Intrahippocampal glucocorticoids generated by 11-HSD1 affect</span></p>
<p style="top:287.2pt;left:52.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">memory in aged mice. Neurobiol Aging 2015;36(1):334</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">43.</span></p>
<p style="top:295.2pt;left:37.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[93]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Sooy K, et al. Partial de</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt;color:#2e3092">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">ciency or short-term inhibition of 11 beta-hydroxysteroid</span></p>
<p style="top:303.1pt;left:51.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">dehydrogenase type 1 improves cognitive function in aging mice. J Neurosci 2010;</span></p>
<p style="top:311.1pt;left:51.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">30(41):13867</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">72.</span></p>
<p style="top:319.1pt;left:37.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[94]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Leiva R, et al. Design, synthesis and in vivo study of novel pyrrolidine-based 11</span></p>
<p style="top:327.1pt;left:52.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">beta-HSD1 inhibitors for age-related cognitive dysfunction. Eur J Med Chem</span></p>
<p style="top:335.0pt;left:52.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">2017;139:412</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">28.</span></p>
<p style="top:343.0pt;left:37.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[95]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Sarabdjitsingh RA, et al. Inhibiting 11 beta-hydroxysteroid dehydrogenase type 1</span></p>
<p style="top:351.0pt;left:52.0pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">prevents stress effects on hippocampal synaptic plasticity and impairs contextual</span></p>
<p style="top:358.9pt;left:52.0pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">fear conditioning. Neuropharmacology 2014;81:231</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">6.</span></p>
<p style="top:56.1pt;left:305.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[96]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Llovera G, Liesz A. The next step in translational research: lessons learned from the</span></p>
<p style="top:64.1pt;left:319.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt;color:#2e3092">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">rst preclinical randomized controlled trial. J Neurochem 2016;139(S2):271</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">9.</span></p>
<p style="top:72.0pt;left:305.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[97] WHO. Body mass index - BMI. [cited 2019 20/08/2019]; Available from:</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> http://</span></p>
<p style="top:80.0pt;left:320.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">www.euro.who.int/en/health-topics/disease-prevention/nutrition/a-healthy-</span></p>
<p style="top:87.9pt;left:320.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">lifestyle/body-mass-index-bmi</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">; 2019.</span></p>
<p style="top:95.9pt;left:305.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[98]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> consultation, W.e. Appropriate body-mass index for Asian populations and its im-</span></p>
<p style="top:103.9pt;left:319.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">plications for policy and intervention strategies. Lancet 2004:363.</span></p>
<p style="top:111.8pt;left:305.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[99]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Jack Jr CR, et al. NIA-AA research framework: toward a biological de</span><span style="font-family:AdvTT5235d5a9+fb,serif;font-size:6.4pt;color:#2e3092">&#xfb01;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">nition of</span></p>
<p style="top:119.9pt;left:320.5pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">Alzheimer</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2019;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">s disease. Alzheimers Dement 2018;14(4):535</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">62.</span></p>
<p style="top:127.8pt;left:301.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[100]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Leiros BG, et al. Prevalence and concordance between the clinical and the post-</span></p>
<p style="top:135.8pt;left:320.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">mortem diagnosis of dementia in a psychogeriatric clinic. Neurolog&#xed;a (English Edi-</span></p>
<p style="top:143.7pt;left:320.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">tion) 2018;33(1):13</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">7.</span></p>
<p style="top:151.7pt;left:301.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[101]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Gallezot J-D, et al. Imaging the enzyme 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt;color:#2e3092">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">-hydroxysteroid dehydrogenase type 1</span></p>
<p style="top:159.7pt;left:319.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">with positron emission tomography: evaluation of the novel radiotracer 11C-</span></p>
<p style="top:167.6pt;left:319.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">AS2471907 in human brain. J Nucl Med 2019;60(8):1140</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">6.</span></p>
<p style="top:175.6pt;left:301.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[102] Trial, U.-C.C. UMIN000024482. [cited 2020 04/Mar/2020]; Available from:</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> https://</span></p>
<p style="top:183.6pt;left:319.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000028177</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">.</span></p>
<p style="top:191.6pt;left:301.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[103]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Gray GA, et al. Getting to the heart of intracellular glucocorticoid regeneration:</span></p>
<p style="top:199.6pt;left:320.4pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt;color:#2e3092">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">-HSD1 in the myocardium. J Mol Endocrinol 2016;58(1).</span></p>
<p style="top:207.5pt;left:301.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[104]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Richardson RV, et al. Cardiac GR and MR: from development to pathology. Trends</span></p>
<p style="top:215.5pt;left:319.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">Endocrinol Metab 2016;27(1):35</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">43.</span></p>
<p style="top:223.4pt;left:301.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[105]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Pitt B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ven-</span></p>
<p style="top:231.4pt;left:320.0pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">tricular dysfunction after myocardial infarction. New England J Med 2003;348</span></p>
<p style="top:239.4pt;left:320.0pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">(14):1309</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">21.</span></p>
<p style="top:247.4pt;left:301.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[106]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Zannad F, et al. Mineralocorticoid receptor antagonists for heart failure with re-</span></p>
<p style="top:255.3pt;left:320.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">duced ejection fraction: integrating evidence into clinical practice. Eur Heart J</span></p>
<p style="top:263.3pt;left:320.3pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">2012;33(22):2782</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">95.</span></p>
<p style="top:271.3pt;left:301.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[107]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Sun K, Yang K, Challis JR. Differential expression of 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt;color:#2e3092">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">-hydroxysteroid dehydroge-</span></p>
<p style="top:279.2pt;left:319.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">nase types 1 and 2 in human placenta and fetal membranes. J Clin Endocrinol</span></p>
<p style="top:287.2pt;left:319.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">Metabol 1997;82(1):300</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">5.</span></p>
<p style="top:295.2pt;left:301.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[108]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Alfaidy N, et al. Late gestation inrease in 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt;color:#2e3092">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">-hydroxysteroid dehydrogenase 1 ex-</span></p>
<p style="top:303.1pt;left:319.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">pression in human fetal membranes: a novel intrauterine source of cortisol. J Clin</span></p>
<p style="top:311.1pt;left:319.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">Endocrinol Metabol 2003;88(10):5033</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">8.</span></p>
<p style="top:319.1pt;left:301.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">[109]</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092"> Wang W, et al. 11</span><span style="font-family:AdvTT5235d5a9+03,serif;font-size:6.4pt;color:#2e3092">&#x3b2;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">-HSD1 in human fetal membranes as a potential therapeutic tar-</span></p>
<p style="top:327.1pt;left:319.9pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">get for preterm birth. Endocr Rev 2018;39(3):241</span><span style="font-family:AdvTT5235d5a9+20,serif;font-size:6.4pt;color:#2e3092">&#x2013;</span><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt;color:#2e3092">60.</span></p>
<p style="top:37.7pt;left:33.7pt;line-height:6.4pt"><span style="font-family:AdvTT5235d5a9,serif;font-size:6.4pt">18</span></p>
<p style="top:37.7pt;left:190.4pt;line-height:6.4pt"><span style="font-family:AdvTT94c8263f.I,serif;font-size:6.4pt">S. Gregory et al. / Metabolism Clinical and Experimental 108 (2020) 154246</span></p>

</div>
